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i 
Abstract 
 
The diketopiperazine scaffold can be found in a large number of natural products and 
commercialised drugs. Conversely, the triketopiperazine one is far less common in Nature and 
scarce research has been conducted to determine its utility. The project goal was to develop 
enantioselective organocatalysis on these two frameworks. Chapter 1 gives an introduction on 
their presence in Nature and the pharmaceutical industry, the most relevant synthetic advances 
as well as an overview of the organocatalysis tools previously reported. 
Although diketopiperazines have been the subject of intense research, no asymmetric methods 
have been previously reported despite the myriad of available methodologies. Chapter 2 
discusses the particular organocatalytic precedents that motivated this project and the initial 
efforts devoted to develop such methodology. Unfortunately, diketopiperazines showed 
complete lack of reactivity under a wide range of conditions. 
Our interest in developing this enantioselective method in heterocycles related to 
diketopiperazines made us turn our attention to the triketopiperazine scaffold. The successful 
application of a cinchona alkaloid derived catalysed Michael addition on this scaffold is 
described in Chapter 3. Progresses made in the manipulation of the chiral products are also 
included. 
An extension of the previously developed methodology, where selected Michael acceptors 
afford bicycle[2.2.2]diazaoctane derived products via a tandem Michael–ring-closure process, 
is discussed in Chapter 4. 
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IR  infrared spectroscopy  
J  coupling constant (in nuclear magnetic resonance spectroscopy) 
kcal  kilocalorie 
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nOe   nuclear Overhauser effect 
NOESY  nuclear Overhauser effect spectroscopy 
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OTf  trifluoromethanesulfonate (triflate) 
PK   pharmacokinetics 
Ph  phenyl 
PHN  9-phenanthryl 
PMB   para-methoxybenzyl 
PMP   para-methoxyphenyl 
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PTSA  para-toluenesulfonic acid 
Py  pyridine 
rt   room temperature 
x 
Rƒ   retardation factor 
SAR   structure-activity relationship  
SET  single electron transfer 
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TFAA   trifluoroacetic anhydride 
THF   tetrahydrofuran 
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TMS   trimethylsilyl 
TMSI   trimethylsilyl iodide 
UV  ultraviolet spectroscopy 
 
Note: ee is used in this document only for the literature values originally reported using this 
nomenclature. All the enatiomeric data generated within this thesis using chiral HPLC is 
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Chapter One 
 
Introduction 
 
1.1  Diketopiperazines 
The diketopiperazine framework has gained a privileged status due to the abundance 
of this motif in natural products and the diverse biological activities they display. Three 
regioisomers of the diketopiperazine core can be identified: 2,3-diketopiperazines 1, 2,6-
diketopiperazines 2 and 2,5-diketopiperazines 3 (Figure 1.1). 
 
Figure 1.1 Structure of diketopiperazines 
Herein we will focus on 2,5-diketopiperazines 3, also known as 2,5-piperazinediones and 
abbreviated as DKPs hereafter, which can be understood as constrained cycles formed by the 
condensation of two α-amino acids.  
Despite their apparent simplicity, the rigid scaffold can be substituted in up to four positions, 
and stereochemistry controlled at both methylene positions. This source of diversity has been 
the subject of intensive synthetic research for a long period of time. In addition, the 
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pharmaceutical industry has also showed strong interest in these structures owing to the 
relevance of amidic groups, as the ones present in DKPs, in the medicinal chemistry context.  
Although the first report of a DKP, cyclo[Leu-Leu] or "Leucinimide", was in 1849 and the 
first DKP synthesis,1 cyclo[Gly-Gly], occurred in 1888 from the corresponding glycine ester,2 
it was not until the 20th century that DKPs were acknowledged as a unique class of 
compounds. In the early 1900s, DKPs were no longer considered mere by-products of 
polypeptide manipulations. Their abundance in Nature became evident as simple symmetrical 
and unsymmetrical DKPs were found to exist in polypeptide hydrolysates as well 
fermentation broths and cultures of yeast, lichens and fungi.3 From the determination of their 
physical properties to their use in polypeptide sequence elucidation, synthetic and naturally 
isolated DKPs were broadly studied by the scientific community.4 
 
Figure 1.2 Planar (4), boat (5) and twist-boat (6) conformation for DKPs cyclo[Gly-Gly] 
However, little was known about the precise conformation these molecules adopted in the 
solid phase. Cyclo[Gly-Gly] was shown to be planar (4) by the X-ray crystal structure solved 
by Corey in 1938.5 This result highlighted the conformational strain the small six membered 
ring was subjected to in the solid phase. Nonetheless, DKPs were shown to be flexible in 
solution by NMR studies. Results from these studies suggested that the cyclo[Gly-Gly] ring 
Chapter 1   Introduction
  
 
3 
departs from planarity and its conformation interchanges between two equally populated boat 
5 or twist-boat 6 states due to the low energy barrier between conformers (Figure 1.2).6 
Recent measures of the DKP ring microwave spectrum in the gas phase have confirmed the 
boat conformation (5) to be the prevalent and preferred state.7 Ab initio calculations have also 
supported this statement although the predicted difference in favour of boat conformer is 
negligible.8 These studies conclude that while the boat conformer constitutes the minimum 
energy, the planar one is a transition state. However, the small energy difference between 
forms is easily surpassed in the crystal environment and thus, cyclo[Gly-Gly] is forced to 
stack in planar (4) and linear hydrogen-bonded tapes.9  
Substituted DKP conformers vary depending on the nature of the amino acid side chains. If 
the side chain is an alkyl group, the energy difference between forms becomes unimportant in 
solution and NMR studies suggest the ring is planar (7, R1=alkyl, R2=H). Contrarily, when R1 
incorporates an aromatic side chain, such as a histidyl chain, the boat conformation is 
prevalent by close to 3 kcal/mol. The aromatic ring is suggested to fold over the DKP ring (8). 
This effect is not solvent dependent, which suggests the presence of a strong enough dipole-
dipole interaction between the amide groups and the aromatic ring π-electron cloud for 
dipolar solvents to compete (Figure 1.3).6a  
 
Figure 1.3 Substituted DKP conformations 
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Boat or twisted-boat states become the generally established conformation for the 
symmetrically cis-disubstituted six-membered ring in both solid and solution phase (9).10 
Empirical data was confirmed by different X-Ray crystal structures such as cyclo[L-Met-L-
Met]11 or cyclo[L-Glu-L-Glu]12, where the boat geometry is adopted with the side chains 
folded above the DKP ring. On the contrary, the conformation of trans-disubstituted DKPs 
varies from planar to flattened-chair (7, R1= R2=alkyl).9 
DKPs incorporating proline constitute a special case on their own. The additional strain 
imposed by the fused five-membered ring makes the six-membered one adopt a boat 
conformation in almost every amino acid DKP combination (10).13 
DKPs are a common scaffold embedded in numerous complex natural products from the 
fungus, bacteria, plant or animal kingdom. These systems not only constitute a novel and rich 
biologically active family of compounds but are also a source of new structurally diverse 
scaffolds for therapeutic applications. In addition, these small heterocycles have been 
employed as peptide surrogates in many drug discovery projects because they are structurally 
similar to peptides but allow the potential drug candidates to bypass their undesirable physical 
and metabolic properties.14 Owing to the wide diversity of possible chiral amino acids and 
employing recent advances in solid-phase chemistry, DKPs have been widely used to create 
libraries of enantioenriched heterocycles valid for combinatorial medicinal chemistry projects. 
These chiral templates have also been exploited as chiral catalysts and chiral auxiliaries as a 
result of the reliable methods developed to access a wide variety of derivatives.15 
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1.2  2,5-Diketopiperazines in Nature and drugs 
In light of the broad diversity and complexity the DKP subunit can bear, there are an 
ever-increasing number of structures exhibiting interesting biological activities both isolated 
from natural sources and synthesised as part of drug discovery projects. The conformationally 
rigid scaffold enables these molecules not only to incorporate different functional groups with 
defined stereochemistry but also to bind to multiple biological sites and receptors via H-
bonds. The drug industry has taken advantage of this motif by: (1) exploring the structure-
activity relationship (SAR) to develop pharmaceutical compositions from the hit stage by 
means of tuning the physicochemical properties in the optimization process, (2) confining 
linear peptides into rigid and robust scaffolds while maintaining their biological purpose and, 
(3) using naturally occurring DKPs to both exploit and improve their biological activity. 
 
1.2.1  Medicinal Chemistry 
A variety of DKP cores have been found to be excellent examples of how a hit can be 
transformed and optimised through SAR studies to develop the most potent lead. These 
studies are designed to understand the key functionalities in the molecule triggering the 
desired biological effect. Chemical, regiochemical or stereochemical modifications play a key 
role in tuning the potency of the drug candidate. The following examples of drugs developed 
by the pharmaceutical industry help to illustrate the process that takes place.  
Oxytocin (OC) is a nonpeptidic mammalian neurohypophyasial hormone whose main 
function is the distension of the cervix and the uterus during labour. Atosiban is an oxytocin 
antagonist aimed at repressing premature labour. This polypeptidic drug is administrated 
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intravenously and the pharmaceutical industry has devoted great efforts to find an appropriate 
non-peptidic oral substituent for it. Researchers at GlaxoSmithKline (GSK) screened 
numerous compound libraries to detect effective antagonist activity at the OC receptor. DKP 
11 (Scheme 1.1) showed promising results as an inhibitor of human OC as an α-aryl 
glyciamide mixture of epimers.16 Initial SAR studies pointed to DKP 12 where the substituent 
at C-3 evolved into an isobutyl chain. A four carbon branched alkyl chain was found to be 
optimal while smaller chains led to decreased antagonist activity. Position C-6 became an 
indanyl residue as any other aromatic substituent diminished the drug’s activity. R 
configuration on the α-aryl glyciamide was found optimal in this study. The (3R,4’R,6R) 
compound was 10-fold more potent than the corresponding (3R,4’R,6S) isomer. 
 
Scheme 1.1 Evolution of nonpeptidic DKP OC antagonist through SAR studies 
Initial SAR also highlighted the importance of preserving the DKP N-H and carbonyl C-2 
unaltered to maximise potency. The aryl group on the N-4-glyciamide could not be replaced 
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by non-aromatic cycles without weakening the potency. By contrast, para- and meta-
substitutions on this aromatic ring, with a variety of different groups, enhanced it. Alkylation 
of the glyciamide was also tolerated.17 These led to DKP 13 after optimisation of different 
pharmacokinetics (PK) properties. Oral exposure, selectivity toward the closely related 
vasopressin receptors and safety profile improved significantly. Potency, compared to 
atosiban, was over 60 fold superior in vitro at the human OC receptor and comparable in 
rats.18  
 
 
Table 1.1 Potency values for SAR of nonpeptidic DKP OC antagonist 
However, solubility was poor and further transformations were required. Increasing the 
polarity of both the amide and the aryl substituents did improve solubility albeit with a 
corresponding worsening of the PK profile. Maintaining the good PK properties of 13 while 
increasing its solubility was achieved by changing the aryl group for a more polar heterocycle, 
a 2-methyl-1,3-oxazol. Final tuning included a morpholine amide substituent and a different 
branching pattern in the C-3 position, which gave rise to DKP 14, so called retosiban. Despite 
displaying similar potency levels to DKP 13, solubility, selectivity over vasopressin receptors 
and safety profiles were significantly improved. However, poor solubility still posed a 
significant barrier to overcome and further changes had to be made. Substituting the oxazole 
by a 2,6-dimethyl-3-pyridyl ring lead to DKP 15, epelsiban, which not only had the best 
solubility in the series but also displayed an excellent PK profile and selectivity. Newly 
DKP OC antagonist 11 12 13 14 15 
Potency (pKi) 6.5 8.4 9.2 9.2 9.9 
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discovered roles of OC antagonist, such as sexual dysfunction or prevention of benign 
prostate hyperplasia, have motivated further studies and modifications of this drug molecule.19  
The optimisation of aplaviroc also represents an excellent hit-to-lead development example. 
This drug is an intended antagonist of the CCR5 chemokine receptor for inhibiting the entry 
of HIV-1, constituting another approach to the treatment of AIDS.20 Spiro-DKP scaffold 16 
was identified as a lead compound using a combinatorial chemistry approach. This readily 
available template can be modified in three positions and stereochemistry can be introduced in 
one of them (Scheme 1.2).  
Initial SAR studies suggested the R1 position to be a para-functionalised benzyl for maximum 
activity. An n-alkyl chain was preferred at R2, an unbranched 4 carbon chain being optimal 
while a cyclohexamethyl or an isobutyl was the chosen substituent at R3, leading to the first 
bioactive DKPs 17, 18 and 19. 
This generation showed nanomolar activity, high antiviral in vitro potency and high affinity 
for CCR5 compared to related receptors. However, the PK profile was far from optimal, 
having a high clearance rate in rats and poor solubility.20 These issues were addressed by 
either adding a para electron-withdrawing substituent to the ether biphenyl chain, such as the 
acid moiety in 20, or asymmetrically hydroxylating the R3 side chain to give spiro-DKP 21. 
Antiviral 20 has an improved potency compared to 19 (IC50 = 13 nM to 28 nM), whilst 
significantly overcoming the PK downsides. Oral exposure, bioavailability and solubility 
were notably improved.21 Compound 19 was also modified to give the (3R, 1ʹR) hydroxylated 
adduct 21 with the aim of improving the antagonist activity against the CCR5 receptor. Not 
only was 21 more potent than DKP 19, but also more selective and soluble. Combining this 
configuration with the improved PK properties of lead 20 was expected to yield the optimal 
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CCR5 antagonist. Spiro-DKP 22, or Aplaviroc, did show potent activity against an array of 
HIV-1 strains, with excellent selectivity for CCR5 while maintaining a good PK profile.22 
Despite being a suitable HIV-1 antiviral treatment, a small percentage of the patients 
contracted hepatitis during phase III clinical trial and, therefore, the trials were halted.  
 
Scheme 1.2 Evolution of spiro-DKP 16 towards the final clinical drug 22 
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Further examples can be identified where medicinal chemists have employed DKPs as the 
central core to design drugs for different applications such as cancer inhibitors, antifungal, 
antibiotic or anxiolytic agents. In addition, DKPs are also used as a template for the 
preparation of a small range of privileged heterocycles, such as decorated piperazines, 
through the manipulation of the DKP subunit in the pharmaceutical industry.23 The excellent 
properties of DKPs will surely be found suitable in the development of future drug discovery 
projects. However, as it will be outlined, the stereochemistry displayed around the DKP core 
is generally introduced by means of the chiral natural and non-natural amino acids 
constituting the central scaffold prior to the formation of the heterocycle. 
 
1.2.2  Peptidomimetics 
Embedding two amino acids in a closed heterocycle allows building constrained peptide 
analogues of the related linear sequence whilst protecting the amino acids from possible 
transformations the linear strand would suffer. Bioactive properties are mimicked by 
displaying the appropriate residues in the same orientation as the corresponding polypeptidic 
secondary structure. The activities DKP derivatives can mimic range from hormonal 
regulation to opioid antagonists among others.24 
 
1.2.3  Bioactive Natural 2,5-Diketopiperazines  
The DKP motif has been identified in numerous isolated natural products. Their distinctive 
framework, often incorporated into complex structures, has attracted researchers’ attention, 
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not only for the challenge of accomplishing the corresponding total syntheses but also for the 
intriguing and diverse biological activities these compounds display. Thus, the scientific 
community has relentlessly pursued more facile and efficient syntheses or biosyntheses to 
access these DKPs and exploit their medicinal potential. 
It was noted in the 1970s and onwards that even the simplest DKP could show interesting 
bioactive properties. Several studies led to the confirmation that four unsymmetrical DKPs, 
cyclo[His-Pro],25 cyclo[Leu-Gly],26 cyclo[Tyr-Arg],27 and cyclo[Asp-Pro],28 exhibited varied 
biological activities in mammals. Later, an increasing number of natural products were 
discovered with DKP embedded in their structures and structural complexity ranging from 
symmetrical cyclic peptides, such as fellutanine A 23, to highly functionalised and decorated 
scaffolds such as okaramine O 24 or dimers such as ditryptophenaline 25 (Figure 1.4). 
 
Figure 1.4 Complex DKP structures 
Various classes have been categorised depending on their DKP amino acid constituents and 
numerous families have been reported based on common framework substituents and 
functionalities. Among all, the cyclo[L-Trp-L-Pro] derivatives are a prevalent class of 
compounds with dauntingly complex structures and promising biological properties. The 
recurrence of this scaffold can be understood as due to both the predisposition of the proline 
amino acid about the tertiary amide bond to adopt a cis-conformation and, thus, facilitating 
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the formation of a DKP, and the high nucleophilicity of the indole heterocycle and the vast 
number of transformations this ring can undergo. Further functionalization often involves the 
insertion of isoprenyl (dimethylallyl) chains and different modes of cyclisation towards the 
indole ring. 
 
Figure 1.5 Examples of cyclo[L-Trp-L-Pro] derived natural products 
The bioactive molecules in Figure 1.5 are excellent examples of the diversity and framework 
complexity these scaffolds can display. This isomeric evolution starts from the annulation of 
the isoprenyl chain in tryprostatin A (26) to the DKP amide nitrogen to form the polycyclic 
derivative 27, fumitremorgin C. The formation of the spiro moiety, with concomitant 
oxidation of the indole, represent the highest degree of specialization in this family of 
compounds rendering extremely intricate molecular architectures, such as spirotryprostatin A 
(28), that exhibit promising biological properties. Among others, tryprostatin A and 
fumitremorgin C deactivate the multidrug resistance protein (BCRP) responsible for the 
resistance to chemotherapeutics in breast cancer treatments,29 whilst tryprostatin A and 
spirotryprostatin A show cell cycle inhibitory activities at the MAP2, blocking microtubule 
assembly, and the G2/M phase respectively.30 Owing to the combination of powerful 
biological properties with their fascinating framework, numerous research groups have 
devoted considerable efforts to achieve their syntheses.31 
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1.2.4  Bioactive Bridged 2,5-Diketopiperazines  
Bicyclic DKPs are an important and extensive class of compounds that can be divided based 
on the nature of the bridge across the DKP subunit, either a carbon backbone or a sulfur one. 
A prevalent group of naturally occurring bicyclic DKPs are the cyclo[L-Trp-L-Pro] with a 
bicyclo[2.2.2]diazaoctane core embedded within the structure. In addition, they also have at 
least one isoprenyl chain present forming elaborated ring systems.Two groups can be clearly 
distinguished, simply by categorising the nature of their ring architecture, whether it is a spiro 
or a fused system. The spiro group is formed of alkaloids such as brevianamide A and B, 
sclerotamide, versicolamides or paraherquamides while notoamides, aspergamides, 
avrainvillamide or stephacidin are members of the fused group (Figure 1.6). 
These complex molecules, exhibiting intriguing biological properties such as insecticidal, 
antitumor, anthelmintic, or antibacterial,32 have represented compelling targets and numerous 
different approaches have resulted in several total syntheses.33 
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Figure 1.6 Members of the bicyclo[2.2.2]diazaoctane family 
Also noteworthy is the antibacterial agent bicyclomycin 40, whose molecular structure, 
relative and absolute stereochemistry were elucidated employing 1H, 13C NMR techniques 
and X-ray crystal diffraction analysis.34 Isolated from Streptomyces sapporonensis35 and 
Streptomyces aizunensis,36 this unique bicyclic DKP is specifically active against a wide array 
of Gram-negative bacteria by inhibiting the RNA transcription terminator factor rho.37 This 
useful characteristic combined with its efficient production from fermentation broth and its 
low toxicity have helped to market this antibiotic, commonly known as bicozamycin, as a 
nonspecific diarrhoea treatment in humans and a treatment for bacterial diarrhoea in calves 
and pigs.38 
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Scheme 1.3 Biosynthesis of bicyclomycin 
The intricate bicyclic architecture of bicyclomycin has motivated great efforts in the scientific 
community. Biosynthetically, bicyclomycin has been shown to originate from the 
condensation of L-leucine 35 and L-isoleucine 36 to form DKP 37 as shown in Scheme 1.3 
which, after sequential oxidations and dehydrogenations, results in bicyclomycin (40).39 
Several groups attempted the total synthesis after the structure determination, leading to 
several synthetic studies of the bicyclomycin core and, eventually, the racemate synthesis by 
Goto40 in 1983 and the enantiopure synthesis by Williams in 1984.41 
Other members of the bridged DKP family are the epipolythiodioxopiperazines (ETPs), 
natural compounds with a disulfur bridge across the DKP ring. Scaffold 42 in Figure 1.7 
represents the common architectural feature of ETPs. Both the number of sulfur atoms and the 
stereochemistry of the sulfur bridge vary between natural products. Consequently, two 
distinctive types of structure can be generated, gliotoxin and glionitrin A being two 
representative members of them.  
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Figure 1.7 ETP containing DKPs 
ETPs are secondary metabolites present in fungi and lichens exhibiting a wide array of 
promising properties. Predominantly, they are known for their cytotoxic effect on tumour cell 
lines. However, their associated high toxicity has precluded them from usage in clinical trials. 
The sulfur bridge is directly linked with this high toxicity, as a result of: (1) inactivating 
protein activity through the formation of mixed disulfide bonds with sulfur dependent 
enzymes and (2) producing superoxide ions and hydroxyl radicals during redox cycles in 
cells.42 
Apart from the already known chemotherapeutic properties of gliotoxin 41, the most common 
ETP also exhibits selective immunosuppressive properties and induces apoptosis in certain 
cells, particularly in the immune system, by breaking DNA strands.43 Its extensive usage 
prompted a flurry of synthetic advances that culminated in the enantioselective total synthesis 
by Kishi.44 
Sulfur derived DKPs also form open ring systems as metabolites in the same fungi species. 
The absence of the polysulfur bridge, and its associated in vivo side reactions, is the reason for 
the greatly reduced toxicity exhibited in the bisdethiodi(methylthio)DKP derivatives.42c 
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1.2.5 Synthesis and Transformations 
DKPs can be synthesised via two distinctive methods: (1) amide bond formation, either 
sequential, by cyclisation of a dipeptide, or direct condensation of two amino acids, or (2) N-
alkylation. The most common and extensively used strategy, the amide coupling, has proven 
effective under a varied range of conditions (Scheme 1.4). 
 
Scheme 1.4 DKP formation via amide coupling 
Either acid catalysis, often coupled with high temperatures,45 or basic media,46 although it has 
caused racemisation of the DKP product on selected cases, have been found optimal in the 
synthesis of DKPs. Thermal methods have also been employed to effect this key amide bond 
formation although microwave assisted cyclisation in aqueous media has recently substituted 
this approach in light of its simplicity and environmentally friendly characteristics.47 DKPs 
embedded in the structure of many natural products have been synthesised through this 
approach, e.g. Williams and co-workers formation of the DKP core as a 1:1 mixture of 
epimers (47 and 48) in the synthesis of versicolamide B (Scheme 1.5).48  
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Scheme 1.5 Formation of DKP in the synthesis of versicolamide B 
The second strategy for the synthesis of DKPs takes advantage of the nucleophilic properties 
of the nitrogen to cyclise onto a range of different electrophiles such as alkyl halides,49 
carbonyls50 or Michael acceptors (Scheme 1.6).51 
 
Scheme 1.6 DKP synthesis via alkylation 
Either method, under the appropriate reaction conditions, has been demonstrated to deliver 
enantiomerically pure DKPs. In fact, this is generally the chosen methodology to access non-
natural chiral DKPs, as the ones used in the synthesis of Epelsiban or Aplaviroc.20,52 
Although many transformations around the DKP core have been reported over the years and a 
vast number of enantioselective methods are currently available, no asymmetric strategies 
have been described in the literature to date. Therefore, the main aim of this project was to 
expand and build upon the existing methodology for substituting the DKP ring 
asymmetrically so a comprehensive review of previous literature was mandatory. 
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As previously mentioned, DKPs are cyclic dipeptides and hence, they will present usual 
amide reactivity. Enolate chemistry can be exploited at both the C-3 and C-6 positions with a 
variety of electrophiles, amidic nitrogens can undergo alkylation and related transformations, 
and carbonyls can, under specific conditions, be subjected to nucleophilic reactions such as 
reductions (Figure 1.8). 
 
Figure 1.8 General DKP transformations 
Using enantioselective methods, prochiral DKP 51 could be conveniently converted into 
chiral DKP 52. However, such methodology is not available to date. 
Nonetheless, various diastereoselective methods have been published for the DKP core. 
Davies and co-workers demonstrated that the valine side chain in cyclo[Val-Gly] 56 could be 
used as a chiral auxiliary. DKP 56 can subsequently undergo highly diastereoselective trans-
alkylations (Scheme 1.7).53 
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Scheme 1.7 Diastereoselective alkylation of 56 
Both bulky protecting groups on the amidic nitrogens (especially PMB) and the minimisation 
of 1,2-torsional strain in the transition state of the alkylation, which sterically protects the si 
face by the C-3 substituent, were proposed by Davies to play an important role in the 
diastereomeric outcome of the reaction (Figure 1.9).53  
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Figure 1.9 Conformation and transition state involved in the trans-alkylation of DKPs  
It was later discovered that any alkyl group on the nitrogen would induce the trans-alkylation 
by minimisation of the torsional strain with the isopropyl chain.54 Outstanding diastereomeric 
ratios were also observed when using a racemic electrophilic source. The DKP enolate was 
also capable of discriminating between the enantiomers of the electrophile to afford trans 
alkylated products 59 and 60 in high de (up to 97.5:2.5, Scheme 1.8).55  
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Scheme 1.8 Diastereoselective alkylation of 56 with racemic electrophiles 
Oxidative conditions to remove the protecting groups followed by acidic treatments were used 
to unveil the constituent amino acids of the DKPs in high enantiomeric ratio (Scheme 1.9). 
 
Scheme 1.9 Unveiling the chiral aminoacids 
In a similar fashion, Simpkins and co-workers used this concept to synthesise a collection of 
trans-alkylated DKPs 65 from simple PMB-protected glycine anhydride 64. Using two 
equivalents of the lithium base and subsequent quench with an excess of alkyl halide 
furnished the desired trans-dialkylated DKPs (Scheme 1.10).56 
 
Scheme 1.10 Trans-alkylation of PMB-protected glycine anhydride 
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Further alkylation of racemic trans-DKPs 65, albeit problematic with standard lithium 
bases,57 did afford the expected product 67 as a single diastereoisomer with the less 
aggregated base 66 (Scheme 1.11). As Davies predicted,54 the transition state of both the trans 
and cis-DKP in this reaction were the same, due to disposition towards epimerisation of 65 to 
minimise torsional strains. Therefore, DKP 67 was the only isolated product when either the 
cis or trans starting material was employed. 
 
Scheme 1.11 Alkylation of trans-DKP with base 66 
Attemps to conduct this reaction asymmetrically, using chiral lithium amides, only showed 
very low levels of enantiomeric excess. Synthesising dialkylated-DKPs 65 from 
corresponding chiral amino acids afforded enantiomerically pure product 67. This trend was 
consistent with unsymmetrical proline DKPs 68 and different electrophiles were effectively 
added into the proline side of the DKP yielding the fully-substituted carbon adducts as single 
diastereoisomers 69 (Scheme 1.12). 
 
Scheme 1.12 Fully-substituted carbon DKPs via alkylation 
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This report discussed the possibility of complementary conformational arrangements during 
the alkylation step. Small groups such as R = Me, did not seem to pose enough steric bulk to 
direct selective alkylation only due to minimisation of torsional strains in the pseudo-axial 
conformation (70). Hence, other factors might play a key role to explain the observed 
diastereoselectivity. In fact, stereoelectronic effects have been found to direct facial 
alkylations on various lactam enolates. The alkylation has been shown to be more favoured 
when the lone pair of electrons on the pyramidilised nitrogen was in anti configuration, as 
supported by ab initio calculations.58 Hence, an additional transition state (71) was proposed 
(Figure 1.10). 
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Figure 1.10 Possible transition states involved in the alkylation of DKPs 68 
Nevertheless, these selective alkylations relied on the shape of the DKP and the inherent 
stereochemistry of the rest of the substituents for the observed selectivity.  
Various other attempts to develop stereocontrolled methods and access enantiomerically pure 
DKPs have been described, such as using chiral inductors on nitrogen,59 but no truly catalytic 
method has been described to date. Therefore, the aim for this project was to develop a novel, 
rapid and stereocontrolled route to access chiral DKPs using recently developed chiral 
organocatalysts.  
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1.3.  Triketopiperazines 
A formal oxidation in one of the methylene positions of a cyclo[Gly-Gly] results in the 
formation of a 2,3,5-triketopipeazine, TKP hereafter (72, Figure 1.11). Although we were 
mainly focused on DKP 3, the TKP can be regarded as a heterocycle were all three examples 
of diketopiperazines are incorporated in the same system. 
 
Figure 1.11 TKP structure 
Its core, compared to the DKP, can be theoretically accessed via a condensation of any amino 
amide with oxalyl transfer reagents such as oxalyl chloride or dialkoxy oxalates. Owing to 
this modification, properties and reactivity significantly change. 
This heterocycle is far less common than the DKP and is only present in a handful of natural 
products (see Figure 1.12). However, it can complement the already known reactions DKP 
can undergo and, hence, expand the knowledge of these small heterocycles. In addition, 
transformations to convert the TKP core into the more common DKP one can be investigated. 
The first isolated TKP dates back to 1917, when Bornwater reported the α-benzyl-TKP after a 
reaction of racemic phenylalanine amide with oxalyl chloride.60 The same TKP was obtained 
by Bergmann and co-workers in 1927 in a seemingly long and inefficient process involving 
amide couplings and ozonolysis.61 Both results proved difficult to reproduce and it was not 
until 1953 when Williams and co-workers reported the first synthesis of a TKP structure from 
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a variation of the barbituric acid skeleton as a result of the effort to find new drugs with 
related scaffolds. The reaction was performed with different free amino amides and an 
equimolar amount of ethyl oxalate 74 in sodium methoxide and refluxing ethanol. The desired 
product was only isolated in moderate yield from the sodium TKP salt.62 In 2001 Bailey et al. 
used the same procedure with an enantiomerically pure amino amide 73.63 Given the reaction 
conditions, the expected racemisation occurred and product 75 was afforded in a comparable 
yield (Scheme 1.13). 
 
Scheme 1.13 Formation of TKP 
Bailey introduced the first strand of research into TKP manipulation and functionalisation. 
Nitrogen and enolate alkylations with different halide derivatives were achieved.63a  
Makino and co-workers reported the first TKP synthesis on solid support using oxalyl 
diimidazole 77 as a mild cyclising agent.64 His group accomplished the synthesis of a wide 
variety of TKPs using enantiomerically pure amino acids as the starting material. Although 
the mild reaction conditions should allow the products to retain their inherent chirality, as 
opposed to Williams’s and Bailey’s TKP syntheses, they did not comment on it in the report. 
The necessity of alkylating the terminal nitrogen on the amino acid in order to fully 
accomplish the cyclised product in good yield was highlighted. Hindered and cyclic amino 
amide precursors underwent the cyclisation successfully and the resulting TKPs were afforded 
in high yields (Table 1.2).  
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Entry R1 Purity (%) Yield 
78a Bn 89 86 
78b Ph 94 90 
78c iBu 94 81 
78d iPr 87 74 
Table 1.2 Solid supported synthesis of several examples of TKPs 
 
1.3.1 Triketopiperazines in Nature 
In contrast to the ubiquity of the DKP architecture in nature, the TKP subunit is considerably 
less abundant. Only a small number have been isolated from fungal sources, usually 
coexisting with ETP and bisdethiodi(methylthio)DKP derived natural products (Figure 
1.12).65 
Both dethiosecoemestrin 79 and neoechinulin 80 were isolated from Emericella striata and 
Aspergillus amstelodami respectively. Its biological properties have not been extensively 
studied yet and no total syntheses have been reported to date.  
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Figure 1.12 TKP containing natural products 
On the other hand, gliocladin C 81 has received more interest from the scientific community. 
Isolated from a strain of Gliocladium roseum by Yoshihide and Usani., together with 
gliocladin A and B, glioperazine, leptosin D and T988A, (+)-gliocladin C 81 is the only 
natural product possessing a TKP within its structure whose synthesis has been studied, 
mainly due to its high cytotoxicity against cultured P388 lymphocytic leukaemia cells.66 The 
first synthesis was published in 2007 by Overman et al.,67 and more elegant and direct total 
syntheses were accomplished by Stephenson, Movassagui and Overman groups independently 
soon after.68 Noteworthy was Overman’s 2011 synthesis as it represented the first example of 
the TKP subunit being synthesised under mild conditions in a non-solid-supported approach. 
While Stephenson and Movassagui introduced the necessary groups and functionalities to 
build the TKP within the molecule linearly, Overman and co-workers synthesised the TKP 
separately to include it at a late stage in the sequence in their convergent approach. The 
cyclisation of the protected amino amide 82 was performed under the same conditions Tsuji’s 
group used on solid support (Table 1.2, vide infra, and Scheme 1.14).68a 
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Scheme 1.14 Overman’s synthetic pathway towards TKP intermediate. 
Since this seminal work, Overman has used protected gliocladin C as a key intermediate to 
accomplish an array of ETP and bisdethiodi(methylthio)DKP derived natural products total 
syntheses, showcasing promising reactivity of the TKP framework.69 
 
1.4  Organocatalysis 
Catalysis is generally understood to be the addition of an external substance, often in a 
substoichiometric quantity, to a chemical reaction which increases the rate of the process by 
lowering the energy barrier of the transition state (activation energy), without affecting the 
overall standard Gibbs energy change. The catalyst is present in the entire reaction and does 
not get consumed with the reactants.70 Therefore, the term organocatalysis refers to the 
addition of an organic compound playing the catalyst’s role. 
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Although the first examples of organocatalysts date back to the 1970s, it was not until the 
early 2000s that the scientific community has fully appreciated organocatalysis as a powerful 
tool for the realisation of a wide variety of transformations. 
Effective, achiral catalysts, such as DMAP or piperazine in the Knoevenagel condensation, 
are widely known but organic molecules particularly excel in the realm of enantioselective 
catalysis.71 
 
1.4.1 Enantioselective Organocatalysis 
Nowadays organocatalysis is considered an equally important branch in the myriad of 
available enantioselective reactions, together with enzymatic catalysis and metal-based 
catalysis. Although metals have undeniable benefits, such as their enormous diversity and 
reactivity patterns achieved by tuning the ligands, they also have some clear disadvantages 
over organic catalysis that help us understand the explosion of interest and rapid growth of the 
field. Often, metal catalysts need to be kept under inert conditions, and metals tend to be toxic 
and are considerably more expensive. On the other hand, organocatalysis can be run under an 
oxygen atmosphere and does not need ultra-dried solvents or special experimental measures. 
The organic precursors, amino acids or natural products, are readily available as single 
enantiomers in large quantities, and so, easily and cheaply transformed into the active 
catalysts. Lastly, these organic molecules are generally non-toxic so research can be carried 
out in a safer environment and the risk of product contamination is greatly reduced. All these 
factors made this recently defined field very accessible and numerous research groups have 
quickly adopted it. This high interest helps to explain the exponential growth in the number of 
publications on the topic during the 2000s.72 Enantioselective organocatalytic methods have 
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proved robust and generally applicable and are a convenient approach for medicinal chemists 
to access enantiomerically enriched drugs, as in the synthesis of anticoagulant warfarin 88 
(Scheme 1.15).73 
 
Scheme 1.15 Organocatalysis applied to Medicinal Chemistry 
Retrospectively, it is surprising how this research area had been overlooked by scientists for 
so long given the advances in understanding the concepts and reaction profiles of enzymatic 
transformations in the last century. But it becomes clearer when analysing the first 
organocatalytic reports, the Hajos-Parrish transformation, in 1974 (Scheme 1.16).  
 
Scheme 1.16 Enantioselective aldol condensation using proline 
Even though the similarities of this enantioselective aldol transformation to a simplified 
biological system where proline acts as an enzyme were pointed out, they failed to underpin 
the critical concepts around this particular mode of action and hence, expand its 
applicability.74 These studies were considered singular and exceptional examples of 
intramolecular chemistry rather than a discrete part of a new research field, and their 
overarching benefits were not extrapolated or demonstrated in further reactions. 
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During the 1980s and 1990s chiral auxiliaries were the cutting-edge and almost unique 
method for introducing asymmetrically a variety of substitutions.75 This trend started to shift 
with the independent studies on organocatalysed epoxidations of alkenes by Yang, Shi and 
Denmark and their co-workers in 1996, using a combination of chiral ketones and oxone as an 
enantiomerically pure source of oxirane.76  
However, it was not until 2000, when MacMillan and co-workers developed the first 
enantioselective organocatalytic Diels-Alder reaction, that organocatalysis became a 
concept.77 In an effort to emulate Lewis acid catalysis, MacMillan suggested the use of 
secondary amines as a way of activating the LUMO of α,β-unsaturated aldehydes by forming 
the corresponding iminium cation, a very electron-deficient species, better suited to act as a 
dienophile. In addition, iminium cations are labile enough so as an equilibrium can be 
established with the aldehyde in aqueous solution, imitating Lewis-acid catalysts turnover. 
Lastly, using a chiral amine in this process would afford the enantioselective products. A 
range of aldehydes were used to successfully yield the corresponding bicyclic adducts, albeit 
in a mixture of endo:exo products (varying from 1:1 to 35:1). An example can be found in 
Scheme 1.17.  
 
Scheme 1.17 Enantioselective organocatalytic Diels-Alder reaction 
The importance of this work lied not only in the discovery of a novel and particular mode of 
activation for the Diels-Alder reaction, but also the recognition that analogous transformations 
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using this general activation strategy and effected by chiral organic molecules may be 
possible. 
Contemporaneously, Barbas, Lerner and List demonstrated the general applicability of the 
intramolecular aldol reaction developed by Hajos et al. almost 30 years before.78 Basing their 
studies on the mechanism of action of aldolases and aldolase antibodies, powerful catalysts 
able to resolve aldol products on gram scale through enamine intermediates in both intra and 
intermolecular transformations,79 they hypothesised proline should also be capable of 
performing the aldol reaction intermolecularly. Addition of acetone 97 to a DMSO solution of 
aldehyde 98 and 30 mol% of catalyst 90 yielded enantioenriched product 99, as shown in 
Scheme 1.18. 
 
Scheme 1.18 Enantioselective organocatalytic intermolecular aldol reaction 
The authors expressed their initial surprise with respect to the selectivity of the reaction and 
the absence of side products apart from dehydration. Different aryl aldehydes gave similar 
outcomes while isobutyraldehyde, gave the aldol product in excellent yield and ee (97% yield 
and 96% ee). However, more importantly, a metal-free stereocontrolled aldol condensation 
was proved to take place in the presence of a safe, cheap catalyst readily available in either 
enantiomeric form. Additionally, it was shown how proline can play a biomimetic role, via 
comparable mechanisms to those used by enzymes. Comprehending the underlying principles 
of the transformation allowed them to successfully predict the existence of novel and more 
selective catalysts and their use in a wide range of related reactions. 
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These two studies initiated a new era for organocatalysis. Improved and unique 
organocatalysts, as well as sometimes unexpected transformations, were reported with 
increasing frequency. The scientific community agreed on the identification of generic 
activation modes, elementary mechanism of catalyst activation, induction and reactivity, to 
categorise different enantioselective reactions sharing common reactive species (Figure 
1.13).80 
 
Figure 1.13 General enantioselective organocatalysis modes of activation 
Enamine catalysis (A): Originally discovered by Hajos’s and Eder’s groups simultaneously in 
the 1970s, it was not until 30 years later that the reaction mechanism was determined. The 
catalyst, typically proline, acts as a bifunctional catalyst forming the enamine of the 
corresponding carbonyl which interacts with the electrophilic partner electrostatically or by 
hydrogen bonds. The HOMO energy is increased so it is closer to the LUMO energy of the 
electrophile.81 
Iminium catalysis (B): Specifically designed as masked Lewis acid catalysis, this chiral 
catalysis, typically with imidazolidinone derivatives, relies on the formation of α,β-
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unsaturated iminium derivatives, with lower LUMO energies, to effect several 
transformations inherently related to Lewis acid catalysis.82 
Hydrogen-bonding catalysis (C): Although there were some early studies in the 1980s 
suggesting that hydrogen bonding between the organocatalyst and nucleophile in the 
transition state was responsible for promoting reactions,83 this mode of action was not 
completely accepted until Jacobsen’s and Corey’s research groups published their works on 
the Strecker reaction.84 This topic will be covered in depth in the next section.  
Phase transfer catalysis (D): Originally reported in 1984 and mechanistically established in 
1986, the first stereocontrolled version, alkylation of a glycine derivative, dates back to 
1989.85 The catalyst, typically a chiral quaternary ammonium salt, forms a unique ion pair 
with the deprotonated nucleophile, normally located at the interface constituted by 
organic/aqueous or solid phases, and diffuses into the organic media to undergo subsequent 
reaction (e.g. alkylation).86 
SOMO (single-electron occupied molecular orbital) (E) and counterion catalysis (F): These 
are novel methods, their modes of action have shown that new reaction pathways and hence, 
modes of action might be left to discover. In the SOMO catalysis, one-electron oxidation of a 
proline-enamine yields a highly reactive three π-electron radical which undergoes rapid 
trapping with a range of “SOMOphiles”-nucleophiles, such as allylsilanes or enolsilanes.87 On 
the other hand, electrostatic binding of chlorine with a thiourea catalyst forms a chiral 
counterion with the electrophile, strong enough to condition the approach of the nucleophile 
to a unique face of the stabilised cationic species.88 
NHC (G): Although the first examples of nitrogen heterocyclic carbene (NHC) date back to 
1943, when a thiazolium salt was discovered to promote the benzoin condensation,89 the 
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catalytic activity remained unclear until 1958,90 when the C-2 position of thiazoliums was 
postulated to hold a carbene. NHCs can be employed as ligands in organometallic chemistry 
as well as enantioselective organocatalysts when chiral functionalities decorate the 
framework. A variety of asymmetric transformations have been achieved including the 
benzoin condensation, Stetter reaction and several cycloadditions.91 
Organocatalysis is now regarded as a powerful method to construct organic bonds 
enantioselectively. Research groups have taken advantage of the recognised generic activation 
modes to develop novel reactions and more selective catalyst families that has helped to 
understand the field better. However, organocatalysis often complements rather than 
competes with metal-catalysis, as some fundamental transformations in modern synthetic 
chemistry, such as C-H activation or photoredox catalysis, are unlikely candidates for 
organocatalysis. In addition, new reports already show how these rather different 
methodologies can greatly benefit from each other chemical influence.92 
 
1.4.2 Hydrogen-Bonding Catalysis 
Generally, the aim of enantioselective organocatalysis is to complete the reaction between an 
electrophile and a nucleophile in a stereocontrolled manner. Thus, activation via a chiral acid 
or a chiral base can be conceived as plausible options to achieve this transformation. 
Historically, Lewis-acidic metals coupled with chiral ligands or chiral lithium amides were 
some of the most typical choices to promote such reactions and little was investigated about 
the possibility of using chiral organic bases instead.93 As aforementioned, organocatalysis was 
born as a way to address this underexplored field. Although early reports suggested that 
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hydrogen-bonds were playing a fundamental role in different reactions such as the 
asymmetric Michael addition of thiols to α,β-unsaturated cycloakenones, catalysed by 
cinchonidine 102, or the stereocontrolled cyanohydrin synthesis from benzaldehyde using 
DKP cyclo[L-Phe-L-His] 105 (Scheme 1.19), hydrogen bonding catalysis was not believed to 
establish strong enough interactions to direct a spatially biased approach.83,94  
 
 
Scheme 1.19 First asymmetric examples of hydrogen-bond catalysis 
A few years later a chiral version of the Strecker reaction was independently developed by 
Jacobsen’s and Corey’s groups, followed by Jacobsen’s β-amino acids synthesis (Scheme 
1.20), proving the hidden potential of this activation mode.84,95 
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Scheme 1.20 Jacobsen and Corey first hydrogen-bond methodology 
Furthermore, the previously mentioned modes of action were also proven to have key 
hydrogen-bond interactions for the reaction to successfully proceed. Regardless of the type of 
mechanism, the catalyst is often engaging in specific hydrogen bonds to arrange both reagents 
in a well-defined three-dimensional transition state before the stereocontrolled reaction 
happens. Proline, for instance, is not only involved in the formation of the enamine with the 
secondary amine but the acid is also establishing interactions with the electrophile via 
hydrogen bonding in the transition state prior to the reaction. The contribution of the 
hydrogen-bond is key to explain the facial selectivity of the newly formed carbon-carbon 
bond and to delocalise the charge increase in the transition state.78  
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In light of these results, novel bifunctional catalysts based on the proline structure and 
catalytic mode of action were developed with a wide variety of hydrogen donating 
components. Additionally, catalysis only based on hydrogen-donor interactions started to be 
considered viable for an array of transformations. Usually, a typical bifunctional hydrogen-
donor catalyst was proposed to display a single or dual acidic hydrogen-bond donor site 
surrounded by functionalities aimed at secondary interaction with the rest of the reactants, 
such as weakly basic or acidic moieties, necessary to trigger the desired reaction.96 The 
hydrogen-donor is typically a thiourea, phenols or guanidines, with pKas ranging from 14 to 
21, while the flanking sites are normally chiral Brønsted bases.97 With those characteristics 
taken into account, different catalysts have been found optimal for enantioselectively 
promoting transformations, e.g. aldol or Michael reaction, and the most distinctive 
transformations will be briefly discussed, based on the type of electrophiles. 
Carbonyl electrophiles 
After List, Lerner and Barbas published their studies on the proline catalysed aldol 
reactions,78 many research groups shifted their interests towards developing new proline-
based catalysts with increased enantio and diastereoselectivity. Despite the proline-catalysed 
reactivity scope having been expanded since this first example,81,98 and its clear advantages, 
i.e. enantiopure accessibility of both catalyst isomers,99 there were also undeniable 
disadvantages such as poor solubility in organic solvents or low selectivity. The hydrogen-
donor site was targeted for subsequent modifications and functionalities, such as acyl 
sulfonamide or tetrazole, replaced the original acid (Scheme1.21).100 
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Scheme 1.21 Enantioselective organocatalytic transformations using carbonyl electrophiles 
Reversible addition of non-hindered tertiary amines, such as DABCO, to electron-deficient 
α,β-unsaturated carbonyls results in the formation of a nucleophilic enolate capable of 
reacting with aldehydes. The versatility of the formed α-methylene-β-hydroxycarbonyl 
compounds (as in Scheme 1.18) is showcased in the myriad of manipulations these substrates 
can undergo or the natural products that can be accessed. With the advent of enantioselective 
organocatalysis this process, known as the Baylis-Hillman reaction, became the focus of 
considerable attention and asymmetric variants were developed.101 For instance, development 
of catalysts based on the axially chiral scaffold of DABN, such as thiourea 120, has shown 
remarkable results (Scheme 1.22).102  
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Scheme 1.22 Stereocontrolled Baylis-Hillman organocatalysed reaction 
Pro-nucleophile nitromethane can be enantioselectively added to carbonyl groups in a process 
known as the nitroaldol or Henry reaction. Bifunctional cinchona alkaloid catalyst 123 
induces high levels of asymmetry delivering β-hydroxynitro compounds (Scheme 1.23).103 
Cyanation of carbonyls can be understood as an analogous reaction, as shown in Scheme 1.19 
(vide supra). 
 
Scheme 1.23 Enantioselective nitroaldol reaction 
Imine electrophiles 
Imines are arguably better electrophiles than carbonyls, owing to their markedly directional 
hydrogen bond acceptor characteristics. Thus, extensive research has been conducted in this 
area and a broad range of applications have been reported. 
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Addition of an enolate, e.g. carbonyl, malonate or silyl enol ether, to the imine carbon centre, 
the Mannich reaction, is a widely employed method in organic synthesis. The stereocontrolled 
version has become a powerful way of accessing β-amino substituted carbon frameworks as in 
Scheme 1.24.104  
 
Scheme 1.24 Asymmetric Mannich examples using hydrogen-bond organocatalysis 
Nucleophiles are not just limited to carbonyl enolates, as asymmetric versions of the nitro-
Mannich,105 aza-Baylis-Hillman,106 Strecker84 or aza-Friedel-Crafts107 have also been 
developed (Scheme 1.25). 
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Scheme 1.25 Selected transformations of imine electrophiles  
α,β-Unsaturated electrophiles 
Addition onto the electrophilic conjugated position of a α,β-unsaturated carbonyl adduct of 
soft nucleophiles constitutes a very important strategy to form new carbon-carbon and carbon-
heteroatom bonds. Enantioselective versions of this reaction have been largely explored and 
cinchona alkaloid derived catalysts have played a prevalent role, demonstrating in numerous 
cases that their bifunctionality is perfectly suited for performing this particular transformation. 
An extended discussion in Section 1.4.3 will follow.  
Since the addition of thiol 101 to cyclohexenone 100 catalysed by cinchonidine 102, first 
example of an asymmetric Michael addition,83 a wide range of Michael acceptors have been 
reported in the literature, such as α,β-unsaturated aldehydes,108 ketones,109 nitroethylenes110 or 
maleimides111 among others. Some examples are depicted in Scheme 1.26. 
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Scheme 1.26 Enantioselective Michael additions using hydrogen-donor organocatalysis 
Heteroatomic electrophiles 
Heteroatoms can be added to a nucleophilic position in a versatile manner using heteroatomic 
electrophilic sources. Only scarce examples of stereocontrolled reactions with electrophilic 
sources are available, compared to the volume of published literature around the 
enantioselective formation of carbon-carbon bonds using organocatalysis. However, a few 
specific substrates are able to provide electrophilic heteroatoms and oxygenations,112 
aminations,113 halogenations114 or oxyamination115 were achieved using chiral hydrogen-
donor Brønsted bases (Scheme 1.27). 
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Scheme 1.27 Stereocontrolled reactions employing heteroatomic electrophiles 
All these catalysts fulfilled the prerequisite aforementioned stating that next to the hydrogen-
donor sites there are always flanking functionalities acting as secondary activators helping to 
prearrange the reagents spatially and electronically to facilitate the enantioselective formation 
of the new bonds. 
 
1.4.3 The Cinchona Alkaloid Family 
Endocyclic basic nitrogen containing molecules isolated from natural sources, excluding 
amino acids and their derivatives, are commonly known as alkaloids.70 This extensive group 
of molecules are all extracted from a variety of animals, plants, fungi or bacteria. The effects 
these molecules exhibit range from medical (e.g. anesthetic, antibacterial or anticancer) to 
stimulant (i.e. psychoactive substances) and even toxic for the human body. Due to the 
absence of structural resemblance among most alkaloids there is not a uniform classification 
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of them. However, different families have been categorised based on carbon skeleton 
similarities or common natural source.  
The cinchona family is one of the most prominent and best known alkaloid groups owing to 
their medicinal properties. Quinine and quinidine, the two most abundant family members, 
with chemical structures constituting a pseudo-enantiomeric pair, have been used for more 
than 300 years thanks to their respective antimalarial and antiarrhythmic activity (Figure 
1.14).116  
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Figure 1.14 Natural members of the cinchona alkaloid family 
These alkaloids, together with the myriad of other compounds belonging to this family are 
isolated from the bark of the cinchona trees, of the Rubiaceae family, native to the western 
part of Amazonas. Despite their formal total syntheses being achieved in 1945 by Woodward 
and Doering,117 and more updated total synthesis being published during the last decade,118 
quinine and quinidine are still extracted from the cinchona bark for commercial use. Apart 
from their therapeutic properties, the cinchona alkaloids have other industrial applications, 
encompassing the addition of quinine to carbonated water, also known as tonic water, or the 
use of cinchonine and cinchonidine crystallisation properties for the resolution of racemic 
mixtures via their diastereomeric salts.119 In the last two decades the cinchona alkaloid family 
has gained considerable interest across the scientific community due to its chiral inductive 
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properties, as shown in the extensive literature published on the matter, particularly marked 
from their use within the asymmetric dihydroxylation catalyst.120  
Based on the pioneering advances by Bredig and Fiske, who reported the first reaction 
catalysed by quinine in 1912,121 Wynberg and co-workers studied several transformations 
where cinchona alkaloids yielded stereocontrolled products.83,122 The catalysts were 
showcasing bifunctional activating properties, making them exceptional candidates for 
simultaneously activating the nucleophile and the electrophile and, hence, capable of 
catalysing a wide range of 1,2 and 1,4-additions of nucleophiles. In addition, owing to their 
constrained scaffolds enantioselectivity could be induced in the reaction products (Scheme 
1.28).  
 
Scheme 1.28 Early examples of cinchona alkaloid catalysis 
In light of these results, the mechanism of action of cinchona alkaloid catalysed reactions was 
studied in an attempt to comprehend the close relationship between the alkaloid conformation 
in the transition state and the induced asymmetry of the reaction products. Initial analysis of 
the alkaloids reveals that the two rigid subunits are connected within the scaffold by a flexible 
carbon chain. Torsion of the carbon-carbon bonds involved, the C8-C9 and C4-C9 (Figure 
1.14), defines the spatial arrangement between the subunits. Molecular mechanics 
optimisation carried out by Wynberg and co-workers led to the identification of four 
minimum energy conformations for the cinchona alkaloid family.123 They have been 
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designated based on the different torsional possibilities of the aforementioned carbon-carbon 
bonds as app-open, app-closed, gauche-open, and gauche-closed (Figure 1.15).124 App and 
gauche refers to the torsion angle around the C8-C9 and hence, the relative orientation of H8 
and H9, being anti in the app confirmation and syn in the gauche. The open and closed 
conformers are related to the C4-C9 rotation and how the quinuclidine bicycle relates to the 
quinoline heterocycle. The more compact disposition of both subunits corresponds to the 
closed conformer whereas the open conformer has both substituents far from each other.  
 
Figure 1.15 Minimum energy conformers of quinidine related cinchona alkaloids members 
The substitution pattern on the framework, solvent or additives are all known to alter the 
preferred conformation of each specific catalyst in solution. nOe experiments were conducted 
in various solvents with differently functionalised catalysts to determine the solvent 
dependency of the conformers. For instance, dihydroquinidine (R = variable, Rʹ = OMe and 
R′′ = Et; DHQD) was chosen to conduct the first complete study for this family.123b When 
bulky substituents (R = p-ClBz, CONMe2 or Ac) were placed on O9 the observed 
conformation was app-closed, as inferred from the nOe correlations between H9 and some 
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aromatic and quinuclidine protons simultaneously. This was additionally supported by 
calculations of dihedral angles based on an empirical modification of the Karplus equation.125 
Further analysis using X-Ray diffraction confirmed that these molecules display a closed 
conformation in the solid state. On the contrary, the natural adduct and methyl ether adduct (R 
= H or Me) had different nOe correlations and coupling constants from the previous 
examples, suggesting that an open (gauche-open) conformation was preferred. 
Concurrently, NMR spectra in a range of different solvents were measured from a 
representative member of each class. While closed conformer (R = p-ClBz) remained 
practically unchanged, only showing some degree of opening in toluene-d8, open conformer 
(R = Me) drastically changed its conformation when measured in dichloromethane-d2 into the 
closed one. Distinctive nOe correlations and couplings confirmed this change.  
Furthermore, additional experiments demonstrated that substrate interaction, i.e. acidic media, 
was responsible for major disruption in the ground state conformations in all cases. When the 
cinchona alkaloids are used as chiral bases, the basic moiety in the catalyst, the quinuclidine 
tertiary nitrogen, accepts the proton forming an ion pair with the deprotonated substrate. In 
the present case, the 1H NMR spectrum of DHQD (R = p-ClBz) in trifluoroacetic acid-d1 
revealed that all nearby protons suffered from extensive line broadening coupled with a 
transition from the coupling constants typical for the closed conformer to those typical for the 
open conformer. 
Similar studies have been subsequently conducted on other cinchona alkaloids members, such 
as quinine123a or cinchonidine derivatives,126 showing that, regardless of depicting variable 
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conformations in solution depending on the nature of the solvent or substitution pattern, they 
all adopt an open-gauche disposition while interacting with acidic substrates. 
However, only mediocre levels of asymmetric induction were obtained across a wide range of 
transformation and the natural members of the cinchona alkaloids were unable to consistently 
deliver outstanding induced enantioselectivity.127 Only the previously shown examples by 
Wynberg and co-workers were reported to give good to excellent enantioselective results. 
Wynberg suggested that substitution of the C-9 hydroxyl position would negatively influence 
the asymmetric reaction as the bifunctional properties and thus, the ability to interact with 
both nucleophile and electrophile and prearrange them before the new bond is formed, would 
be lost. The versatility of the catalysts to promote further transformations enantioselectively 
could not be demonstrated due to the difficulties encountered during the catalyst development 
stage during the 1990s. Simultaneously, the cinchona alkaloids gained tremendous popularity 
owing to the Sharpless dihydroxylation reaction and similar catalysts also started being used 
in desymmetrisation and kinetic resolution processes.128 It was not until Li Deng published his 
first results on the Michael reaction of malonates to nitroalkenes that a functionalised catalyst 
was able to yield virtually perfect stereocontrolled results with both catalyst enantiomers 
(Scheme 1.29). 110a 
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Scheme 1.29 Deng’s first reported Michael addition with modified catalysts 
Key to the catalyst success was demethylating the aromatic ether to unveil a second 
electrophilic activator in the catalyst. Not only is a phenolic hydroxyl group more acidic than 
an aliphatic one, and therefore more prone to establish an H-bond with electrophiles in the 
transition state, but it also allows functionalisation of the C9 hydroxyl group to force the 
catalyst to adopt a more reactive conformation. This conclusion was reinforced by 
consecutive reports from Deng’s group, where a bulkier ether substituent was adopted to 
enhance the open-gauche conformer of the catalyst in the transition state. This change made 
the catalyst able to deliver outstanding results for increasingly complex substrates.108,129 
Based on Deng’s findings, the members of the cinchona alkaloid family were subjected to 
major optimisation studies to appropriately suit a wide array of different enantio and 
diastereoselective transformations. Shortly afterwards, the concept of evolving the 
electrophilic interaction site on the cinchona alkaloid catalysts coalesced with the possibility 
of including a thiourea proton donor site, widely used by Jacobsen. The C9 thiourea-
substituted cinchona alkaloids were simultaneously reported by the Soόs, Connon and Dixon 
groups to perform Michael additions with nitro alkenes 159 and chalcones 162 respectively 
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(Scheme 1.30).130 As part of the synthetic route to afford the desired catalysts, an inversion of 
the C9 stereochemistry occurs, via a Mitsunobu nucleophilic substitution of the hydroxyl for 
an azide. This non-natural diastereoisomer happened to be more reactive than its natural 
counterpart when in combination with the thiourea hydrogen donor functionality. 
Interestingly, and despite this change, Connon observed no inversion in the product 
configuration when compared to their natural starting alkaloids. 
 
Scheme 1.30 Thiourea based cinchona alkaloids catalysed Michael additions 
Mechanistically, the mode of action of this new catalytic approach has been thoroughly 
studied using computational calculations and Takemoto’s proposal regarding thiourea 
bifunctional catalysts was generally accepted. The induced asymmetry of these chiral 
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catalysts relies on the double interaction, electrophile with thiourea and deprotonated 
nucleophile with the protonated tertiary amine forming a ternary complex with an extensive 
hydrogen-bonding network.131 Pápai and co-workers set about to theoretically demonstrate 
this hypothesis by calculating minimum energy conformations for the catalyst, energy 
involved in the proton transfer and formation of the binary catalyst-nucleophile and the 
corresponding energies for the reaction transition state.  
 
Scheme 1.31 Theoretically proposed modes of action for a thiourea derived cinchona catalyst 
These computational mechanistic studies of the thiourea bifunctional catalysts revealed 
important features of the reaction pathway (Scheme 1.31): 
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• The catalyst has a preferred conformation but rotation can freely occur in solution. 
Substrate binding is often responsible for the structural organization of the catalyst in 
a more reactive arrangement.  
• Binding of any substrates to the thiourea is energetically favored for both the 
electrophile and the nucleophile. However the definitive reactive conformer is adopted 
after proton transfer of the nucleophile to the basic centre occurs. The nucleophile 
forms an ion pair with the catalysts (E) where the anionic enolate is stabilised via 
multiple hydrogen bonds involving all three positions.  
• Formation of the ternary complex can be accomplished via two distinctive pathways. 
Association of the electrophile either to the protonated quinuclidine (F) or to the 
thiourea (G) with concomitant displacement of the enolate. Both complexes have 
exothermic energies associated and an equivalent energy barrier to yield the 
stereogenic centre.  
• Attempts to calculate the energy of the transition states corresponding to the opposite 
product stereoisomer resulted in an unfavorable energy difference of about 2.5 
kcal/mol. In addition, the transition state with the adequate pre-arranged 
enantioselectivity has both substrates aligned in a more favorable staggered 
conformation to minimize steric interactions while the opposite enantiomer 
corresponding substrates in the transition state are nearly eclipsed, and thus, sterically 
biased. 
• Takemoto’s proposed mechanism is, therefore, viable both kinetically and 
thermodynamically, although imprecise about the first steps in the catalytic cycle. 
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New hydrogen donor moieties (e.g. squaramides) have been incorporated into the library of 
the cinchona alkaloid catalysts.132 Updated theoretical data is needed to explain the 
mechanistic phenomena for each of the reported asymmetric transformations.  
The cinchona alkaloid family is an excellent example of how the establishment of multiple, 
weak hydrogen donor interactions can be powerful enough not only to catalyse a simple 
electrophile-nucleophile reaction but also to spatially arrange the substrates for the new bond 
to be formed asymmetrically. These catalysts have become a landmark for any synthetic 
chemist and their wide applicability allows them to be reliably employed by those in industry 
similarly to any other enantioselective method known to date. Other aforementioned benefits, 
e.g. inexpensive or robust to atmospheric conditions, are extra reasons to choose this 
chemistry when possible. 
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Chapter Two 
 
Organocatalysis Chemistry of 2,5-Diketopiperazines 
 
2.1. Aims and Objectives 
Numerous total syntheses of natural products incorporating DKPs in their complex structures 
have been successfully accomplished.31,133 However, it is worth noting that the heterocyclic 
ring is often formed in a late stage step, with most of the final target functionalities in place, 
as previously seen in the total synthesis of versicolamide B by Williams and co-workers 
(Scheme 1.5).48 
As far as the total synthesis of bicyclo[2.2.2]diazaoctane natural products is concerned, the 
formation of the bridge DKP core during the final steps of the synthetic plan often represents 
the most challenging step in the process. The distinctive strategies adopted to access the alkyl 
bridge have become prominent landmarks of natural product total syntheses in recent times. 
The approaches used to trigger the bridge-closing step range from Diels-Alder reactions,134 
enolate couplings33b,135 to radical136 or cationic cascades.33d For instance, the bridge-forming 
reaction in Baran’s total synthesis of stephacidin A (Scheme 2.1) is an excellent example of 
how a methodology applied to a unique synthetic challenge prefaced the rebirth of an area of 
research. Firstly investigated in the 1970s,137 the access to 1,4-dicarbonyls by means of intra 
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and intermolecular enolate couplings, using a stoichiometric amount of oxidant (FeIII or 
CuII),138 was expanded owing to the interest motivated by this total synthesis. 
 
Scheme 2.1 Key bridge-closing step in stephacidin A synthesis 
In this particular example, DKP 165 could be envisioned from a hypothetical asymmetric 
Michael addition between methyl acrylate and the DKP enolate selectively formed at the 
proline side. However, this chemistry is not available to date and the stereochemistry at this 
quaternary centre is established by means of Seebach self-reproduction of chirality by α-
alkylation of (S)-proline in an early stage of the synthesis.139  
The limited examples on the manipulation of DKPs stereochemistry are the reason why the 
DKP core is usually formed once the correct substituents, with the desired stereochemistry, 
have already been introduced. Scarce literature can be found on this topic apart from the well-
established diastereoselective alkylation of DKPs using unsymmetrical PMB protected 
cyclo[Val-Gly] DKPs as a chiral auxiliary by Davies and co-workers,53-55 and the 
investigations into the synthesis of quaternary streogenic centres of DKPs by Simpkins and 
co-workers (Schemes 1.7-12).56 
As mentioned in the introduction, the initial proposal was aimed at developing a rapid, 
selective and stereocontrolled route to access DKPs, bearing key functionalities within their 
Chapter 2           Organocatalysis of 2,5-diketopiperazines  
 
57 
frameworks, by applying recently discovered enantioselective organocatalytic methods. We 
envisioned utilising protected cyclo[Gly-Gly] DKPs 167 as prochiral nucleophiles combined 
with alkaloid derivatives to promote asymmetric transformations with selected electrophiles. 
These enantiomerically enriched products would be subsequently subjected to bridge-closing 
conditions to access a wide range of non-natural bicyclic DKPs (Scheme 2.2). 
 
Scheme 2.2 Initial project sequence 
Aware of the lack of examples of asymmetric organocatalysed reactions using simple amides 
as nucleophiles, an additional activating group was concluded to be necessary to facilitate the 
asymmetric step, for example a formyl group as shown in DKP 168. Whilst the requirement 
for an extra carbonyl group may appear to be a disadvantage, this handle could become useful 
to add key functionalities in a diversity orientated approach for the final DKPs. The 
electrophilic partner for this reaction was chosen so as to allow subsequent treatment to 
transform chiral DKP 169 into a bridged product (170).  
Extensive literature can be found where a wide range of Michael acceptors have been 
employed in asymmetric Michael additions using countless different types of nucleophiles. 
Several alkaloid families have been reported to be excellent catalysts to effect asymmetric 
1,4-additions. As shown in the introduction, the cinchona alkaloid family is considered a 
privileged framework in this regard, consistently delivering good results in Michael additions. 
These catalysts have been quickly adopted by the scientific community due to their 
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effectiveness, their easy accessibility, cheapness and flexibility towards modification. In fact, 
selected cinchona alkaloid derivatives have afforded excellent levels of induced asymmetry 
using 1,3-dicarbonyl nucleophiles and Michael acceptors as shown in Scheme 2.3.108,129d 
 
Scheme 2.3 Examples of organocatalysis using Deng´s catalyst 
Arylation of the 9-hydroxyl position of quinidine with phenanthroline (PHN) followed by 
demethylation of the 6-aryl OMe yields the best performing catalyst 172 as demonstrated in 
many different examples in the literature.108,129b,129d As depicted in Scheme 2.3, highly 
reactive β-ketoesters were added into acrolein (136) or α-chloroacrylonitrile (175) in excellent 
yields, enantio and diastereomeric excesses. We wanted to apply the great potential of this 
chemistry in the context of DKP modification, which had scarcely been examined previously.  
Hence, the key step to determine the viability of this project was recognised to be the 
asymmetric Michael addition. Only a handful of examples of this transformation in which the 
1,3-dicarbonyl group featured an amide function had been reported in the literature. As shown 
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in Scheme 2.4, Dixon and co-workers subjected ethylcarboxylactam 178 to asymmetric 
Michael conditions using thiourea catalyst 179.140 Once this reaction was completed, imine 
181 was added to the reaction mixture and underwent a nitro-Mannich/lactamisation tandem 
sequence to furnish polycycle 182 in very good ee. This strategy was used in the total 
synthesis of (−)-nakadomarin A to fix, in one step, two out of the four stereogenic centres of 
the final target.141 
 
Scheme 2.4 First enantioselective β-esterlactam example 
This cascade was the first example where an amide, as part of a 1,3-dicarbonyl, was employed 
for an asymmetric Michael addition using a cinchona alkaloid derived catalyst.  
Similarly, the 1,3-ketoamido system 183 has recently been demonstrated to effectively 
undergo Michael additions using squaramide derived cinchona alkaloid 184 as the 
organocatalyst (Scheme 2.5). Interestingly, the presence of an amide as part of the 
nucleophilic partner seemed to suppress the undesirable bias towards racemisation via 
epimerisation of the 1,3-acidic proton at one of the newly created stereogenic centres in 185, 
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as opposed to the β-ketoester case.142 The increased acidity of the corresponding β-ketoester, 
expected to be around four orders of magnitude greater (ethyl acetoacetate has a pKa of 14.2 
while N,N’-dimethylacetoacetamide pKa is 18.2) was likely to be responsible for this 
phenomenon. 
 
Scheme 2.5 β-ketoamide asymmetric Michael addition 
Furthermore, secondary amides have also been reported in the literature as successful Michael 
donors (Scheme 2.6).143  
 
Scheme 2.6 Secondary amide organocatalytic example 
The presence of the amidic hydrogen and, in particular, the role of the secondary amide 
tautomer, in combination with Takemoto´s thiourea catalyst 134, played a crucial part in the 
reaction pathway. In fact, the more electron withdrawing the secondary group on the amide 
was, the greater the contribution of the imidic acid form (187) was to the tautomeric 
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equilibrium and thus, a higher ee was recorded for the corresponding product, reaching 
complete selectivity when using tosyl instead of the phenyl substituent in 186. Tertiary 
amides, under the same reaction conditions, did not deliver any Michael product. 
As far as organocatalytic chemistry using the DKP framework is concerned, the closest 
precedent available to date were the investigations carried out by Olenyuk and co-workers, 
using α-tert-butyl ester sarcosine anhydride 190. The activated DKP was found to undergo   
α-sulfenylation using quinine as organocatalyst.144 However, only moderate results were 
obtained across all examples, up to 75% ee in the example shown in Scheme 2.7.  
 
Scheme 2.7 Organocatalysed sulfur transfer  
The same group also aimed at developing a methodology to rapidly access tryptophan DKP 
containing natural products (Scheme 2.8).145  
 
Scheme 2.8 Organocatalysed indole transfer 
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An organocatalysed nucleophilic substitution of the sulfonyl group in indole 193 by DKP 190 
was explored. Despite achieving no degree of enantiocontrol, the desired products were 
isolated in a modest 5:1 ratio of diastereoisomers. 
These few but promising examples utilising DKP structures in asymmetric organocatalysis 
clearly suggested there was room to expand this research to include different kinds of 
electrophiles such as Michael acceptors. 
Once conditions for the asymmetric Michael addition of DKP 168 were devised, the exocyclic 
carbonyl functional group would be the perfect handle to explore a broad range of different 
options to close the bridge on the DKPs. Claisen condensation is a perfectly feasible option, 
and has previously been reported by Weigl et al. (Scheme 2.9).146 
 
Scheme 2.9 Dieckmann condensation to bridge-close a DKP 
Enantioenriched DKP 194 was accessed from the condensation of (S)-glutamate and glycine. 
Treatment of this DKP with LHMDS triggered Dieckmann condensation with the side-chain 
ester followed by trimethylchlorosilane quench to yield mixed acetal 195. Hydrolysis of this 
compound furnished the desired bicyclo[2.2.3]diazanonane 196, in good overall yield. This 
short sequence emphasises how Claisen-type chemistry would be a proven strategy to 
accomplish the final bridge-closing step in the synthesis of closely related bicyclomycin 
analogues. In addition, a handful of other approaches have been envisioned to effect similar 
processes such as radical or cationic reactions. The exocyclic activating carbonyl group could 
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also be targeted for further functionalisation via different strategies, e.g. nucleophilic attack 
by a Grignard reagent. 
 
2.2. Synthesis of 1,3-Dicarbonyl N,N’-Alkyl protected DKPs  
Although the literature precedents for the proposed key step were somewhat limited, the 
previously outlined synthetic plan (Scheme 2.3) became the starting point of this project. The 
first priority was to access a small array of N-alkyl protected β-carbonyl DKPs for initial tests 
of the organocatalytic reaction. 
Consequently, the synthesis of the α-carbaldehyde adduct from commercially available 
sarcosine anhydride 197 under reported conditions was accomplished (Scheme 2.10).147 The 
isolated compound was exclusively the corresponding enolic DKP 198 in 98% yield. 
 
Scheme 2.10 Formylated DKP reaction 
Following Olenyuk’s protocol, methyl ester 200a, methyl 200b and phenyl ketone 200c 
substituted DKPs (R1 = Me) were synthesised in a Claisen type reaction using three 
equivalents of potassium tert-butoxide solution in THF, followed by quenching with the 
specific electrophile.144 Benzylated DKP (R1 = Bn), simply synthesised by treating glycine 
anhydride with sodium hydride in DMF followed by addition of benzyl chloride,53 underwent 
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acylation using the same reaction conditions as before. The desired monoacylated DKPs were 
afforded as the only product of the reaction in good yields (Scheme 2.11). 
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Scheme 2.11 Acylated DKP examples 
With these four examples of β-carbonyl DKPs in hand, a number of popular cinchona 
alkaloids were synthesised. Starting from natural members quinine, quinidine, cinchonine and 
dihydroquinine, modified catalysts were synthesised employing reported procedures, and are 
summarised in Figure 2.1.110a,130a,148 
 
Figure 2.1 Cinchona alkaloids used in the project 
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Catalyst syntheses could be divided into two distinctive groups, depending on whether the 
hydroxy group in the aromatic quinoline was unveiled or not. In the first case, synthesis starts 
with protection of the 9-hydroxy group by either a benzyl or a phenanthryl group, followed by 
demethylation of the aromatic ether (Scheme 2.12). 
 
Scheme 2.12 Phenol derived catalyst strategy 
In the second case, Mitsunobu reaction of the 9-hydroxyl function in the presence of 
diphenylphosphoryl azide affords an azide derivative that was in-situ reduced to the 9-amino 
compound. As expected, an inversion of the stereochemistry was observed.130b Nucleophilic 
attack of this amine on either isocyanate 217 or isothiocyanate 218 resulted in the formation 
of urea and thiourea derived compounds 209 and 210 respectively (Scheme 2.13). 
 
Scheme 2.13 Urea derived catalyst strategy 
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With all materials in hand, the organocatalysed Michael reaction could be attempted. Enolic 
DKP 198 was reacted under similar conditions to those reported by Deng and co-workers with 
acrolein as the electrophile.108 Using a substoichiometric amount (10 mol%) of quinine 148, 
the reaction proceeded to give the desired product 219 (Scheme 2.14). 
 
Scheme 2.14 Organocatalysed Michael reaction 
However, 219 was judged to be racemic, based on a zero polarimetric reading. Although the 
catalyst was needed for the completion of the reaction, no product was observed when it was 
excluded; it was not delivering asymmetric results. No stereoselectivity improvements were 
noted upon varying the organocatalyst. 
The rest of the β-carbonyl DKPs were also subjected to these reaction conditions (Scheme 
2.15). Unfortunately, none of the desired products were ever observed and only the staring 
materials and the catalyst were recovered from the reaction mixture. 
 
Scheme 2.15 Organocatalytic Michael reaction on acyl DKPs 
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These results were in clear contrast to the first Michael adduct formed from DKP 198. 
Consequently, the preformed enol was concluded to play a crucial role for the reaction to 
proceed. In the rest of the cases, the bifunctional catalysts, having a simple tertiary amine, 
embedded as the quinuclidine bicycle, were presumably not strong enough bases to 
deprotonate the active site within the 1,3-dicarbonyl in the DKPs.  
The low acidity of the alkyl protected DKPs was believed to be responsible for the lack of 
reactivity towards the cinchona alkaloids derived catalysts. β-Ketoesters (pKa around 15, vide 
supra) were likely to be at the pKa limit where this type of chemistry was still effective, while 
the DKP system was known to be less acidic. The synthesis of acyl protected-DKP, by 
changing the nitrogen protecting groups for carbonyl based ones, e.g. Boc, to bring the pKa of 
the distal proton down into the reactive range, was the next aim of the project. 
 
2.3. Synthesis of 1,3-Dicarbonyl N,N’-Carbonyl protected DKPs  
The main distinctive feature that makes imide α-protons more acidic than those of amides is 
the possibility of the former to delocalise the lone pair of electrons in the conjugate base over 
two carbonyl groups instead of one for the latter case. Accordingly, imides have a lower 
electron density on each carbonyl making them more electrophilic than amides and somewhat 
similar to ketones in terms of acidity. Theoretical calculations have been conducted to 
specifically determine pKa values in acyclic and DKP subunits (Figure 2.3).149 
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Figure 2.2 Theoretical pKa of acyclic and cyclic amides and imides, using B3LYP/6-31+G(d) method 
for the geometries and frequencies in the gas-phase free energy calculations 
The pKa decreases by ten units from acyclic amides to imides. That enormous difference 
brings the pKa value of this subunit to the range of a standard acyclic ketone. The same trend 
is observed within the DKP framework. Although the pKa of unprotected cyclo[Gly-Gly] is 
substantially lower compared with that of an acyclic amide, and also lower than the sarcosine 
anhydride DKP, there is a significant difference compared to the acidity of the α-proton, or 
distal proton, of an imide embedded as part of the protecting group. Thus, acetyl nitrogen 
protection induces a decrease in the pKa of the distal proton of five units. Therefore, carbonyl 
nitrogen protection should bring the pKa of acyl DKPs to an amenable range for the key 
asymmetric reaction to work. In addition, N-butyl succinimidyl esters had previously been 
reported in the literature, using typical thiourea catalyst 222 and nitro-styrene 221, to form the 
corresponding Michael adducts 223 in very good yield, ee and moderate diastereoselectivity 
(Scheme 2.16).150  
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Scheme 2.16 Asymmetric Michael additions of succinimides 
In light of this information, N,N’-diacetyl and N,N’-diBoc protected DKPs were synthesised. 
Glycine anhydride 204 was subjected to literature conditions to afford the desired protected 
DKPs 225a and 225b in very good yields (Scheme 2.17).151 
 
Scheme 2.17 N,N’-dicarbonyl protection of DKPs 
Both DKP products were initially treated under analogous Claisen conditions to those 
performed on the dialkyl protected DKPs to afford the corresponding acyl DKPs. However, 
the reaction did not proceed as smoothly as in the latter case due to the increased reactivity of 
these systems. In the case of N,N’-diBoc DKP 225a, the potential intermolecular enolate 
acylation was overridden by an intramolecular attack of the formed enolate onto the second 
carbonyl group within the heterocycle, forming transannulated product 226.151b,152 No 
inclusion of the electrophile in 226 or traces of the desired product 227 were observed 
(Scheme 2.18). 
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Scheme 2.18 Transannular rearrangement of Boc-DKP 
Nevertheless, this problem could be simply overcome by changing the conditions to lithium 
amide bases, at low temperature combined with highly reactive benzoyl chloride as shown in 
Scheme 2.19.  
 
Scheme 2.19 Acylation of Boc-DKP 
Difficulties were also encountered in the case of the acylation of N,N’-diacetyl DKP 225b 
under classical Claisen conditions. A 22% yield of the final product was the maximum 
achieved in a very sluggish reaction with numerous undesired by-products, despite attempts at 
optimisation.152 A much cleaner reaction with an easier purification process was 
accomplished by means of LHMDS base, low temperature and an acyl chloride reagent 
(Scheme 2.20). 
 
Scheme 2.20 Acylation of Acetyl-DKP 
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With robust routes to access substituted DKPs, the key step was tried prior to building a 
library of N,N’-dicarbonyl protected acylated DKPs. To our surprise, all of the tried reactions 
failed to furnish the desired products. A wide range of conditions were screened, including 
different catalysts, solvents and Michael acceptors, resulting only in the recovery of starting 
materials (70-85%, Scheme 2.21).  
 
Scheme 2.21 Michael additions of N,N’-dicarbonyl DKPs 
Disappointingly, the expected increased acidity of the acyl protected systems did not translate 
into enolate formation by the cinchona alkaloid catalysts action. At this point, the lack of 
reactivity of DKPs under standard organocatalysed conditions seemed conclusive and no 
further transformations on the DKP core were pursued to achieve the organocatalysed 
Michael addition. Devising a reliable route to access the TKP core and determining the 
optimal conditions for the key 1,4-addition step on this system became the next goal. 
 
2.4. Summary and Future Work 
It has been shown how different protected DKPs can undergo acylating chemistry under two 
different type of conditions, accessing a wide range of 1,3-dicarbonyl DKPs. However, we 
have been unable so far to successfully manipulate these DKPs under standard 
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organocatalytic asymmetric Michael conditions. The need for stronger, more basic 
organocatalysis has become apparent for this chemistry. If these types of catalysts are 
developed and optimised then reinvestigation of protected acyl DKPs may be fruitful. 
Out of current catalysts, it might be recommended to try squaramide based catalysts, which 
have been shown to be slightly more reactive than Deng´s catalysts. Alternatively, a phase 
transfer catalytic approach may be more successful. 
Having seen the asymmetric organocatalytic literature around β-ketoamides, how little their 
pKa theoretically differs from the synthesised DKPs, and subsequent information generated by 
this project; it might be worth considering that other factors that will be later discussed might 
be playing a fundamental role in impeding this chemistry. 
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Chapter Three 
 
Enantioselective Synthesis of Polyfunctional 2,3,5-
Triketopiperazines 
 
3.1. Aims and Objectives 
The lack of reactivity exhibited by acylated DKPs, with either alkyl or carbonyl 
protecting groups on the nitrogen, encouraged us to explore further possibilities where an 
organocatalysed Michael addition could be performed. The aim was to develop a molecule 
with an increased acidity of the α-protons by including an imide within the molecular 
framework, without drifting away from the original goal. The synthesis of the 
triketopiperazine (TKP) framework addressed all these conditions. We were determined to 
check whether the key organocatalytic 1,4-addition would now proceed successfully, 
furnishing the desired enantioenriched products as shown in the proposed synthetic plan 
(Scheme 3.1). 
 
Scheme 3.1 TKP proposed sequence 
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TKP 232 bears an imide which has been included within the cyclic skeleton of the molecule 
and so there is only one methylene position available for further functionalisation. 
Once the TKP was in hand, the synthetic plan would be analogous to the one devised for the 
DKPs. The first step would be acylation of the TKP, the extra reactivity provided by the 
activating group would probably still be necessary, followed by the key step, the 
stereocontrolled Michael addition, catalysed by cinchona alkaloid derivatives. To the best of 
our knowledge, the development of organocatalytic methods on this system has not been 
explored. At this point, different options could be considered, involving either bridge-closing 
chemistry or carefully selected transformations to afford enantioenriched DKP. 
As previously mentioned, there is not much literature available for the synthesis of the TKP 
framework itself. Hence, the biggest challenge would initially be to develop a streamlined 
synthesis of the TKP on gram scale. To date, two very similar methods have been reported to 
synthesise TKPs under mild conditions (Scheme 3.2).64,68a 
 
Scheme 3.2 Previous examples of TKP formation 
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It is worth noting that no oxalyl chloride is used to perform these cyclisations, possibly due to 
its highly reactive nature which was probably not compatible with either reactants or 
products. Instead, oxalyl diimidazole 77 was the oxalyl surrogate in the cyclisation step in 
both cases. Either under solid supported conditions or in solution, this method was very 
effective at furnishing the desired TKPs. No comments on the stereochemical outcome of the 
triketopiperazines in the solid supported synthesis were made by the authors in the first 
example, leaving the experimental assignment incomplete. 
 
3.2. Synthesis of 2,3,5-Triketopiperazines 
Similarly to the literature procedures, the formation of the TKP system was devised to 
comprise a di-protected aminoamide, either with the same or different groups on nitrogen, 
followed by the cyclisation step, using oxalyl diimidazole as described in the literature 
examples. A fully stepwise approach was developed initially, involving the benzyl protection 
of the primary amine of glycine ester 235 via reductive amination followed by amide 
formation through long exposure of the aminoester to benzyl amine to finally furnish N,N’-
dibenzyl aminoamide 237 in a 31% yield across the two steps (Scheme 3.3).153 Although it 
was a good starting point for the synthesis of aminoamide 237, the overall synthesis had to be 
thoroughly optimised were gram quantities of TKP to be produced.  
 
Scheme 3.3 First two steps sequence into aminoamides 
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One of the main advantages of this first approach was that it would allow us to introduce 
different protecting groups on each nitrogen and thus reflect that reactivity difference in the 
final TKP core. However, as a proof of concept a symmetrically protected aminoamide would 
be equally valid. Consequently, a second generation approach was envisioned to afford 
compound 237. Starting from methyl bromoacetate (238), a one pot process furnished the 
desired aminoamide via initial nucleophilic substitution of bromine by benzylamine followed 
by slow ester group interchange to form the final aminoamide using an excess of benzyl 
amine (Scheme 3.4). 
 
Scheme 3.4 Methyl bromoacetate approach to dibenzyl amino amide 
Naturally, the first substitution occurs rapidly, with concomitant formation of one equivalent 
of the ammonium bromide salt, which remains in the reaction mixture. Although it did not 
seem to prevent the next transformation from happening, the salt did interfere with the 
purification process given that the crude material was directly chromatographed when no 
more ester intermediate could be detected. The large excess of benzylamine was also 
problematic as it often co-eluted with the desired product. Finally, when applied on large 
scale, the reaction time for the complete formation of the desired product was unpractically 
lengthy, sometimes taking weeks. In an attempt to avoid some of these difficulties a third 
approach was investigated. Highly reactive bromoacetyl bromide (239) was employed to form 
the desired benzyl bromoacetamide at low temperature. Second bromine substitution occurred 
overnight to yield 237 in twelve hours (Scheme 3.5).154 
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Scheme 3.5 Established method to access dibenzyl amino amide in gram scale 
One equivalent of excess amine for each substitution was necessary to neutralise the hydrogen 
bromide generated in the course of the reaction. In fact, the corresponding salt was 
precipitated out of the reaction and successfully removed by an aqueous extraction. These 
reaction conditions enabled us to overcome all difficulties previously encountered: no large 
excess of amine was needed in the reaction to reach completion, the bromide salt was no 
longer interfering with the purification and the reaction time was short and reproducible. 
However, these two steps in a one-pot sequence became inefficient when using other primary 
amines, such as para-methoxy benzyl amine, as different molecular aggregates could be 
identified from the reaction mixture over a comparable reaction time (Scheme 3.6). 
 
Scheme 3.6 Side product present in PMB amino amide formation 
In light of this result, this option was no longer pursued under the present project. With a 
robust reaction to provide high quantities of aminoamide 237 the synthesis was taken forward 
to the cyclisation step. The first reaction conditions tried were those published by Overman 
and co-workers using 1,1’-oxalyldiimidazole.68a In this case, reaction of 237 in DME afforded 
the desired cyclic adduct in 68% (Scheme 3.7). 
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Scheme 3.7 TKP formation using oxalyl diimidazole 
Although the yield of 242 was not outstanding, it was comparable with the results Overman 
and co-workers observed for the formation of their TKP in solution. Despite being a reliable, 
robust route to access the TKP scaffold, it was considered that new conditions for this last 
step needed to be found due to the high cost of the commercial oxalyl reagent. Gram 
quantities of the desired TKP had to be readily available, and so affordable oxalyl cyclising 
surrogates were screened. 1,1’-Oxalyldiimidazole synthesis was attempted, using oxalyl 
chloride, DIPEA and imidazole in various solvents only to see poor conversion into the TKP 
system, with a maximum yield of 10-15%, upon in-situ reaction with aminoamide 237.155 
Oxalyl 1,1’-dibenzotriazole, developed by Katritsky, was employed next.156 Originally used 
for the formation of substituted oxamides using secondary amines, its synthesis was easily 
accomplished but, treatment of 237 only afforded little amounts of the desired product. It was 
subsequently found that this was directly linked to the inherent lower reactivity of oxalyl 1,1’-
dibenzotriazole compared to the corresponding diimidazole. However, this issue could be 
easily overcome by subjecting the reaction to harsher conditions, i.e. THF at 150 ºC in a 
microwave reactor, to give comparable yields to the previously developed method (Scheme 
3.8). 
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Scheme 3.8 Developed TKP formation using oxalyl dibenzotriazole 
At last, an optimised, reliable sequence that was suitable for producing gram quantities of the 
desired product quickly and in an affordable manner was achieved. This method enable the 
production of TKP 242 in up to 10 gram batches. 
 
3.2.1. Synthesis of 6-Acyl Triketopiperazines 
Having established a route to access the TKP core 242, the project could be continued as 
outlined in the plan. Introduction of an acyl group was considered essential for the key 
Michael reaction to be successful. We wished to build several examples of acylated TKPs 
suitable for undergoing the asymmetric 1,4-addition. Olenyuk’s conditions for the acylation 
of N,N’-alkyl DKPs were screened first on the TKP system but, unfortunately, no product was 
recovered from the reaction crude (Scheme 3.9). 
 
Scheme 3.9 First acylation attempt on TKP 242 
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The formed enolate was hypothesised to be incompatible with the acylation with dimethyl 
carbonate as the reaction mixture warmed up to room temperature, and a complex mixture of 
products was formed that could not be separated or identified. 
As explored with the acyl protected DKPs, more reactive electrophiles in combination with 
LHMDS and lower temperatures were subsequently tried. Several acyl chloride reagents were 
tested to form the desired TKP derivative (Table 3.1). 
 
Entry R Eq of ClCOR Yield (%) 
246 OMe 3 23 
247 Ph 3 56 
248 Me 5 - 
Table 3.1 Acylation results LHMDS and acyl chlorides 
Reactions were somewhat sluggish and the final product was isolated in an acceptable yield 
only with benzoyl chloride (247) as the electrophile. In the case of methyl chloroformate, the 
reaction afforded a mixture of mono and di acylated TKPs together with some O-acylated 
adduct. Separation of this crude mixture was extremely difficult and only a small amount of 
the desired material (246) was successfully recovered. Acetyl chloride mainly furnished the 
O-acylated adduct and no trace of the desired product was observed. It was therefore 
concluded that this approach was unreliable for the formation of acylated TKPs. 
Further exploration of different options was necessary. From our point of view, the perfect 
acylating agent would have an intermediate electrophilicity between an acyl chloride and an 
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ester or a carbonate. Thus, we turned our attention to the work developed by Mander and co-
workers. Their team synthesised a different kind of electrophile where the leaving group was 
a cyanide anion instead of the chloride.157 Their reports included reactions where this reagent 
was able to furnish the desired acylated products under soft conditions. It was also worth 
noting that full transformation was accomplished by letting the crude mixture warm up from 
−78 °C to around 0 °C, thus hinting that the actual transformation needed a higher 
temperature for completion compared to the acyl chlorides. 
Treatment of TKP 242 with Mander’s reagent 249 under the previously outlined conditions 
led to the formation of the desired derivative as the only product in very good yields (Scheme 
3.10). 
 
Scheme 3.10 Acylation of TKP 242 using Mander’s reagent 
Not only could this compound be made using this approach but different acyl groups could be 
theoretically accessed should the appropriate reagent be in hand. Under these conditions, the 
proposed Michael donor was finally accessed in a robust and short route with a good overall 
yield of 57% over three steps linearly from commercially available materials. 
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3.3. Enantioselective Michael Reactions on 2,3,5-Triketopiperazines derivatives 
With a reliable access to acyl TKPs, the asymmetric organocatalysed 1,4-addition to 
different Michael acceptors was explored. Firstly it was necessary to check whether the 
reaction would take place with the TKP substrates. Upon subjecting substrate 246 and vinyl 
ketone 188 to substoichiometric amounts of triethylamine, in dichloromethane, we were 
delighted to observe full conversion to Michael adduct 250 in less than one hour at room 
temperature (Scheme 3.11). 
 
Scheme 3.11 First attempt of a Michael addition using TKPs 
The optimisation of the reaction conditions for the asymmetric version of this transformation 
was targeted next. Some of the cinchona alkaloid bases (Figure 2.1,vide supra) in hand were 
employed in this optimisation study using different solvents and varying temperature with 
methyl vinyl ketone as the Michael acceptor in all cases. A summary of these results is given 
in Table 3.1. 
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Entry Catalyst Temp. (°C) Solvent time
a
 Yield (%)b er (%)c 
1 142 r.t. CH2Cl2 20 94 82:18 
2 148 r.t. CH2Cl2 20 91 25:75d 
3 210 r.t. CH2Cl2 20 98 31:69d 
4 201 r.t. CH2Cl2 20 99 96:4 
5 201 r.t. THF 20 98 95:5 
6 201 r.t. toluene 20 98 94:6 
7 201 r.t. MeCN 20 99 94:6 
8 201 0 CH2Cl2 60 99 98:2 
9 201 0 CH2Cl2 120 91e 97:3 
10 204 0 CH2Cl2 20 82 2:98d 
[a] Minutes. [b] Isolated yield after chromatography. [c] Determined by HPLC analysis. [d] 
Enantiomeric product with respect to entry 1. [e] Reaction conducted using 1 mol% catalyst. 
Table 3.1 Reaction optimisation  
The naturally occurring members of the cinchona alkaloid family, quinine 148 and quinidine 
142 furnished the desired product in good chemical yield but, not unexpectedly, the er was far 
from optimal (entry 1 and 2). As expected, this pseudo-enantiomeric pair of catalysts afforded 
enantio-complimentary results of TKP 250. Surprisingly, although the thiourea derivative 210 
furnished the Michael adduct 250 in very good yield, the er was disappointing. This is in 
contrast to the literature examples previously shown, where this catalyst was found to be the 
most efficient in a wide range of transformations (entry 3). The optimal catalyst for this 
transformation was found to be benzyl derivative 201 (entry 4). Further conditions screening 
suggested that dichloromethane was the best solvent in which to run the reaction. Lower 
temperatures afforded the desired compound in comparable yields and higher er. Under these 
conditions, the catalyst loading could be dropped to 1 mol% without any downside apart from 
the extended reaction time (entry 9). As expected, benzyl derived quinine derivative 204 
yielded the opposite enantiomer of the TKP Michael adduct with equivalent er (entry 10).  
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The scope of the reaction was subsequently explored using differently substituted enones 
under the previously optimised conditions and results are depicted in Figure 3.1. Catalyst 
loading was maintained at 10 mol% and the temperature had to be even lower (−20 °C) to 
guarantee consistently high levels of induced asymmetry across the full set of examples with 
corresponding longer reaction times. 
 
 
Figure 3.1 Scope of the asymmetric Michael reaction  
Very good results, both in terms of yields and levels of induced asymmetry, were observed in 
all examples. A variety of alkyl or aryl groups, either with electron withdrawing or electron 
donating properties were placed on the enone. The absolute stereochemistry of all the 
examples was inferred from the X-ray crystallographic data of a compound appearing later in 
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this section. The possibility of incorporating different substitution patterns on the Michael 
acceptor, either at the α- or β-position on the conjugated alkene was explored next. However, 
no reaction took place when using the methyl substituted versions of acrolein, methacrolein 
257 and crotonaldehyde 258, under the optimised conditions, and only TKP 246 was 
recovered from the crude mixture (Scheme 3.12). 
 
Scheme 3.12 Sterically hindered electrophiles showed an absence of reactivity 
The increased steric was probably the reason behind this lack of reactivity and it was 
concluded that when using enones, no alkyl substituent on the alkene was tolerated. However, 
Michael additions with enones bearing electron withdrawing groups in β-position, which 
should enhance the electrophilicity of the alkene, might be reactive under the present reaction 
conditions. Upon subjecting TKP 246 to the optimised conditions in the presence methyl        
E-4-oxo-2-pentanoate 261, the reaction afforded the desired Michael adduct 263. Similarly, 
reacting the same starting material with the doubly activated ethyl Z-(β-cyano)acrylate 262 
also furnished the desired product 264, albeit only the racemic product could be formed. 
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Perhaps, due to the low basicity of the chiral catalyst, compared to trimethylamine, no 
reactivity was observed in this case (Scheme 3.13). 
O
10 mol% 201
CH2Cl2, 20 °C
BnN
NBn
O
O
O
MeO2C
246 263
261
MeO2C
BnN
NBn
O
O
O
CO2Me
MeO2C
O
67%
92:8 er
CO2Et
10 mol% Et3N,
CH2Cl2, 20 °C
BnN
NBn
O
O
O
MeO2C
246
262
264
CN
BnN
NBn
O
O
O
CO2Me
NC
EtO2C
97%
 
Scheme 3.13 Doubly activated electrophiles used in Michael additions 
Interestingly, only one diastereoisomer was observed from the reaction mixture (see crystal 
structures data of compounds 263 and 264 in Appendix 2). While it was expected that 261 
would react as an activated enone, rather than the opposite way, as an α,β-unsaturated ester, it 
was pleasing to observe that the cyanoester only formed product 264 resulting from the 
reaction of the activated unsaturated ester.  
Other types of activation of the β-position of enones were explored next, with weaker electron 
withdrawing substituents. Chalcone was the selected electrophile as it is commercially 
available. Disappointingly, no desired product was observed upon reaction of TKP 246 with 
chalcone 265 under the optimised conditions (Scheme 3.14). 
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Scheme 3.14 Chalcone Michael addition with TKP 246 
As this reagent was only slightly electronically enhanced, it is probable that the steric 
hindrance was overriding this factor and impeding the transformation from occurring.  
In our desire to increase the number of examples where this catalytic approach could be 
applied, other Michael acceptors that had been used in previous literature examples were 
sought. Deng and co-workers reported an organocatalysed reaction using                                
α-chloroacrylonitrile.129d Analogously, TKP 246 was treated with this Michael acceptor under 
the optimised reaction conditions (Scheme 3.15). Interestingly, thiourea catalyst 210 was 
found optimal for this particular transformation.  
 
Scheme 3.15 Activated acrylonitrile Michael addition 
The electron withdrawing properties of the chorine in the α-position of the Michael acceptor 
are probably contributing to increase the reactivity of 175 equivalent to a ketone adduct. It is 
also small enough not to hinder the reaction as in the case of methacrolein 257. Product 267 
was afforded in good yield and er an only one diastereoisomer was observed (see crystal 
structures data for compound 267 in Appendix 2). The same group published another paper 
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employing vinyl sulfones as the Michael acceptor.158 Likewise, this electrophile could also be 
applied to the TKP system (Scheme 3.16). 
 
Scheme 3.16 Vinyl disulfone Michael addition 
In this case, disulfone TKP 269 was produced in good yield but with poor selectivity. 
Therefore, although 269 shows the expected stereochemistry from this thiourea 210 
organocatalysed reaction, in the absence of the absolute configuration information, we are not 
completely certain of the predominant stereoisomer. This result suggested that further reaction 
optimisation was required for this Michael acceptor and reflects the chemical disparity 
between this α,β-unsaturated derivative and the enones. Nevertheless, showing such a broad 
reactivity was a great asset for this system to become more useful to the scientific community. 
Lastly, the widely used nitro olefins were tried on the TKP 246. Typically nitro styrenes are 
the most commonly used systems and so two examples to test on the TKP were synthesised. 
Michael reaction with the TKP system gave the desired products as depicted in Scheme 3.17. 
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Scheme 3.17 Nitro olefins Michael addition 
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Both reactions gave the desired products in good yield and only one diastereoisomer could be 
observed from the crude reaction mixture (although the relative stereochemistry is already 
known from an X-ray crystal structure data, the sample has not been fully refined to date). 
However, the present conditions did not induce great levels of asymmetry (61:39 er) and the 
shown isomer in Scheme 3.17 reflects only the expected product in accordance with the 
relative configuration information obtained in the X-ray and the employed catalyst. Expecting 
a similar er value for the para-fluoro nitro TKP derivative, the HPLC value was not 
determined. Despite showing great potential, thorough optimisation studies will have to be 
carried out, screening different catalysts, to furnish products with greater levels of 
enantioselectivity. Although further Michael acceptors were tried for these systems, they will 
be covered in-depth in the next chapter due to key differences in the reaction outcome.  
To gain more insight on the catalyst-substrate interaction before the Michael addition, various 
NMR studies were performed. Stoichiometric amounts of catalyst 201 and TKP 246 were 
mixed and their proton NMR spectra recorded and compared against those of pure compounds 
in deuterated acetonitrile (Figure 3.2). No substantial variations were observed in the mixed 
spectra. The presence of the α-proton in the lower NMR, as well as the rest of the signals 
corresponding to the TKP, in the same position suggests that the enolate form of the TKP was 
not present. 
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Figure 3.2 1H NMR spectra of TKP 246 (a), catalyst 201 (b) and mixture (c) in CD3CN 
However, slight variations between the pure catalysts and the one in the mixture were present. 
Although no direct conclusion can be made, these features might be related to the presence of 
H-bonds between the TKP and the catalyst. The slight shift (∆ = 0.02 ppm) observed in the 
signals corresponding to the AB system of the benzyl methylene, as in the left expansion of 
Figure 3.3, is a clear example. The significant broadening in the NMR region that belongs to 
the protons surrounding the basic nitrogen (3.3 – 2.5 ppm), in the right expansion, may be 
related with the likely H-bond created on that centre. 
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Figure 3.3 Expansions comparing 1H NMR spectra of 201 (a) and mixture with TKP 246 (a) 
In order to identify the nature of the enolate by NMR, stoichiometric amounts of TKP 246 
and DBU were used in an analogous study (Figure 3.4). 
 
 
Figure 3.4 1H NMR spectra of TKP 246 (a), DBU (b) and mixture (c) in CD3CN 
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DBU, which is considerably more basic than any cinchona alkaloid catalyst (pKb of DBU is 
12.5 in DMSO while quinuclidine is 9.5159) was capable of fully deprotonating 246. In the left 
expansion of Figure 3.5 it could be seen how the two benzylic AB systems became broad 
singlets and were strongly shifted downfield, from 4.93 ppm to 5.46 ppm and 4.70 ppm to 
5.06 ppm respectively. Simultaneously, the singlet corresponding to the α-proton disappeared 
in the presence of DBU. These changes were in accordance with the presence of the enolate 
form. DBU signals were also drastically changed when mixed with TKP 246, as seen in the 
right expansion, indicative of the transformation of the structure upon protonation.160 
 
Figure 3.5 Expansions comparing 1H NMR spectra of pure samples signals (b) and mixture (a) of 
TKP 246 and DBU 
In our desire to understand the different reactivity of TKP 246 in comparison with the less 
acidic parent TKP, the DBU study was extended to compound 242. In an analogous manner, 
the NMR spectra of pure TKP, DBU and an equimolar mixture of both were obtained and 
compared (Figure 3.6). Interestingly, noticeable differences could be observed in contrast 
with the experiment with carboxymethyl TKP 246. First, although the integrals for the three 
methylene positions remain the same, the signal corresponding to the α-position (4.27 ppm) 
showed significant broadening, indicative of an interaction with the base.  
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Figure 3.6 1H NMR spectra of TKP 242 (a), DBU (b) and mixture (c) in CD3CN 
Likewise, the DBU signals in the mixture, albeit generally shifted compared to the signals of 
pure DBU, were at different ppm values from the ones observed in the previous experiment 
with TKP 246 (Figure 3.7). 
The combination of these two features might indicate that DBU pKb might not be strong 
enough, or the α-protons not acidic enough, to fully form the enolate of TKP 242. Hence, 
protonated DBU was not observed as in Figure 3.4, and only the interacting acid-base 
complex is present in the mixed spectrum. Signal shifts, in the case of DBU, and broadening, 
in the parent TKP, can be associated with the H-bond network that was probably established 
in the crude mixture.143b 
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Figure 3.7 Expansion comparing 1H NMR spectra of pure DBU (c), in combination with TKP 246 (b) 
and 242 (a) 
In light of these experiments, it became evident that TKP 242 might display interesting 
reactivity on its own as a nucleophile due to the unusually low pKa. Overall, the reactivity and 
good levels of stereocontrol achieved with the carboxymethyl TKP 246 was remarkable but 
somehow predictable as it was essentially a 1,3-dicarbonyl system embedded in a cyclic 
scaffold, similar in pKa to the system reported in the literature. However, we were curious to 
explore the limits of the Michael addition’s reactivity in the context of the less activated TKP 
242. 
It was clear that TKP system 246, in sharp contrast with the corresponding DKPs, reacted 
under literature conditions for the organocatalysed Michael addition very rapidly. Although 
no direct measure of TKP 246 pKa has been carried out, and only taking the chemical shift of 
the α-proton as an approximation of its acidity, this TKP system seemed to be considerably 
less acidic in comparison with the α-proton of acyl protected DKPs (5.94 ppm of DKP 229 
Chapter 3   Synthesis of 2,3,5-triketopiperazines
  
 
95 
compared to 4.82 ppm of TKP 246 in chloroform). Although it may appear counterintuitive, 
this result implies that not only might the acidity of the system be playing a fundamental role 
in this transformation. It could be hypothesised that a TKP, bearing an extra sp2 centre within 
the ring, could form a more stable aromatic intermediate 274, in equilibrium with the reactive 
enolate 273, which, overall, enhances its reactivity towards Michael acceptors (Scheme 
3.18).63b 
 
Scheme 3.18 Proposed reactive TKP intermediate 
Should the proposed intermediate 274 be part of the reaction and bearing in mind the highly 
reactive system in hand, as shown by the NMR study of TKP 242 with DBU, it was 
hypothesised whether any extra activating group (Y) was necessary for the Michael addition 
to occur. TKP 242 might be reactive enough under the present optimised reaction conditions 
and so, in order to check this premise, it was subjected to the Michael addition reaction with 
trimethylamine at room temperature (Scheme 3.19). 
 
Scheme 3.19 Initial Michael addition test on parent TKP 
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In the absence of literature references, the rapid consumption of the starting material to 
furnish an approximate 2:1 mixture of two products after one hour of reaction, resulting from 
the mono (276) and double Michael addition (277) to the parent TKP was surprising. As seen 
in the 1H NMR spectrum of the reaction mixture in Figure 3.8, both products can be readily 
identified (see Chapter 5: Experimental Part for a detailed analysis of the mono addition 
compound). 
  
Figure 3.8 1H NMR spectra of the mixture of mono and double Michael adducts 
Not only the activating group was unnecessary for the Michael addition to proceed but the 
double Michael product observed meant that even α-alkyl TKPs could undergo this reaction. 
Furthermore, by carefully controlling the stoichiometry and temperature, different tandem 
1,4-additions could be sequenced to furnish double-Michael products where two different 
electrophiles were used (Scheme 3.20).  
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Scheme 3.20 Proposed reactivity of alkyl-TKP 278 and TKP 242 
It is also worth noting that this reaction is one of the first examples of asymmetric 
organocatalysis using a purely mono-activated nucleophile. Only a handful of examples of 
this type have been described, for example Barbas and co-workers reported an organocatalytic 
Michael addition of nitro olefins to pyrazoleamide substrates using a urea-based catalyst 282 
(Scheme 3.21).161 
 
Scheme 3.21 Barbas mono-activated amide surrogate 
Although this example constituted the first report on organocatalysis of mono-activated 
amides, this substrate could not be considered a standard amide. The N-pyrazole substituent 
was likely contributing to bring the pKa of the α-proton lower than that of a normal amide. 
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The authors commented on how the ester or the pyrrolidinyl amide showed a complete lack of 
reactivity under these conditions while the electron-rich pyrrolyl amide showed less 
enantioselectivity, underlining the importance of the more electron withdrawing 
characteristics of the pyrazole amide. In addition, the combination with an electron deficient 
aromatic ring makes this substrate more prone towards deprotonation by typical 
organocatalysts. Nevertheless, excellent results were obtained across all examples in the 
paper, reaching high levels of diastereo and enantioselectivity. Also noteworthy is the ability 
to furnish the desired product in very good er. Although the acidic hydrogens in the final 
product could have been problematic, no er erosion or byproducts were reported. The same 
group published another organocatalysed reaction involving nitro olefins and oxindoles using 
a newly synthesised thiourea-based catalyst 285 (Scheme 3.22).162 
 
Scheme 3.22 Barbas monoactivated imide surrogate 
An imide is the sole activating group in this case although reactivity of the system was 
probably enhanced by both the nature of benzylic position and the aromatic enolate. An alkyl 
group is tolerated in the α-position and did not seem to interfere with the reaction outcome. 
Hence, we were confident about the potential of the alkyl TKPs to become valuable substrates 
for the asymmetric organocatalytic approach. Different simple imides have also been reported 
in the literature to perform well under typical organocatalytic conditions. γ-Butyrolactam 287, 
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in essence an imide surrogate, has also been employed in asymmetric vinylogous Michael 
additions (Scheme 3.23).163 
 
Scheme 3.23 γ-Imide Michael addition 
N-Boc protection proved of utmost importance to achieve the vinylogous reaction, providing 
the appropriate imide functionality within the system. Enolate attack has also been explored 
on this same system, although an activated carbonyl was the electrophile in that case.164  
With this limited number of precedents the same reaction previously explored with the 
activated TKP was investigated with the parent compound under analogous conditions 
(Figure 3.9). 
The scope of the reaction was highly reproducible, and good yields were obtained across all 
substrates. However, enantiomeric excesses were somewhat inconsistent. This was probably 
due to the presence of a highly acidic proton in the final products which, as seen in the initial 
experiment, was prone to form the double-Michael adduct. In fact, er erosion could be 
witnessed when 290, with the enantiomeric ratio of 96:4 already determined, was re-exposed 
to the same reaction conditions without the electrophile in the mixture. After two hours, the 
isolated material er had been eroded to 89:11. So in this particular transformation, reaction 
time and low temperature were crucial to avoid er erosion and further addition of another 
electrophile to the TKP core.  
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Figure 3.9 Scope of mono-activated Michael addition  
In the present study, chalcones were very well tolerated by the nucleophilic substrate, 
presumably due to the absence of the extra hindrance at the reactive centre. Longer reaction 
times compared to the non-substituted enones, were necessary, typically five to seven hours. 
However, it was noteworthy that no overreaction was ever observed in these cases, very likely 
due to the extra bulkiness around the reactive centre. Products in excellent yields and very 
good levels of enantioselectivity were afforded in both cases, and only a single 
diastereoisomer could be detected in the crude reaction mixture.  
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X-Ray quality crystals were grown from TKP adducts 295 and 296 to help us determine the 
absolute and relative stereochemistry of the catalysis products. Compound 296 (Flack 
parameter: -0.027(3)) is depicted in Figure 3.10 and 295 can be found in Appendix 2.  
 
Figure 3.10 TKP 296 crystal structure with 50% of ellipsoid probability 
As observed in the X-ray crystal structure, both hydrogens at the reactive centre of the TKP 
and β-position are staggered along the newly created carbon-carbon bond, while the phenyl 
substituent at the β-position and the TKP ring seem to arrange themselves in a gauche 
conformation. This feature enabled the larger bromophenyl ketone group and the heterocycle 
adopt an antiperiplanar disposition. This crystal structure helped to propose and rationalise an 
interaction model that explained the observed stereochemistry. Basing this proposal on 
Deng’s previous reports, a model where the three components of the reaction were arranged 
was suggested as depicted in Figure 3.11. 
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Figure 3.11 Proposed interactions in the transition state of the Michael addition 
In this model, the nucleophile and electrophile organised themselves spatially in the required 
manner for the newly formed carbon-carbon bond to reflect that specific disposition of the 
substituents in the final product. Although the endo arrangement of the β-phenyl group from 
the Michael acceptor with respect to the TKP cycle may appear sterically disfavoured, this 
stacked conformation is plausible owing to the all-sp2 planar nature of both rings and explains 
the disposition observed in the crystal structure. Taking this model into account, the 
stereochemistry for all previous asymmetric 1,4-additions was confidently expected to remain 
consistent at the α-position of the TKP ring with 296 X-ray. 
In an attempt to extend the scope of the reaction, standard alkyl group in either the α or β 
position, such as those in methacrolein and crotonaldehyde, on the electrophile were found 
unable of delivering the desired product under standard conditions. Again, the lack of any 
form of activation combined with the increase hindrance around the reactive centre was 
considered responsible for the absence of reactivity. 
Conversely, employing activated Michael acceptors, with electron withdrawing groups in 
either of the two positions of the alkene, such as 261 or 262 dicarbonyl derivatives, α-
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chloroacrylonitrile or nitro olefins 178 and 270, as used in the case of TKP 242, did not 
furnished a clean product. Instead, the high reactivity of these substrates was hypothesised to 
be responsible of yielding a mixture of diastereoisomers of both the mono and double Michael 
products. The separation of this mixture proved daunting and these reactions were concluded 
to be impractical from a synthetic point of view. However, exclusive mono-substituted TKP, 
albeit in a complex mixture of inseparable diastereoisomers was isolated when the reaction 
was interrupted after only 20 minutes of reaction between the parent TKP and nitro olefin 
270, as it was inferred from spectroscopic data analysis (Scheme 3.24). 
 
Scheme 3.24 Nitroolefins Michael addition to TKP 242 
In light of these results, the absence of the ester substituent on the TKP was not only reducing 
the theoretical acidity of the α-proton and, evidently, opening up a second position for further 
nucleophilic attacks should the conditions be optimal, but it also appears to have a clear 
impact on the diastereoselectivity, especially when highly reactive electrophiles were 
employed. When the carboxymethyl TKP 246 was employed, the nucleophilic TKP 
resembled a 1,3-dicarbonyl moiety. It is conceivable that a more tightly locked catalyst 
arrangement during the catalyst arrangement, with a higher number of H-bonds, could be 
responsible for the increased diastereocontrol and faster reaction rate observed with this TKP.  
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It is also worth mentioning how different reactivity was observed when two very similar 
electrophiles, such as nitroolefin 178 and chalcone 265 were employed. While the β 
substitution is the same for both, they differ in the nature of the electron withdrawing 
carbonyl or nitro group. The nitro group is known to be more electron withdrawing, resulting 
in a more reactive α,β-unsaturated derivative. However, both Michael acceptors played 
different, yet revealing, roles in the scope when used in this reaction. Whilst the nitro olefin 
was reactive enough when TKP 246 was screened, the high reactivity was presumably the 
origin of the lack of selectivity in the scope of TKP 242. Conversely, chalcone’s lower 
reactivity did not meet the necessary reactivity requirements in the TKP 246 scope when 
combined with the high steric clash between the aromatic ring and the methyl ester at the 
nucleophilic reactive centre. However, in the absence of the ester group in TKP 242, this 
Michael acceptor had the perfect reactivity balance to furnish a diastereoselective product of 
the mono-Michael adduct. 
Further electrophiles, such as 1,1'-vinyldisulfone 268, were employed in this scope. As 
expected from its lower reactivity compared with other α-activated Michael acceptors and the 
absence of any diastereoselective challenge, the mono Michael product 298 was the only 
isolated product from the reaction mixture (Scheme 3.25). 
 
Scheme 3.25 Vinyl disulfone Michael addition 
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The rather low yield could be associated with the poor solubility of formed TKP 298 and its 
immediate crystallisation out of the reaction mixture, which could also be linked with the 
absence of any double Michael product. However, the catalyst did not induce great levels of 
stereocontrol in this example and TKP 298 represents the expected isomer but we are not 
absolutely certain about it. 
 
3.4. Synthesis of 6-Alkyl Triketopiperazines 
Having established the limits of the asymmetric Michael transformations on the activated 
TKP 246 and the inactivated parent 242, we next sought to explore the possibility of effecting 
these reactions on α-alkylated TKPs. Bearing in mind the possible difficulties, in particular 
the likely steric clash between the alkyl chain and the electrophile, combined with the absence 
of further activation and, thus, probable decrease of reactivity, we set about optimising a 
method that would allow us to introduce different alkyl chains effectively. The first approach 
consisted of employing LHMDS and allyl bromide (Scheme 3.26)  
 
Scheme 3.26 TKP alkylation using lithium bases 
Unfortunately, the desired product was never observed, most likely due to the incompatibility 
of the highly reactive lithium enolate in the temperature ranges where alkyl halides are 
reactive enough. More typical alkylation conditions using sodium hydride and higher 
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temperatures were subsequently envisaged. Initially, THF at 0 °C was tried, but optimal yields 
were achieved using DMF as solvent (Table 3.3) 
 
Entry RX Yield (%) 
299 AllylBr 82 
300 BnBr 83 
301 nPrI 81 
302 MeI 80a 
[a] Combined yield for the mono and dimethylated TKP 
Table 3.3 Alkyl TKP formation 
The temperature had to be carefully controlled, especially when smaller electrophiles were 
employed so as to avoid double alkylation. However, when the methyl iodide was employed, 
no experimental variations avoided the formation of considerable amounts of 302 together 
with dialkylated product, in an approximate ratio of 2:1. Apart from this case, three alkylated 
TKPs were successfully synthesised in very good yields as shown in the previous table. 
The organocatalysed asymmetric Michael addition was subsequently tried employing the 
optimised conditions previously used. Since these substrates could not undergo double 
addition, all experiments were conducted at 0 °C to accelerate the reaction rate. In spite of 
this, sluggish transformations with considerably extended reaction times, between five to 
seven days, were observed across all examples, depending on the nature of the electrophile 
(Figure 3.12). 
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Figure 3.12 Scope of asymmetric Michael additions on alkyl TKPs 
The enantiomeric excess was only determined for the methyl vinyl ketone and phenyl vinyl 
ketone adducts (303-305, 310 and 311). A maximum er of 77:23 was measured and it was not 
expected to drastically improve in the rest of the examples. The low basicity of the catalyst, 
combined with the extra hindrance at the reactive centre was considered responsible for the 
poor reactivity and selectivity. Nevertheless, this was a remarkable transformation only 
reported once before in the Barbas example of organocatalysed Michael additions to alkyl 
oxindoles, a benzylated centre which was inherently more activated than this present example 
(Scheme 3.22).  
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It was initially conceived that only one enantiomer of the starting material would react faster 
than the other in the presence of the cinchona catalyst, i.e. a kinetic resolution. However, due 
to the yield of the reaction being over 50% consistently and the absence of any enantiomeric 
excess in the unreacted starting material from unfinished experiments that assumption proved 
to be invalid. 
An improvement of the selectivity was pursued and increasing the basicity of the catalyst, in 
order to have a higher enolate concentration in the reaction, was believed to be crucial. Few 
examples where stronger bases have been employed in organocatalysis are reported in the 
literature. We became interested in the triarylamino phosphorane derived catalysts optimised 
by Dixon and co-workers for the stereocontrolled Henry reaction of nitromethane and 
substituted N-diphenylphosphinoyl ketimines such as 314 (Scheme 3.27).165 
 
Scheme 3.27 Dixon superbase catalyst example 
Typically, tertiary amines have a pKBH+ of 18.8 in acetonitrile while these new 
aminophosphoranes were in the range of 22.7, approximately four orders of magnitude more 
basic than the commonly used triethylamine. Chiral bifunctional derivative 315 combines this 
basic moiety with the recurrent thiourea proton donor site in a chiral skeleton, using the 
corresponding amino acid, phenylalanine in this case, as the starting material. Whilst a 
standard cinchona alkaloid catalyst showed no reactivity in this study, a range of 
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enantioselective Henry products such as 316 were isolated when catalyst 315 was employed. 
More interestingly, asymmetric Michael reactions from Scheme 2.4, previously optimised 
with cinchona alkaloid derived thiourea catalyst 179 were completed in a matter of hours 
rather than days with comparable levels of stereocontrol.  
Inspired by this result, catalyst 315 was synthesised as reported in this paper to test it on alkyl 
TKP 300 asymmetric 1,4-additions. Unfortunately, the catalyst failed to deliver the desired 
results as the level of enantioselectivity achieved was only 60:40 er. Nevertheless, reaction 
time was drastically shortened and the products were formed in only one day at −30 °C 
(Scheme 3.28).  
 
Scheme 3.28 Dixon base application on alkyl TKPs 
In conclusion, although the reaction rate was improved, the spatial layout of the bifunctional 
catalyst was not probably suit able for substrate 300 in the asymmetric reaction. In 
comparison with structure of cinchona alkaloids derivatives, this catalyst appears to be much 
more flexible and different minimum energy conformers might be present in solution. This 
feature could justify the low level of induced asymmetry as a high bond rotation around the 
active sites in the catalyst may not be capable of locking the substrates into a fixed 
arrangement before the carbon-carbon bond was made.  
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Having both active sites very close together in the catalyst, only separated by a two carbon 
chain, seemed to be suitable for Dixon’s work. However, it is evident that both electrophile 
and nucleophile involved in this reaction were considerably larger in size than these literature 
substrates. Thus, optimal interaction in such close proximity might be considerably hindered, 
and the new bond could not be formed entirely stereoselectively (Figure 3.13).  
 
Figure 3.13 Comparison of proposed models leading to TKP 305 with catalysts 201 and 315 
Taking this input into account, i.e. in terms of reactivity and conformation, a completely new 
catalyst could be tailored to meet the specific needs of our reaction system. Although this 
issue was not cover under the present project, a few proposals will be outlined in the future 
plans based on the ideas generated from all the gathered information. 
Lastly, sequential Michael additions with different electrophiles were explored by controlling 
temperature and stoichiometry. Essentially, the first Michael could be run as the ones 
optimised from Figure 3.12, where a low temperature (−20 °C at least) and addition of 
equimolar amount of the acceptor furnished the mono Michael product. Once the reaction was 
finished, a superstoichiometric amount of a second acceptor was added. This second reaction 
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could be treated as an alkyl TKP Michael addition, so the temperature could be raised to 0 °C 
and the reaction times were extended. The initial tests are depicted in Scheme 3.29. 
 
Scheme 3.29 Sequential Michael addition 
Sequential use of ethyl vinyl ketone, under the same conditions of the mono Michael product, 
followed by addition of acrolein or methyl vinyl ketone at 0 °C for two days afforded 
products 317a and 317b in good yield. Interestingly, the reaction time of the second addition 
was shorter if compared with the standard alkyl groups previously tried. Although the reaction 
was run with a chiral catalyst, no er could be determination due to lack of separation of the 
racemic adducts in any of the chiral columns available.  
Further tests, with other electrophiles were pursued. Highly reactive nitro olefins were chosen 
to take part as the second Michael acceptor. There were some concerns about the reactivity of 
this class of electrophiles as they feature a fairly bulky group at the reactive centre. The lower 
reactivity of alkyl TKPs could prevent the second addition of these electrophiles from even 
occurring. However, we were pleasantly surprised to isolate not the expected product but 
spiroTKP 318 (Scheme 3.30). 
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Scheme 3.30 Spiro TKP formation 
Product 318 arose from the Henry reaction between the nitro enolate and the electrophilic side 
chain ketone. This transformation proved to be highly diastereoselective as only one product 
was observed in a reaction forming four contiguous stereogenic centres. However, the 
stereochemical assignment could not be completed as the crystallographic data has not been 
elucidated yet. Lastly, upon subjecting the parent TKP to phenyl vinyl ketone followed by 
nitrostyrene under the previous reaction conditions, spiroTKP 319 was isolated from the 
reaction (Scheme 3.31), similarly to the previous example. 
 
Scheme 3.31 Attempt to Spiro-TKP dehydration 
Analogous to spiro TKP 318, the reaction was highly diastereoselective. No enantiomeric 
ratios could be determined in these last two examples, as none of the available columns prove 
effective for any of the spiro-TKPs. Although an optimal catalyst might need to be found for 
these transformations, the possibility of performing sequential stereoselective Michael 
additions represents a remarkable and unprecedented feature to date. 
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3.5. Further Transformations 
Having established organocatalytic methods for the enantioselective synthesis of 
various TKPs, and having set the scene for the synthesis of other TKPs to be optimised in the 
near future, we became interested in the different chemical alternatives our enantioenriched 
products could undergo given the key functionalities present within the molecules. Therefore, 
we focused our efforts on developing routes to access chiral DKPs starting from the TKPs and 
using chiral TKP systems to form bridged DKPs. Ultimately we aimed to devise a mild 
method that would enable us to either hydrolyse the TKP ring so the newly formed 
enantiopure non-natural amino acid could be unveiled or remove the benzyl protecting groups 
from the nitrogens. Work carried out in these three areas will be subsequently described. 
 
3.5.1. Reduction of the C-3 position 
Selective reduction of the carbonyl group belonging to both the imide and the oxalyl 
moieties, also referred as the C-3 carbonyl, would provide us with a very wide set of tools to 
access different types of molecules. For instance, complete reduction to the methylene group 
would furnish the chiral DKP while radical reduction would likely affect this position and the 
side chain carbonyl group furnishing various bridge-closed structures. Fortunately, the C-3 
position has been demonstrated to show distinctive electrophilic properties compared to C-2 
and C-5. The possibility of a Grignard reagent to selectively attack this position was shown to 
be completely selective on this position in the case of unsaturated TKP 320 by Overman and 
co-workers (Scheme 3.32).69a 
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Scheme 3.32 First hint of TKP reactivity 
Furthermore, in the same publication, a unified method to access various ETP natural 
products was described based on the reactivity α-hydroxylactam 321 displays, mainly via 
nucleophilic substitutions of the N-acyl iminium centre generated under acidic treatment. This 
approach could be easily adopted should the regioselectivity of any nucleophilic attack be the 
same for the TKPs. Hence, a simple experiment on the parent TKP in the presence of a simple 
aldehyde or ketone reductant, such as sodium borohydride, helped us to determine whether or 
not the attack on the C-3 carbonyl occurred exclusively (Scheme 3.33). 
 
Scheme 3.33 Reduction on a model TKP 
Typical reaction conditions afforded hydroxy-DKP 322 in good yield. The use of the same 
reductant afforded diol 323 from TKP 251 by reducing the side chain aldehyde witch 
concomitant attack to the TKP C-3 position exclusively (Scheme 3.34). 
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Scheme 3.34 Reduction of a chiral TKP 
Dihydroxy adduct 323 was isolated in a 1:1 diastereomeric mixture. Many other reducing 
agents were tried on a range of chiral TKPs to achieve selectivity on the C-3 carbonyl over the 
diverse side chain groups.  
Bulky reducing agents were also screened in a desire to only affect the more rigid and less 
encumbered region of the molecule. In fact, the reaction of L-selectride with chalcone TKP 
295 afforded hydroxy DKP 324 as the only product of the reaction in good yield and only one 
single diastereoisomer (Scheme 3.35). 
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Scheme 3.35 Selective reduction of C-3 carbonyl 
The steric clash provided by the two phenyl substituents around the side chain ketone was 
probably hindering the approach of the large reducing agent and preventing any reaction on it. 
As it can be inferred from product 295, not only were the side chain substituents obstructing 
the reduction of the ketone but they were also presumed to impede the approach of the 
reductant from the top face where the side chain was and thus, explaining why only one 
diastereoisomer could be observed in the crude reaction mixture. The assignment was also 
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confirmed by indirect nOe correlation. Whilst no direct H-3/H-6 correlation was detected in a 
NOESY experiment, there was a correlation between the OH and the sidechain β-hydrogen 
that could only exist in the shown diastereoisomer (Figure 3.14). 
  
Figure 3.14 NOESY spectra of hydroxyDKP 324 
However, this method could not be generally applied to all cases since β-substitution proved 
essential for the selective reaction of the C-3 carbonyl. A mixture of ketone, C-3 and both 
functionalities reduction were observed from the reaction crude upon subjecting TKP 276 and 
292 to these reaction conditions and only very small amounts of the desired products were 
eventually isolated. 
Hence, the aim was to discover a particular set of conditions that allowed the C-3 position of 
the TKPs to be reduced selectively. Further reducing agents were tried in order to convert the 
TKP into a DKP as desired (Scheme 3.36) 
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Scheme 3.36 Desired reduction  
Borane is very well known for reducing carbonyl groups such as carboxylic acids or amides, 
in the presence of esters and sometimes ketones (Scheme 3.37).166 
 
Scheme 3.37 Borane amide reduction 
However, upon applying these conditions to the TKP system no reaction took place and only 
the starting material was recovered from the reaction mixture. It is known that sodium 
borohydride reduction works via hydride addition to the electrophilic centre, and thus, the 
more electrophilic the carbonyl is, the more facile the reduction. On the other hand, borane is 
reactive towards amides or acids due to the particularly high electron density these carbonyls 
have via successive coordination of borane molecules empty orbitals to the lone pair of 
electrons of the oxygen in the carbonyl group. Hence, the more electron density on the 
carbonyl, the better it would be reduced. In the TKP case, the cyclic carbonyls are not 
particularly highly charged, as they are imides rather than amides.  
Other amide reduction methods were investigated such as silane hydrides (triethyl silane 
hydride and triethoxy silane hydride) in the presence of the Lewis acid, boron trifluoride and 
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TFA. Unfortunately, only the starting materials were recovered after the reaction in all cases 
but one. The side chain ketone was reduced in the presence of BF3•OEt2 and (Et)3SiH to the 
alcohol leaving the C-3 position completely untouched and furnishing the product in 81% 
yield and a 1:1 mixture of diastereoisomers (Scheme 3.38). 
 
Scheme 3.38 Silane reduction of side-chain ketone 
Although few catalytic methods are available in the literature for the selective reduction of 
amides, there have been recent reports by Beller and co-workers where zinc complexes, in the 
presence of silane hydrides, have been employed to effect such transformations, notably, in 
the presence of ketones (Scheme 3.39).167 
 
Scheme 3.39 Zn(OAc)2 catalysed amide reduction 
Unfortunately, upon treatment of chiral TKP 250 under the same conditions, no reaction took 
place and the starting materials could be recovered. 
Mechanistically, these reaction conditions were proposed to form the reactive complex 
between the zinc acetate and the silane before it reacts with the carbonyl centre. The 
hemiaminal silane-ether intermediate was presumed to be formed after the first hydride 
addition. At this stage, the lone pair of electrons from the nitrogen expelled the oxygen as part 
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of a zinc-silane aggregate, furnishing the iminium cation intermediate that got subsequently 
reduced by a second zinc-silane complex. The lone pair of electrons from the amidic nitrogen 
was reported to play a key role in the amide reduction. In the TKP cases, they are delocalised 
among more than one centre, forming an imide and an oxalyl amide and, hence, they are not 
as readily available as this method demands. 
Given the low success with hydride type of reductions, we shifted our attention to radical 
based reducing methods. The TKP system was hypothesised to excel at forming the radical 
anion intermediate due to both the possibility of delocalising the electron into the contiguous 
carbonyl and the anomeric stabilisation provided by the imidic nitrogen (Scheme 3.40). 
 
Scheme 3.40 Proposed radical stabilisation on standard TKP system 
Typical radical conditions, such as AIBN or light as the radical initiators and tributyltin 
hydride, tris(trimethylsilyl)silane or bis(tributyltin) were firstly screened in refluxing toluene 
with no success.168 Hereafter, we focused our attention on single electron transfer (SET) 
reagents. Our interest in this type of chemistry was stirred by the work recently published by 
Procter and co-workers in which they selectively reduce the most electrophilic carbonyl group 
within the ring of barbituric acid derivatives 334 (Scheme 3.41).169 
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Scheme 3.41 Procter mono-reduction of barbituric acid derivatives 
Samarium iodide, in THF with superstoichiometric amounts of water, was employed as the 
reducing agent in this SET followed by acid quench to furnish hydroxy lactams 336. The 
reducing potential of samarium iodide had to be slightly modified so it could reduce the 
imidic position by forming a more reactive complex with water.170 Likewise, the same 
activated imidic position was devised to be readily reduced intheTKPs. The side chain 
carbonyl group reductive potential would also be within range so it was assumed that two 
molecules of SmI2 would be necessary to reduce the Michael adducts. Diradical reaction 
intermediate 338 would then collapse, forming a new carbon-carbon bond, and furnishing 
bicyclo[2.2.3]diazanonane structures such as 339, essentially a bridged DKP, in a formal 
reductive carbonyl coupling (Scheme 3.42) 
 
Scheme 3.42 Proposed SmI2 reaction sequence on TKP adducts 
With this proposal in mind, trials with Michael adducts in dry THF were firstly carried out to 
check whether or not these systems were reactive under those conditions, as Procter stated in 
the barbituric derivatives chemistry. Inthis case, we were delighted to isolate a new compound 
from the reaction mixture. However, upon thorough spectroscopic analysis, this novel 
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structure did not match with the proposed reactivity course, but with fused bicyclic 
compounds 340-346. The reactivity profile was maintained throughout a wide range of 
different TKP Michael products both asymmetric, such as TKPs 250 and 276, and racemic, 
like alkyl TKPs 303, 304, 305, 308 and 309 (Figure 3.15). 
 
 
Figure 3.15 Scope of reactions with SmI2 in THF 
The reaction proved highly diastereoselective, as only one single diastereoisomer could be 
observed in the reaction mixture. X-Ray crystal structure from compound 340 unequivocally 
demonstrated the structure and absolute stereochemistry (Flack parameter: -0.01(4)) of this 
product (Figure 3.16). 
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Figure 3.16 Crystal structure of 340 with 50% of ellipsoid probability, d (O-H) = 1.86(3) Ǻ 
As it can be seen in the crystal structure, the α-DKP substituent and the two newly generated 
hydroxy groups are all directed to the back of the molecule. 
In order to thoroughly explore this chemistry, the reaction of the same TKP substrates to the 
conditions first proposed, SmI2 in THF/water, was also set to check whether the observed 
reactivity was maintained under a more reactive media and whether the envisioned radical 
cyclisation was feasible. To our surprise, no traces of the fused DKP systems were observed 
and the predicted bicyclic systems were solely isolated from the reaction mixture. However, 
only the more stable alkyl TKPs underwent this transformation and in a lower overall yield 
compared with the previous examples (Figure 3.17). 
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Figure 3.17 Scope of reactions with SmI2 in THF/H2O 
The reaction was not completely diastereoselective and inseparable mixtures of 
diastereoisomers, on the bridge fully-substituted carbon, from 2.5:1 to 4:1, were furnished. 
Likewise, the structural conformation was further checked by X-ray crystallography to 
confirm the proposed bicyclic DKP from compound 348 (Figure 3.18). 
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Figure 3.18 Crystal structure of 348 with 50% of ellipsoid probability 
The crystal structure of 348 clearly showed the three carbon bridge over the DKP. The 
structures from both diastereoisomers can be found in the crystal set, the major one being 
displayed in Figure 3.18. Although the set of results from this last transformation may not 
appear to be optimal, the possibility of changing the reaction outcome by the simple addition 
of water is an outstanding feature of these particular TKP Michael products. In the literature, 
there are only a handful of examples showcasing this interesting property. Procter and co-
workers published a samarium iodide mediated transformation where lactone 353 was 
subjected to radical reducing conditions using two different additives, MeOH and tBuOH.171 
Interestingly, two set of results could be easily distinguished. MeOH mediated reaction 
afforded spirolactone 352 while using tBuOH furnished cyclobutanol derivative 354 (Scheme 
3.43).  
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Scheme 3.43 Example of additive dependant SmI2 reaction 
The mechanistic insight behind this phenomenon was based upon the relative rate of proton 
donation by each of the additives. Fast protonation of the anion generated in the β-position of 
the unsaturated lactone by MeOH affords the radical enolate of the ester that attacked the 
ketone electrophilic position after a second electron transfer by samarium affording spiro 
lactam adduct 352. On the other hand, if that protonation was slow, as in the tBuOH case, the 
anion could live long enough to attack the ketone carbonyl forming the cyclobutanol ring. 
Second electron donation, followed by relactonisation, furnished product 354.172 Two more 
types of examples by the same group are available where a change of additive swapped the 
reaction outcome.173 However, the first comprised a reaction between alkenes and ketones 
while the last one was essentially an additive promoted transformation after the samarium 
reduction is over. There are no examples in the literature where an additive is responsible for 
a change in the reaction regioselectivity involving different carbonyl centres and furnishing 
two different pinacol outcomes.  
Mechanistically, the formation of fused bicyclic framework 357 could be explained by 
determining which carbonyl was the most susceptible to being reduced. In spite of the C-3 
position being a very good radical receptor, as previously stated, the side chain carbonyl still 
had, in comparison, a more accessible reductive potential. Since the initial potential of the 
standard SmI2 in THF solution is not high enough to affect the imidic carbonyl, only the 
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ketone or aldehyde gets an electron transferred upon treatment with superstoichiometric 
amounts of the samarium solution. This new species is probably forming an intermediate 
where Sm (III) is tethered to the closest, less hindered carbonyl group, being the C-5 carbonyl 
as in 355. This intermediate presumably exists before the second SET as suggested in the 
literature.174 The second electron might be transferred while the new carbon-carbon bond is 
made in a 5-exo-trig manner to form the fused bicycle. However, this electron can also get 
transferred before the new bond is formed, as in the previous examples by Procter. Hence, the 
transformation could be considered a formal unpolung cyclisation of the side chain ketyl 
carbanion to the C-5 carbonyl position. The high diastereoselectivity could be reasoned due to 
the proposed tethered transition state where the two oxygen atoms are forced into a cis 
conformation which, as a result, dictates the spatial arrangement of the rest of the groups 
around the newly created bond (Scheme 3.44, left side).  
On the contrary, when there was water present in the reaction mixture the reducing potential 
was increased. Although the first SET was presumed to occur on the same centre, addition to 
the carbonyl with the lowest potential energy, donation of a second electron could rapidly 
occur to the next most electrophilic carbonyl in the molecule given the increased potential of 
the SmI2 solution. As previously envisioned, homocoupling of diradical species 359 would 
form a new carbon-carbon bond furnishing bicyclo[2.2.3]diazanonane type of structures in a 
formal reductive cyclisation (Scheme 3.44, right side). 
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Scheme 3.44 Proposed mechanistic pathways for the SmI2 reactions 
The poor diastereoselectivity was proposed to be due the absence of a tethered intermediate 
between the di-radical centres which allowed free bond rotation of the side chain radical. If 
this intermediate could live long enough for the adjacent bond to rotate freely a 1:1 mixture of 
diastereoisomers would be furnished as a result. The fact that some diastereocontrol was 
observed could indicate that both these phenomena, the free rotation and the formation of the 
new bond, are in a similar half-life scale. Changing the additives, such as an alcohol with a 
slower proton release rate, e.g. tBuOH, may also result in a better diastereoselectivity of this 
type of bicyclic DKPs. It is also worth noting that no byproducts were the C-3 carbonyl was 
the only reduced centre was observed in any of the two pathways. 
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In summary, SmI2 mediated transformations successfully furnish two different sets of pinacol 
products depending on the addition of water to the media. Combined with the previously 
reported reductive approaches, a wide range of transformations, affording very diverse results, 
could be accomplished for the TKP substrates. 
 
3.5.1.1 Cyclisations via N-Acyl Iminium 
Overman and co-workers employed the hydroxy lactam intermediate 321 to synthesise a 
myriad of ETP natural products by means of N-acyl iminium chemistry. In a similar manner, 
Procter and co-workers showed how the reduced barbituric adducts 336 could be reacted with 
very useful nucleophilic building blocks using, once more, N-acyl iminium chemistry 
(Scheme 3.45).  
 
Scheme 3.45 Scope of N-acyliminium driven reactions of mono-reduced barbituric acids 
In our desire to build bicyclic DKPs with a clear structural relationship to bicyclomycin 40 we 
focussed our attention on Williams and co-workers enantioselective total synthesis of this 
natural product.41a With dihydroxy DKP 365 in hand, an intramolecular N-acyl iminium 
cyclisation was triggered upon addition of silver triflate as the Lewis acid. The nitrogen lone 
pair of electrons expelled the thioaryl group, aided by the Lewis acid, with concomitant 
nucleophilic attack of this new electrophilic carbon by the side chain hydroxy groups. [2.2.4] 
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Bicycle 366 was formed in preference to the [2.2.3] option with high diastereoselectivity 
(Scheme 3.46). 
 
Scheme 3.46 Bridged DKP formation during bicyclomycin synthesis 
Likewise, dihydroxy adduct 323 , resulting from the reduction of TKP 251, was envisioned to 
behave similarly under Williams N-acyl iminium conditions. Unfortunately, silver triflate 
conditions did not prove reactive enough for DKP 323. However, employing TMS triflate, the 
desired intermolecular cyclisation was accomplished in less than an hour affording 
bicyclomycin surrogate 367 in good yield and selectivity (Scheme 3.47). 
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Scheme 3.47 Bridged DKP formation from TKP adduct 323 
Since aldehydes were not compatible with the available HPLC chiral columns, er of TKP 
adduct 251 was determined using this approach. Bicyclic DKP 367 was a valid substrate for 
further N-acyl iminium reactions and, consequently, it was subjected to a second iteration. In 
order to determine whether the ether bridge would transmit any stereochemical information, a 
subsequent nucleophilic addition of a thiol to this position, promoted by TFA, was envisioned 
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(Scheme 3.48). The aim was to determine if the reaction happened in a concerted way, rather 
than reacting in a stepwise process where the nucleophile independently attacks the iminium 
ion. 
 
Scheme 3.48 N-acyliminium promoted bridge opening 
No retention of the stereochemical information was observed and product 368 was isolated as 
a 1:1 mixture of diastereoisomers as determined by NMR spectroscopy. Hence, it was 
concluded that further acidic conditions would trigger full formation of the N-acyl iminium 
intermediate on this position prior to the nucleophilic attack. No diastereoselectivity at the C-
3 position was enhanced by the fixed stereocentre C-6. 
 
3.5.1.2 Synthesis of Polyfunctional 2,5-Diketopiperazine 
As seen in Scheme 3.45, internal cyclisations or attacks via chalcogen nucleophilic attacks 
were not the sole possibilities for this transformation but a wide range of nucleophiles could 
be used in combination with a Lewis acid to add into the iminium position. Taking Procter’s 
examples into account, hydroxy DKP 324 was subjected to N-acyl iminium conditions with 
BF3•Et2O using triethyl silane as the nucleophilic reductant to furnish enantioselective DKP 
369 (Scheme 3.49). 
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Scheme 3.49 DKP formation via N-acyl iminium chemistry 
This process afforded chiral DKP 369 from the product of a stereocontrolled Michael addition 
with no erosion of er in comparison with original TKP 295 and in an overall yield of 71%.  
Although DKPs from Michael adducts 276 and 292 were also synthesised, the poor selectivity 
of the initial reduction step only afforded small quantities of the desired hydroxy DKP 
intermediate. Not until a selective agent for the exclusive reduction of the C-3 carbonyl is 
found can this approach become routinely applied for the formation of chiral DKPs from the 
corresponding TKPs. 
 
3.5.2. TKP Deprotection 
TKPs and DKPs present in nature are usually found without substituents on their amidic 
nitrogens. Thus, we also became interested in devising a set of conditions that would allow us 
to take the benzyl groups off once the desired transformations around the core were finished. 
With this proposal in mind different methods to facilitate removal of the benzyl groups were 
investigated. Although benzyl protecting groups are widely used in organic chemistry, and 
various deprotection strategies have been optimised, we soon realised that the removal 
appeared to be a daunting challenge on many occasions in the past for many research groups. 
For instance, the total synthesis of bicyclomycin had to be fully redone with PMB protecting 
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groups instead of benzyl ones due to the impossibility of removing them in a late stage of the 
synthesis without altering the rest of the functional groups.41b Likewise, Simpkins and 
Frebault chose O-benzyl hydroxylamine in their total synthesis of ent-malbrancheamide B to 
avoid dealing with the highly resilient standard benzyl group.33d Since all the TKP examples 
had been accomplished with benzyl protecting groups on amides, establishing a method to 
remove them effectively became highly important. 
Firstly, hydrogenolysis was investigated as it is the most commonly used method to remove 
benzyl groups. Typical conditions were applied to TKP 250, i.e. 1 atmosphere of H2 in the 
presence of palladium on carbon (Scheme 3.50). 
 
Scheme 3.50 Attempt to remove benzyl protecting groups 
Unfortunately, no debenzylation was observed. The only product of the reaction was the 
reduction of the side chain ketone, affording product 328 as a 1:1 mixture of diastereoisomers 
as observed in the Et3SiH reduction. Birch reduction is also a very widely used method to 
deprotect benzyl groups, although harsher conditions are required.175 Upon treatment of TKP 
250 to the standard sodium in liquid ammonia conditions, no desired product was observed 
after 30 minutes of reaction and all starting material was fully degraded. The same reaction 
outcome was observed when other methods, such as TMSI175 or AlCl3176 were employed 
(Scheme 3.51). 
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Scheme 3.51 Failed conditions for benzyl group removal 
No desired deprotected TKP was ever observed under any of the tried conditions. Should the 
deprotection became of utmost importance, related TKPs, with similar protecting groups such 
as PMB, could be synthesised. Owing to their wider and more facile deprotection strategies, 
and assuming they would display similar reactivity, they would become good candidates to 
try in the future. 
 
3.5.3. Unveiling the Amino Acid 
Lastly, we were very interested in developing selective conditions to remove the oxalyl 
moiety from chiral TKPs. As a result, a non-natural enantioenriched amino amide would be 
furnished. Developing new methods to synthesise this type of compounds is always one of the 
highest priorities of organic chemists. Synthetic amino acids can often be found active against 
particular diseases and its prospective application in the drug discovery process can be of 
crucial importance. This asymmetric Michael addition was affording masked all-substituted 
amino acids derivatives, using glycine amide as the starting material. Hence, opening the 
cyclic system would yield the desired amino acid precursors. Firstly, the TKP systems were 
hypothesised to behave similarly to the pseudoephedrine and oxazolidinone chiral auxiliaries 
Chapter 3   Synthesis of 2,3,5-triketopiperazines
  
 
134 
during their final deprotection step.177 Essentially, we envisioned to break similar bonds while 
preserving the stereochemical information of the newly created stereocentre (Scheme 3.52).  
 
Scheme 3.52 Oxazolidinone and pseudoephedrine deprotection conditions on TKP adduct 250 
Acidic and basic conditions similar to the optimised methods to break both oxazolidinone and 
pseudoephedrine auxiliaries were employed with TKP substrate 250. However, application of 
these conditions did not yield the desired amino amide. Instead, either the starting material 
was recovered or the TKP was fully degraded in the course of the reaction. It is worth noting 
that full conversion to compound 372 was observed when subjecting alkyl TKP 305 to basic 
conditions (Scheme 3.53). 
 
Scheme 3.53 Unexpected reaction of TKP 305 
Surprisingly, product 372 was cleanly furnished as the only product of the reaction. 
Mechanistically, this compound arose from the enolate attack of the side chain ketone into the 
C-3 carbonyl of the TKP. Instead of fully dehydrating, impossible due to the bridge-head 
location of the hydroxy group, and rather than doing a normal retroaldol, the carbonyl was 
regenerated with concomitant breakage of the C-3/N-4 bond. It seemed that the newly formed 
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molecule preferred an enol resonance form as confirmed by NMR spectroscopy and X-ray 
crystallography (Figure 3.19). 
 
Figure 3.19 Crystal structure of 372 with 50% of ellipsoid probability, d (O-H) = 2.05(3) Ǻ 
Although no er was determined, the stereochemical information from 305 was presumed to be 
transferred to 472 as the transformation did not interfere with the first created stereocentre. 
Nicolaou and co-workers found trimethyl tin hydroxide was an excellent reagent to mildly 
cleave esters and amides bonds when more classical and harsher options failed.178 Subjecting 
TKP 295 to these reaction conditions failed to deliver the desired product but an inseparable 
mixture of starting material and bridged DKP 373 was formed (Scheme 3.54). 
 
Scheme 3.54 Trimethyl tin hydroxide attempt to cleave TKP 295 
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No matter how much conditions were altered, with extended reaction times, 
superstoichiometric amounts of tin and solvent changes, full conversion was never achieved. 
The tin derivative acted as a Lewis acid, catalysing the aldol reaction of the side chain ketone 
to the C-3 carbonyl. The desired aminoamide was not detected in the reaction mixture. 
Interestingly chromatographic purification only furnished 75% of the starting material back, 
demonstrating the instability of bridged DKP 373, which was never isolated. 
Finally, the possibility of expelling the amino amide by reaction of the TKP systems with a 
bidentate nucleophile, such as a diamine, was devised. First addition onto the most reactive 
centre C-3 would yield an acyclic system that would hopefully react in situ, driven by the 
entropic component of the reaction, to form a new cyclic product plus the desired amino 
amide. It is conceivable that the overall loss of steric clashes would drive the whole process 
forward under mild conditions. Initial studies with parent TKP 242 and 
dimethylethylenediamine (DMEDA) were conducted. The starting material was consumed 
overnight to presumably form intermediate acyclic adduct 374 that was subsequently 
transformed under slightly more forcing reaction conditions, mild heating and extended 
reaction times, to the dibenzyl amino amide 237 (Scheme 3.55). 
 
Scheme 3.55 Initial test of proposed TKP cleavage 
However, upon subjecting chiral TKPs 250 and 295 to these reaction conditions, the isolation 
of the starting material was the only observed phenomenon. It was not until alkyl TPK 305 
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was exposed to similar reaction conditions over a period of 4 days that no starting material in 
the reaction mixture was observed. Instead, 375 was the only isolated compound (Scheme 
3.56) 
 
Scheme 3.56 Alkyl TKP 305 cleavage  
The side chain ketone formed a hemiaminal group with the secondary amine after the 
aminoamide was extruded from the oxalyl moiety. Although this result is the only example of 
this type of chemistry we are confident the mild reaction conditions will make the rest of alkyl 
TKPs undergo the exact same transformation.  
 
3.6. Summary and Future Work 
TKPs have been demonstrated to be highly flexible adducts for the asymmetric 
organocatalysed Michael addition reaction. A wide number of enantioenriched products have 
been synthesised using TKP 242 and 246 as the nucleophiles and important breakthroughs in 
the inclusion of alkyl TKPs have been made. Although not all of the examples have been 
furnished in high er, the inclusion of mono-activated and hindered α-alkyl TKPs in this type 
of catalysis is an extremely remarkable feature in itself that may help to extend 
organocatalysis to other related substrates. A wide range of subsequent transformations are 
possible onto the Michael TKP adducts. The samarium iodide chemistry is particularly 
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noteworthy owing to the unique possibility of varying the reaction outcome by the simple 
addition of superstoichiometric amounts of water to the media.  
Subsequent research in this project will be needed to shed light on some unclear areas. 
Optimising the catalyst to furnish highly enantioenriched Michael products from alkyl TKPs 
should be one of the first priorities by either finding the right catalyst in the literature or 
developing an entirely new one to suit our specific needs based on recent advances in the 
literature such as the inclusion squaramides in the cinchona alkaloid scaffolds. Studies 
presented in this chapter should be of great help in the process. 
Different TKPs, such as α-arylated ones, can also be synthesised to expand the reaction scope. 
Likewise, various other electrophiles can be screened, not only carbon based ones, e.g. 
carbonyls or Mannich ones, but also heteroaromatic ones such as dithiols or 
azadicarboxylates. 
As far as the TKP deprotection is concerned, studies in our laboratory have already 
demonstrated that PMB can be a suitable protecting group, prone to deprotection and reliably 
delivering high er across many examples. Amino acid unveiling will have to be thoroughly 
explored but, as aforementioned, the initially developed conditions should prove consistent 
across all carbon substituted alkyl-TKPs and, possibly, aryl ones in the future.  
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Chapter Four 
 
Synthesis of Bridged [2.2.2] Diketopiperazines 
 
4.1. Aims and Objectives 
Methodology orientated projects often have the ultimate goal of applying the targeted 
reaction to the total synthesis of natural products. The Simpkins group in particular has had a 
longstanding interest in the synthesis of natural products with DKPs embedded in their 
structure, especially those belonging to the bicyclo[2.2.2]diazaoctane family. Their intricate 
frameworks, coupled with the potent antitumoural properties they display,32d have motivated 
many research groups worldwide to attempt their total syntheses. Different approaches have 
been adopted for the cyclisation step, and different cascade processes were developed in our 
group to tackle the total synthesis of some members of this family (Scheme 4.1, 4.2).33d,136a 
 
Scheme 4.1 Cationic cascade to form bicyclic DKP core of ent-malbrancheamide 
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Scheme 4.2 Radical cascade to form bicyclic DKP core of stephacidin A 
Cationic and radical cascades were optimised to furnish key intermediates in the total 
syntheses of ent-malbrancheamide and stephacidin A in a diastereomeric ratio of 4:1 and 3:1 
respectively, favouring the desired epimer at the bridged DKP position. The stereochemical 
outcome can be explained by minimisation of steric hindrance between the nitrogen 
protecting group and the gem-dimethyl of the prenyl chain in the respective transition states. 
Although these reports, in combination with the rest of the bridge closing strategies, are 
impressive pieces of research, we aimed to apply the TKP methodology to synthesise 
bicyclo[2.2.2]diazaoctane derivatives. Chiral TKPs were hypothesised to be capable of bridge 
closing under specific conditions after the Michael addition step as shown in Scheme 4.3. 
Specifically, the possibility of developing a tandem process where the enolate intermediate 
from the Michael addition would be reactive enough to attack the proven electrophilic C-3 
position was particularly appealing. 
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Scheme 4.3 Bicyclic DKP proposed sequence 
As outlined in the previous chapter, several conditions such as trimethyltinhydroxide or 
potassium hydroxide achieved this goal albeit either not to completion or the bicyclic system 
was cleaved due to the very reactive media. Clearly, the Michael acceptors would have to play 
a fundamental role for the tandem transformation to be successful. Ketones or aldehydes 
would not fulfil this role as previously observed. A α,β-unsaturated carbonyl derivatives 
whose resulting enolate from the Michael additions could be reactive enough to perform an 
aldol-type condensation onto the C-3 carbonyl would be needed. For instance, ketone α-
protons are very labile (pKa ≤ 20) and hence, the corresponding enolates are relatively stable 
and not so reactive, whilst other derivatives, such as nitriles or esters, have less acidic α-
protons and so their enolates are less stable and more reactive. Therefore, using Michael 
acceptors that produce highly reactive enolate intermediates might trigger the desired tandem 
process and furnish the bicyclic structures in a two-step-one-pot sequence. 
 
4.2. Organocatalysed Tandem Michael-Aldol Reaction on Triketopiperazines 
Initially, the literature was examined to find examples of Michael acceptors different 
from the ones used in the previous chapter and reported to participate in asymmetric 
organocatalysed Michael additions. Disappointingly, just a handful of publications were 
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available with different acceptors. For instance, phenyl vinyl sulfone, a fairly stable Michael 
acceptor, was employed in the 1,4-addition of 1,3-cyanoesters using thiourea derived chiral 
catalyst 389 (Scheme 4.4).179 
 
Scheme 4.4 Previous examples with phenyl vinyl sulfone 
Good yields and ee were obtained, not only using this Michael acceptor but the disulfone 
analogue too. As far as simple α,β-unsaturated esters were concerned, two studies have been 
recently published where ketone enolates are responsible for the intramolecular attack to 
furnish chiral cyclic structures, such as 393, and three stereocentres are generated enantio- and 
diastereoselectively (Scheme 4.5).180 
 
Scheme 4.5 Intramolecular Michael addition of α,β-unsaturated ester 
This desymmetrisation was promoted via enamine catalysis, similarly to List’s proline 
catalysed aldol reaction. Lastly, the work published by Shen et al. showed a similar 
transformation to the envisioned tandem sequence using guanidine chiral catalyst 396 
(Scheme 4.6).181 
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Scheme 4.6 Organocatalysed formal Diels-Alder reaction 
Nucleophilic attack of 394 onto the unsaturated position of the N-phenyl maleimide, followed 
by aldol-type condensation furnished bicyclic adduct 397, in a formal Diels-Alder type 
reaction. Differently N-substituted maleimides were employed in this study, as well various 
fumarate ester derivatives, such as the ones used in Scheme 3.13. Hence, we were determined 
to use maleimides as part of the scope to determine whether they would fall under the open 
TKP category or it would do the tandem sequence.  
Although literature precedents were scarce, simple Michael acceptors were explored to 
determine whether they show any reactivity. Typical conditions were used with activated TKP 
246 and acrylonitrile as the Michael acceptor to afford achiral DKP 398 (Scheme 4.7). 
 
Scheme 4.7 First attempt to synthesise bicyclic DKP 398 using acrylonitrile 
Pleasantly, not only could this Michael adduct promote the desired 1,4-addition, but also the 
envisioned tandem process was spontaneously triggered in the reaction mixture with no other 
additives required in a completely diastereoselective process. The greater nucleophilicity of 
the enolate intermediate was presumed to be playing a fundamental role in the subsequent 
Chapter 4   Synthesis of bridged [2.2.2] diketopiperazines 
  
 
144 
bridge closing reaction. The reaction conditions were optimised using this type of electrophile 
(Table 4.1). 
 
Entry Catalyst Solvent timea Yield (%)b er (%)c 
1 142 CH2Cl2 8 99 84:16 
2 148 CH2Cl2 8 98 88:12d 
3 201 CH2Cl2 24 80 95:5 
4 207 CH2Cl2 24 82 90:10d 
5 204 CH2Cl2 30 82 96:4d 
6 210 CH2Cl2 8 88 97:3d 
7 210 THF 8 50 85:15d 
8 210 Toluene 10 80 96:4d 
9 210 MeCN - - - 
10 210 CHCl3 8 78 95:5d 
[a] Hours. [b] Isolated yield after chromatography. [c] Determined by HPLC analysis. [d] 
Enantiomeric product with respect to entry 1. [e] Reaction conducted using 1 mol% catalyst. 
Table 4.1 Reaction optimisation  
Due to the inherent lower reactivity of the electrophile, all reactions were run at 0 °C in order 
not to extend the reaction times excessively. Noteworthy, use of the natural catalysts 142 and 
148 (entry 1 and 2), as well as thiourea derived catalyst 210 (entry 6), resulted in complete 
reaction in shorter periods of time compared to previously optimal benzyl derived catalysts 
201 and 204 (entry 3, 4 and 5). The distance between the reactive centres in the catalysts 
seemed to have a clear relationship with this phenomenon, being closer in the first case (210), 
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just a two carbon chain linking both functionalities, while remaining further apart in the latter 
(201, Figure 4.1).  
 
Figure 4.1 Optimal catalysts for tandem Michael-aldol reaction 
The effect of this feature might be also linked with increased recorded reaction times, an 
average of three times longer. Owing to the reduced reaction time, and the greater er recorded 
(entry 6), catalyst 210 was chosen to be optimal for this asymmetric transformation. It was 
also worth mentioning that certain solvents had a clear negative influence on the reaction 
outcome. During the reaction optimisation in the previous chapter, the solvent was only 
witnessed to have a minor effect on the asymmetric reaction. Conversely, in the present case, 
some solvents made the reaction sluggish, such as THF (entry 7), or prevented it from 
happening, like acetonitrile (entry 9). Dichloromethane, in combination with catalyst 210, was 
found to be the optimal conditions. 
With these optimised conditions in hand, other Michael acceptors that could undergo this 
tandem transformation were screened (Figure 4.2). 
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Figure 4.2 Scope of the reaction utilising TKP 246. [a] Enantiomeric product of displayed compound 
Simultaneously, the same optimised conditions were tried on the parent TKP 242 to check 
whether the reaction outcome was maintained (Figure 4.3). 
 
Figure 4.3 Scope of the reaction utilising TKP 242. [a] Enantiomeric product of displayed compound 
This reaction proved to be remarkably diastereoselective as three stereogenic centres were 
formed, albeit two of them were fixed by initial recognition. Bicyclic structures were afforded 
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as the only product of the reaction regardless of the TKP starting material used and only one 
diastereoisomer was isolated in all cases. No special care had to be taken during the 
asymmetric Michael addition of TKP 242 as the enolate could not be formed using the 
bridgehead proton and only the mono Michael bicyclic adduct was observed.  
Previously optimised conditions did not seem universally applicable to all cases. Every 
electrophile used in this scope was different from one another, so this lack of homogeneity 
was not entirely surprising. Employing catalyst 201, which was also found to deliver great 
results in this case albeit extended reaction times, gave improved results in some cases. 
Arguably, it could be inferred that catalyst 210 was optimal when the size of the Michael 
acceptors remained small (acrylonitrile or maleimides). When larger α,β-unsaturated 
electrophiles were employed, e.g. acrylic esters or vinyl sulfones, the distance between the 
active sites in the catalyst was reasoned not to be enough for an optimal interaction between 
nucleophile and electrophile in the transition state. 
As far as er were concerned, mixed results were observed across the board, and no consistent 
trend could be easily extrapolated, which was not entirely surprising due to the great disparity 
among the electrophiles. Pleasingly, maleimides behaved in the same fashion as previously 
reported by Shen et al. although the levels of enantioselectivity were good, using TKP 246, to 
poor with TKP 242. Absolute stereochemistry (Flack parameter: 0.04(8)) was assigned by X-
ray crystal determination of structure 406 (Figure 4.4). X-Ray crystal structure from 
compound 407 was also elucidated and is included in Appendixes 2.  
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Figure 4.4 X-Ray crystal structure of bicyclic DKP 406 with 50% of ellipsoid probability 
As inferred from the crystal structure, the substituent on the bridged chain was located above 
the less hindering of the two possible functional groups, i.e. the carbonyl instead of the 
benzylated nitrogen selectively. Also noteworthy, this configuration was in accordance with 
the relative stereochemistry observed in the bicyclo[2.2.2]diazaoctane natural products so a 
total synthesis using this approach might be accessible once the full potential of this 
methodology was explored. 
The reactivity of these types of electrophiles bearing different substituents in either α or β 
position was explored next. The scope of this study was limited by the electron withdrawing 
properties of the substituents in either position of the double bond. Analogous to the previous 
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chapter, Michael acceptors having a methyl substituent in either of the positions were tested 
under the optimal catalytic conditions (Scheme 4.8). 
 
Scheme 4.8 Attempts with both α and β methyl substituted acrylonitrile 
Disappointingly, no reaction took place employing any of the methyl acrylonitrile derivatives 
in Scheme 4.8. However, this lack of reactivity was expected given the aldehyde counterparts 
did not give any sign of reactivity either. No more substitution patterns were explored as they 
were presumed either unreactive or unable to furnish the bicyclic adducts in a tandem process, 
as it was demonstrated in the previous chapter. 
The tandem Michael-aldol type reaction on alkylated TKPs was subsequently investigated. 
Using TKP 299 and the optimised conditions, product 413 was successfully isolated from the 
reaction mixture (Scheme 4.9).  
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Scheme 4.9 Alkyl TKP Michael reaction 
Moderate yields of product were isolated albeit in good levels of induced asymmetry and as a 
single diastereomer. This feature was in sharp contrast with the reaction outcome using the 
more basic Dixon’s triarylamino phosphorane catalyst 315.165 Upon subjecting TKP 299 to 
the same reaction conditions, and only changing the organocatalyst, a separable mixture of 
diastereoisomers were isolated in a 1:1 ratio, although the reaction time was notably reduced 
and no starting material was recovered (Scheme 4.10). 
 
Scheme 4.10 Alkyl TKP Michael reaction 
This lack of diastereocontrol could be related to the unrestricted rotation of the catalyst, which 
might not adopt a fixed conformation during the transition step, affording an epimeric even 
distribution on the nitrile α-position, despite the increased hindrance of the benzyl nitrogen 
position. 
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4.3. Further Transformations 
With a set of optimised conditions to afford enantiomerically enriched bridged DKPs 
in hand, we turned our attention to develop new strategies to make those products more 
synthetically attractive. For this type of molecule, with a structure clearly related to the DKP 
core of an extremely important class of natural products, a mild deprotection method was 
thought to be critically important should the natural product structure ever be attempted.  
Similar conditions to the ones applied to the open TKPs were also tried here. The most 
common benzyl deprotection procedures were used (Scheme 4.11). 
 
Scheme 4.11 Attempts to debenzylated DKP 398 
Unfortunately, and similar to previous results, little success was observed in any of the 
explored conditions. Once more, amidic benzyl protecting groups proved highly resistant. 
However, an analogous outcome to the open TKP version was observed when the bicyclic 
system was subjected to soft basic media (Scheme 4.12). 
 
Scheme 4.12 Bicyclic opening 
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Deprotonation of C-3 hydroxyl group followed by regeneration of the carbonyl moiety with 
concomitant TKP ring opening by breaking the adjacent carbon-nitrogen bond and enol 
formation afforded product 415. Although no er was measured, it was expected to remain 
unvariable from the starting material 398. 
 
4.4. Summary and Future Work 
An unprecedented tandem asymmetric Michael addition-aldol type transformation, in 
a formal Diels-Alder manner, was optimised to yield bicyclic DKP adducts equivalent to the 
core present in the bicyclo[2.2.2]diazaoctane natural product family. An ample range of 
uncommon electrophiles, scarcely used in the literature, were employed. The different 
functionalities on the bridge would give enough site selective reactivity for subsequent 
transformations.  
Catalyst optimisation to furnish DKP adducts in better er will be necessary for selected 
electrophiles, such as maleimides, and possibly once this methodology is extended to the 
alkyl TKPs. In addition, other conditions should be explored in order to access an even wider 
range of electrophiles that are unreactive under the present conditions, e.g. α,β-unsaturated 
amides. 
Further studies on different TKP starting materials as well as on the reactivity of the products 
will be of utmost importance so as the bicycle[2.2.2]diazaoctane products resemble more 
closely the natural members were a total synthesis ever attempted. Firstly, this methodology 
should be applicable to a proline TKP adduct. An ongoing PhD project in the Simpkins 
laboratory has demonstrated that this system is very capable of doing an analogous 
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transformation with an even larger number of electrophiles, probably due to the conformation 
forced by the fused five member ring. Secondly, a mild strategy for the removal of the C-3 
hydroxy group should be devised as it is not present in the structure of natural products. This 
could also be used to introduce further functionalities needed in this position. As this hydroxy 
lactamic group is located in a bridge head position, no N-acyliminium chemistry is likely to 
work due to the impossibility for this centre to adopt a sp2 conformation. Hence, other 
approaches, such as radical chemistry could prove useful in this particular case. 
Lastly, a deprotection strategy needs to be optimised. If this chemistry is easily reproduced on 
the PMB or OBn protected TKPs, it may be recommended to use them instead due to the 
theoretically more feasible and milder deprotection strategies. 
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Chapter Five 
 
Experimental part 
 
5.1. General Methods  
Reactions were carried out under nitrogen using dry solvents. All reagents were used as 
received from commercial suppliers unless otherwise indicated. Melting points were measured 
using a Gallenkamp melting point apparatus and are uncorrected. Infrared spectra were 
recorded on a Perkin Elmer Spectrum 100 FT-IR spectrometer. Absorption maxima (νmax) are 
reported in wavenumbers (cm-1). NMR data were recorded on a Bruker AVIII300, or 
AVIII400 spectrometer. Chemical shifts (δ) are quoted in ppm and coupling constants (J) are 
shown in Hz to one decimal place. Spectra were recorded in deuterated chloroform (unless 
otherwise indicated) and calibrated using residual solvent resonances (1H = 7.26 ppm; 13C = 
77.16 ppm). The multiplicities of 1H NMR signals are abbreviated as follows: s (singlet), d 
(doublet), t (triplet), q (quartet), m (multiplet). Data for 1H NMR spectroscopy is reported as 
follows: chemical shift (multiplicity, coupling constant, number of protons, assignment); and 
for 13C NMR spectra: chemical shift (assignment). 2-Dimensional homonuclear (1H-1H) and 
heteronuclear (1H-13C) NMR experiments, as well as PENDANT spectra, were regularly used 
for unequivocally assignments. All atoms are labelled to simplify assignments. These 
numbers do follow IUPAC naming conventions as strictly as possible. The progress of 
reactions was monitored by thin layer chromatography using Merck silica gel 60 F254 plates, 
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which were visualized with UV light and p-anisaldehyde, acidic potassium permanganate or 
ninhydrin. Flash column chromatography was carried out using Davisil 60Å silica gel and the 
indicated solvent systems. Optical rotations were measured as dilute solutions in the indicated 
solvent in a 25 mm glass cell using an Optical Activity PolAAr 2001 automatic polarimetre 
fitted with a sodium lamp. High performance liquid chromatography (HPLC) analysis was 
performed using a P580 Pump from Dionex, Chromeleon Client, version 6.80 SP1 Build 
2238, Daicel Chiralcel OD Column (250 x 4.6 mm); Daicel Chiralpak AD Column (250 x 4.6 
mm); Daicel Chiralpak IB (250 x 4.6 mm); Phenomenex Lux Cellulose-3 (250 x 4.6 mm), and 
Waters 996 Photodiode Array Detector for the UV detection, monitored at 210 nm, 220 nm or 
230 nm.  
 
5.2. Experimental for Chapter 2 
Preparation of catalysts 
Catalysts 142, 148, 149 and 102 were purchased from Aldrich Inc. and Acros Inc. 
Catalysts 160, 163, 172, 201 – 213 and 315 were prepared according to reported procedures 
and the spectroscopic data matches the corresponding literature.130,165,182 
 
General Procedure A144 
To a solution of the N,N’-dialkyl-2,5-DKP in dry THF under an atmosphere of nitrogen at −78 
°C, a 1.0 M in THF solution of KOtBu (2.5 eq) was added. After the mixture was stirred for 5 
min, the electrophile (5 eq) was added dropwise via syringe and the solution was stirred for 15 
min at the same temperature. The reaction was allowed to warm to room temperature and left 
to stir for 5 hours. When the starting material was consumed the reaction was quenched with 
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saturated NH4Cl and diluted with EtOAc. The aqueous phase was extracted with EtOAc (3 x 
20 mL) and the resulting organic layers were washed with brine (15 mL), dried over MgSO4 
and concentrate under vacuum. The crude was purified by column chromatography on silica 
gel (CH2Cl2/acetone) to afford the product. 
 
Synthesis of (E)-3-(hydroxymethylene)-1,4-dimethylpiperazine-2,5-dione 198147 
 
To solution of sarcosine anhydride 197 (250 mg, 1.8 mmol) in dry THF (20 mL) under an 
atmosphere of nitrogen at −78 °C, a solution of the KOtBu 1.0 M in THF (4.6 mL, 4.6 mmol) 
was added. After 5 min ethyl formate (0.528 g, 8.8 mmol, 0.54 mL) was added dropwise via 
syringe. The solution was stirred for further 15 min at the same temperature, allowed to warm 
to room temperature and left to stir for 5 h. The crude was cooled to 0 °C and the resulting 
cake was filtered and washed with THF, leaving a yellowish, sticky solid. This solid was 
subsequently dried under vacuum for 12 h. The dried cake was redisolved in water and 
acidifies with HCl 1.0 M until pH 3-3.5. The water was evaporated under reduced pressure 
and the resulting solid was washed with CHCl3. The organic layer was evaporated affording 
product 198 (295 mg, 97%) as a white solid. m.p. 92 - 95 °C; IR νmax /cm-1 3356, 2951, 1738, 
1661, 1424, 1405, 1323, 1255, 1165, 1043, 988, 920, 747, 678; 1H NMR (300 MHz, CDCl3) δ 
12.50 (d, J = 11.2 Hz, 1H, OH), 7.00 (d, J = 11.2 Hz, 1H, H-9), 4.05 (s, 2H, H-6), 3.10 (s, 3H, 
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H-7), 2.99 (s, 3H, H-8); 13C NMR (100 MHz, CDCl3) δ 163.6 (C-5), 159.7 (C-2), 146.0 (C-9), 
111.7 (C-3), 51.6 (C-6), 32.7 (C-8), 28.2 (C-7); m/z (ES) C7H11N2O3 [MH]+ 171.1. 
 
Synthesis of methyl 1,4-dimethyl-3,6-dioxopiperazine-2-carboxylate 200a 
 
General procedure A using sarcosine anhydride 197 (500 mg, 3.52 mmol), dimethyl carbonate 
(1.3 mL, 10.6 mmol), THF (30 mL), 1.0 M solution of KOtBu in THF (9.2 mL, 9.2 mmol) 
was followed to synthesise product 200a (432 mg) as a white solid in 62% yield after being 
purified by flash column chromatography (gradient: CH2Cl2/acetone = (8:2) to (7:3). m.p. 123 
- 125 °C; IR νmax /cm-1 2956, 2902, 1733, 1674, 1438, 1402, 1239, 1211 1185, 1039, 1066; 1H 
NMR (300 MHz, CDCl3) δ 4.60 (s, 1H, H-2), 4.20 (d, J = 17.3 Hz, 1H, H-5b), 3.86 (d, J = 
17.3 Hz , 1H, H-5a), 3.86 (s, 3H, H-8), 3.01 (s, 3H, H-10), 2.97 (s, 3H, H-9); 13C NMR (100 
MHz, CDCl3) δ 166.9 (C-7), 164.6 (C-3), 160.1 (C-6), 66.0 (C-2), 53.7 (C-8), 51.7 (C-5), 33.9 
(C-9), 32.9 (C-10); m/z (ES) C8H12N2O4 [MNa]+ 223.1.  
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Synthesis of 3-acetyl-1,4-dimethylpiperazine-2,5-dione 200b 
 
General procedure A using sarcosine anhydride 197 (1.0 g, 7.05 mmol), EtOAc (3.1 g, 35.2 
mmol, 3.2 mL), THF (60 mL), 1.0 M solution of KOtBu in THF (18.3 mL, 18.3 mmol) was 
followed to synthesise product 200b (1.03 g) as a white solid in 80% yield after being purified 
by flash column chromatography (gradient: CH2Cl2/acetone = (8:2) to (7:3). m.p. 134 - 135 
°C; IR νmax /cm-1 2986, 2946, 1721, 1658, 1487, 1446, 1405, 1328, 1226, 1170, 1026; 1H 
NMR (300 MHz, CDCl3) δ 4.75 (s, 1H, H-3), 4.01 (d, J = 17.3 Hz, 1H, H-6b), 3.78 (d, J = 
17.3 Hz, 1H, H-6a), 2.94 (s, 3H, H-10), 2.85 (s, 3H, H-7), 2.41 (s, 3H, H-9); 13C NMR (100 
MHz, CDCl3) δ 199.7 (C-8), 164.8 (C-2), 160.1 (C-5), 73.1 (C-3), 51.7 (C-6), 33.9 (C-7), 33.1 
(C-10), 27.9 (C-9); m/z (ES) C8H12N2O3 [MNa]+ 207.1.  
 
Synthesis of 3-benzoyl-1,4-dimethylpiperazine-2,5-dione 200c 
 
General procedure A using sarcosine anhydride 197 (250 mg, 1.76 mmol), methyl benzoate 
(719 mg, 5.28 mmol, 0.66 mL), THF (15 mL), 1.0 M solution of KOtBu in THF (4.6 mL, 4.6 
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mmol) was followed to synthesise product 200c (236 mg) as a white solid in 55% yield after 
being purified by flash column chromatography (gradient: CH2Cl2/acetone = (8:2) to (7:3). 
m.p. 114 - 116 °C; IR νmax /cm-1 3054, 3008, 2923, 2895, 1675, 1663, 1594, 1482, 1449, 
1399, 1262, 1231, 1216, 1020, 960, 688; 1H NMR (300 MHz, CDCl3) δ 8.26 (dt, J = 8.6, 1.7 
Hz, 2H, H-10), 7.66 (m, 1H, H-12), 7.52 (m, 2H, H-11), 5.62 (s, 1H, H-3), 4.22 (d, J = 17.3 
Hz, 1H, H-6b), 3.84 (d, J = 17.3 Hz, 1H, H-6a), 2.92 (s, 3H, H-13), 2.87 (s, 3H, H-7). 13C 
NMR (100 MHz, CDCl3) δ 191.7 (C-8), 166.1 (C-2), 160.4 (C-5), 134.8 (C-12), 133.9 (C-9), 
130.1 (C-Ar), 128.9 (C-Ar), 68.6 (C-3), 52.1 (C-6), 34.0 (C-7), 33.1 (C-13); m/z (ES) 
C13H14N2O3 [MNa]+ 269.1.  
 
Synthesis of 1,4-dibenzylpiperazine-2,5-dione 199183 
 
To a suspension of glycine anhydride 224 (570 mg, 5 mmol) in dry DMF (10 mL), NaH (600 
mg, 60% suspension in mineral oil, 15 mmol) and benzyl chloride (1.30 g, 1.18 mL, 10.25 
mmol) were added sequentially at 0 °C, warmed to room temperature and stirred overnight at 
room temperature. The reaction was quenched with water (15 mL) and dissolved in EtOAc 
(12 mL). Both layers were separated and the aqueous phase was extracted with EtOAc (3 x 10 
mL), the combined organic layers were washed with water (2 x 10 mL), brine (10 mL), dried 
over MgSO4 and condensed under reduced pressure. The crude was purified by 
recrystallization with EtOAc to afford the title compound 199 (1.05 g, 71%) as a white solid. 
Chapter 5   Experimental
  
 
160 
m.p. 149 - 151 °C; IR νmax /cm-1 3029, 2936, 1650, 1469, 1455, 1423, 1331, 1274, 1069, 934, 
745, 722, 697; 1H NMR (300 MHz, CDCl3) δ 7.41 – 7.26 (m, 10H, H-Ar), 4.60 (s, 4H, H-5), 
3.95 (s, 4H, H-3); 13C NMR (100 MHz, CDCl3) δ 163.3 (C-2), 134.9 (C-6), 129.0 (C-Ar), 
128.6 (C-Ar), 128.2 (C-9), 49.3 (C-3), 49.2 (C-5); m/z (ES) C18H18N2O2, [MNa]+ 317.1.  
 
Synthesis of 3-acetyl-1,4-dibenzylpiperazine-2,5-dione 200d 
 
General procedure A using DKP 199 (294 mg, 1 mmol), EtOAc (440 mg, 0.45 mL, 5.0 
mmol), THF (15 mL), 1.0 M solution of KOtBu in THF (2.6 mL, 2.6 mmol) was followed to 
synthesise product 200d (189 mg) as a white solid in 56% yield after being purified by flash 
column chromatography (gradient: CH2Cl2/acetone = (8:2) to (7:3). m.p. 125 - 126 °C; IR νmax 
/cm-1 3031, 2930, 1729, 1686, 1659, 1494, 1451, 1432, 1356, 1319, 1267, 1229, 1157, 1071, 
946, 729, 695; 1H NMR (300 MHz, CDCl3) δ 7.40 – 7.32 (m, 6H, H-Ar), 7.24 – 7.15 (m, 4H, 
H-Ar), 4.99 (d, J = 14.7 Hz, 1H, H-7b), 4.75 (s, 1H, H-3), 4.63 (d, J = 14.6 Hz, 1H, H-11b), 
4.48 (d, J = 14.6 Hz, 1H, H-11a), 4.11 (d, J = 14.7 Hz, 1H, H-7a), 3.97 (d, J = 17.2 Hz, 1H, 
H-6b), 3.82 (d, J = 17.2 Hz, 1H, H-6a), 2.23 (s, 3H, H-10); 13C NMR (100 MHz, CDCl3) δ 
200.0 (C-9), 165.0 (C-2), 160.5 (C-5), 134.7 (C-12), 134.5 (C-8), 129.1 (C-Ar), 129.0 (C-Ar), 
128.4 (C-Ar), 128.3 (C-Ar), 128.1 (C-Ar), 69.9 (C-3), 49.8 (C-11), 49.5 (C-6), 48.7 (C-7), 
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27.8 (C-10); 1 signal in the C-H aromatic region was not observed due to having equivalent 
resonances; m/z (ES HRMS) C20H20N2O3Na, 359.1374, found [MNa]+ 359.1372.  
 
Synthesis of 1,4-dimethyl-3,6-dioxo-2-(3-oxopropyl)piperazine-2-carbaldehyde 219  
 
To a solution of DKP 198 (51 mg, 0.3 mmol) in CH2Cl2 (0.7 mL) catalyst 148 (9.73 mg, 0.03 
mmol) was added. When the mixture became homogeneous acrolein (42 mg, 50 µL, 0.75 
mmol) was added dropwise via syringe and the reaction was left to stir at room temperature 
for 24 h. The crude was filtered through a silica pad and washed with EtOAc (5 mL) to 
remove the catalyst. The reaction was purified by column chromatography on silica gel 
(CH2Cl2/acetone (1:1) to afford compound 219 as a colourless oil (23.7 mg, 35%). IR νmax 
/cm-1 2921, 1720, 1650, 1452, 1400, 1338, 1249, 1124, 1071, 1016, 734; 1H NMR (300 MHz, 
CDCl3) δ 9.75 (t, J = 1.0 Hz, 1H, H-10), 9.46 (s, 1H, H-7), 4.06 (m, 2H, H-5), 2.99 (s, 3H, H-
12), 2.86 (s, 3H, H-11), 2.77 (m, 1H, H-8b), 2.50 (m, 2H, H-9), 2.21 (m, 1H, H-8a); 13C NMR 
(101 MHz, CDCl3) δ 199.5 (C-10), 193.1 (C-7), 164.2 (C-3), 161.5 (C-6), 73.9 (C-2), 51.0 (C-
5), 37.8 (C-9), 33.9 (C-12), 29.6 (C-11), 23.3 (C-8); m/z (ES HRMS) C10H15N2O4 requires 
227.1032, found [MH]+ 227.1024; = 0.00 (c 1.24, acetone)  
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Synthesis of di-tert-butyl 2,5-dioxopiperazine-1,4-dicarboxylate 225a 
 
To a suspension of glycine anhydride 224 (2.00 g, 17.5 mmol) in dry DMF (20 mL), DMAP 
(0.43 g, 3.5 mmol) and di-tertbutyl dicarbonate (8.03 g, 36.8 mmol) were added sequentially. 
The mixture was heated at 50 °C and stirred overnight. The reaction was quenched with water 
(15 mL) and dissolved in EtOAc (20 mL). Both layers were separated and the aqueous phase 
was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine 
(3 x 20 mL), dried over MgSO4 and condensed under reduced pressure. The crude was 
purified by column chromatography on silica gel (Petrol/EtOAc (8:2) to afford compound 
225a (4.60 g, 84%) as a white solid. m.p. 125 - 126 °C; IR νmax /cm-1 2976, 1787, 1721, 1674, 
1323, 1291, 1185, 1136, 945, 853; 1H NMR (300 MHz, CDCl3) δ 4.42 (s, 4H, H-3), 1.52 (s, 
18H, H-7); 13C NMR (100 MHz, CDCl3) δ 164.5 (C-2), 149.5 (C-5), 85.1 (C-3), 49.5 (C-6), 
27.9 (C-7); m/z (ES) C14H22N2O6, [MNa]+ 327.1. 
 
Synthesis of 1,4-Diacetylpiperazine-2,5-dione 225b 
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A suspension of glycine anhydride 224 (1.53 g, 13.4 mmol) in acetic anhydride (8 mL) was 
refluxed for 5 h. The reaction was allowed to cool down to room temperature, the solvent was 
azeotropically removed under reduced pressure (MeOH and Toluene) and the resulting brown 
solid was purified by recrystallization (Et2O), to afford compound 225b (2.39 g, 90%) as a 
white solid. m.p. 97 - 98 °C; IR νmax /cm-1 2926, 1700, 1416, 1358, 1306, 1261, 1225, 1179, 
1129, 1078, 1040, 975, 947; 1H NMR (300 MHz, CDCl3) δ 4.60 (s, 4H, H-3), 2.59 (s, 6H, H-
6); 13C NMR (100 MHz, CDCl3) δ 170.7 (C-5), 165.9 (C-2), 47.2 (C-3), 26.7 (C-6), m/z (EI) 
C8H10N2O4, [M]+ 198.1.  
 
Synthesis of tert-butyl 3-((tert-butoxycarbonyl)amino)-4-hydroxy-2-oxo-2,5-dihydro-1H-
pyrrole-1-carboxylate 226152 
 
General procedure A was followed using di-tert-butyl 2,5-dioxopiperazine-1,4-dicarboxylate 
225a (160 mg, 0.48 mmol), EtOAc (220 mg, 0.23 mL, 2.5 mmol), THF (7 mL), 1.0 M 
solution of KOtBu in THF (1.3 mL, 1.3 mmol). Compound 226 was obtained (122 mg, 75%) 
as a white solid. m.p. 64 - 66 °C; IR νmax /cm-1 3333, 2982, 1770, 1710, 1681, 1658, 1532, 
1360, 1279, 1257, 1152, 936, 774; 1H NMR (300 MHz, CDCl3) δ 11.26 (s, 1H, OH), 6.57 (s, 
1H, NH), 4.14 (s, 2H, H-5), 1.55 (s, 9H, H-12), 1.50 (s, 9H, H-8); 13C NMR (100 MHz, 
CDCl3) δ 165.0 (C-2), 155.7 (C-6), 150.7 (C-4), 148.9 (C-10), 104.0 (C-3), 83.3 (C-11), 83.0 
(C-7), 47.0 (C-5), 28.1 (C-12, C-8); (ES) C14H22N2O6, [MNa]+ 337.1.   
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Synthesis of di-tert-butyl 3-benzoyl-2,5-dioxopiperazine-1,4-dicarboxylate 228 
 
To a solution of DKP 225a (78.3 mg, 0.25 mmol) in dry THF under an atmosphere of 
nitrogen at −78 °C, a 1.0 M in THF solution of LHMDS (0.26 mL, 0.26 mmol) was added. 
After the mixture was stirred for 10 min, the electrophile (30.5 µL, 0.26 mmol) was added 
dropwise via syringe and the solution was stirred for 45 min longer at the same temperature. 
When the starting material was consumed the reaction was quenched with saturated NH4Cl 
and diluted with EtOAc. The aqueous phase was extracted with EtOAc (3 x 20 mL) and the 
resulting organic layers were washed with brine (15 mL), dried over MgSO4 and concentrate 
under vacuum. The crude was purified by column chromatography on silica gel (Petrol/EtOAc 
(8:2) to afford compound 228 (68.1 mg, 65%) as a white solid. m.p. 141 - 143 °C; IR νmax 
/cm-1 2986, 1780, 1728, 1686, 1451, 1401, 1370, 1296, 1227, 1143, 1083, 978, 723, 687; 1H 
NMR (400 MHz, CDCl3) δ 8.27 (m, 2H, H-12), 7.77 (m, 1H, H-14), 7.55 (t, J = 7.8 Hz, 2H, 
H-13), 6.47 (s, 1H, H-3), 4.73 (d, J = 17.9 Hz, 1H, H-6b), 4.26 (d, J = 17.9 Hz, 1H, H-6a), 
1.52 (s, 9H, H-9), 1.49 (s, 9H, H-17); 13C NMR (101 MHz, CDCl3) δ 190.6 (C-10), 164.5 (C-
5), 160.6 (C-2), 149.9 (C-15), 149.4 (C-7), 133.1 (C-14), 130.3 (C-11), 129.3 (C-12), 128.9 
(C-13), 85.6 (C-8), 85.4 (C-16), 65.8 (C-3), 49.1 (C-6), 27.8 (C-9, C-17); m/z (ES HRMS) 
C21H26N2O7Na requires 441.1638, found [MNa]+ 441.1651. 
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Synthesis of 1,3,4-triacetylpiperazine-2,5-dione 229152 
 
General procedure A was followed using 1,4-diacetylpiperazine-2,5-dione 225b (100 mg, 
0.51 mmol), EtOAc (66.7 mg, 68.5 µL, 0.76 mmol), THF (5 mL), 1.0 M solution of KOtBu in 
THF (0.76 mL, 0.76 mmol). Compound 229 was obtained as a colourless oil (25.8 mg, 22%). 
IR νmax /cm-1 2941, 1682, 1598, 1449, 1369, 1229, 1086, 966, 712, 685; 1H NMR (300 MHz, 
CDCl3) δ 5.94 (s, 1H, H-3), 5.04 (d, J = 18.1 Hz, 1H, H-6b), 3.90 (d, J = 18.1 Hz, 1H, H-6a), 
2.63 (s, 3H, H-12), 2.60 (s, 3H, H-8), 2.49 (s, 3H, H-10); 13C NMR (101 MHz, CDCl3) δ 
197.5 (C-9), 171.2 (C-11), 170.6 (C-7), 165.0 (C-5), 162.3 (C-2), 68.5 (C-3), 46.5 (C-6), 27.4 
(C-8), 26.8 (C-10), 26.6 (C-12); m/z (ES) C10H12N2O5Na, [MNa]+ 263.1. 
 
Synthesis of 1,4-diacetyl-3-benzoylpiperazine-2,5-dione 230 
 
To a solution of DKP 225b (198.2 mg, 1 mmol) in dry THF under an atmosphere of nitrogen 
at −78 °C, a 1.0 M in THF solution of LHMDS (1.05 mL, 1.05 mmol) was added. After the 
mixture was stirred for 10 min, the electrophile (174 µL, 1.5 mmol) was added dropwise via 
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syringe and the solution was stirred for 45 min longer at the same temperature. When the 
starting material was consumed the reaction was quenched with saturated NH4Cl and diluted 
with EtOAc. The aqueous phase was extracted with EtOAc (3 x 30 mL) and the resulting 
organic layers were washed with brine (20 mL), dried over MgSO4 and concentrate under 
vacuum. The crude was purified by column chromatography on silica gel (Petrol/EtOAc (8:2) 
to (2:1) to afford compound 230 (158 mg, 52%) as a colourless oil. IR νmax /cm-1 1701, 1418, 
1366, 1201, 1169, 1089, 1040, 963, 680; 1H NMR (400 MHz, CDCl3) δ 8.27 (m, 2H, H-11), 
7.73 (m, 1H, H-13), 7.58 (m, 2H, H-12), 6.85 (s, 1H, H-3), 5.09 (d, J = 18.2 Hz, 1H, H-6b), 
4.14 (d, J = 18.2 Hz, 1H, H-6a), 2.66 (s, 3H, H-15), 2.55 (s, 3H, H-8); 13C NMR (101 MHz, 
CDCl3) δ 190.0 (C-9), 171.4 (C-14), 170.8 (C-7), 166.0 (C-5), 162.4 (C-2), 135.3 (C-13), 
132.9 (C-10), 130.3 (C-11), 129.0 (C-12), 64.0 (C-3), 47.0 (C-6), 27.0 (C-8), 26.6 (C-15); m/z 
(ES HRMS) C15H14N2O5Na requires 325.0800, found [MNa]+ 325.0787. 
 
5.3. Experimental for Chapter 3 
Preparation of triketopiperazine precursors 
1,1’-(1,2-Dioxoethane-1,2-diyl)bis-1H-benzotriazole was synthesised according to literature 
procedures.156 
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Synthesis of N-benzyl-2-(benzylamino)acetamide 237154 
 
To a solution of benzylamine was added (50 mL, 460 mmol)dissolved in dry acetonitrile (500 
mL) bromoacetyl bromide (10 mL, 115 mmol) portion wise at 0 °C over a period of 10 
minutes under nitrogen. The reaction was left warm to room temperature overnight. After the 
reaction went to completion, it was quenched with saturated NaHCO3 (100 mL), extracted 
with EtOAc (3 x 200 mL), the organic layer was washed with brine (1 x 200 mL), dried over 
MgSO4, filtered an evaporated to afford a colourless oil. The crude product was purified by 
column chromatography on silica gel (EtOAc/Petrol (1:2) to EtOAc (100%) to afford the 
desired product 237 (25.8 g, 88%) as a colourless oil. IR νmax /cm-1 3303, 3063, 3030, 2924, 
2879, 1650, 1523, 1496, 1454, 1426, 1266, 1028, 910, 731, 696; 1H NMR (300 MHz, CDCl3) 
δ 7.59 (s, 1H, H-3), 7.44 – 7.19 (m, 10H, H-Ar), 4.48 (d, J = 6.0 Hz, 2H, H-4), 3.78 (s, 2H, H-
7), 3.38 (s, 2H, H-2), 1.90 (s, 1H, H-6); 13C NMR (100 MHz, CDCl3) δ 171.4 (C-1), 139.3 (C-
8), 138.4 (C-5), 128.7 (C-Ar), 128.6 (C-Ar), 128.1 (C-Ar), 127.7 (C-Ar), 127.4 (C-Ar), 127.4 
(C-Ar), 54.0 (C-7), 52.0 (C-2), 43.0 (C-4); m/z (ES HRMS) C16H19N2O requires 255.1497, 
found [MH]+ 255.1501. 
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Synthesis of 1,4-dibenzylpiperazine-2,3,5-trione 242 
 
To a suspension of 1,1’-(1,2-Dioxoethane-1,2-diyl)bis-1H-benzotriazole (153.2 mg, 0.53 
mmol) in dry THF (1.5 mL) in a microwave vial, N-benzyl-2-(benzylamino)acetamide (127.0 
mg, 0.50 mmol) was added in one portion. After the vial was closed and the reaction was 
stirred for 10 min the crude was subjected to the microwave reaction for 1h at 150 °C. The 
solvent was then evaporated and the residue was purified by column chromatography on silica 
gel (CH2Cl2/acetone (95:5) to afford the desired product 242 (102 mg, 67%) as a yellow solid. 
m.p. 177 - 180 °C; IR νmax /cm-1 3062, 3036, 2956, 2923, 1748, 1670, 1604, 1425, 1392, 
1359, 1341, 1264, 1211, 981, 954, 723, 693; 1H NMR (400 MHz, CDCl3) δ 7.37 (m, 2H, H-
Ar), 7.31 – 7.26 (m, 3H, H-Ar), 7.25 – 7.19 (m, 5H, H-Ar), 4.93 (s, 2H, H-9), 4.61 (s, 2H, H-
7), 4.12 (s, 2H, H-6); 13C NMR (101 MHz, CDCl3) δ 164.7 (C-5), 156.3 (C-3), 152.1 (C-2), 
135.1 (C-10), 133.7 (C-8), 129.7 (C-Ar), 129.2 (C-Ar), 129.0 (C-Ar), 128.8 (C-Ar), 128.6 (C-
Ar), 128.3 (C-Ar), 50.5 (C-7), 49.8 (C-6), 44.2 (C-9); m/z (ES HRMS) C18H17N2O3 requires 
309.1239, found [MH]+ 309.1231. 
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Synthesis of 6-benzoyl-1,4-dibenzylpiperazine-2,3,5-trione 247 
 
Triketopiperazine 242 (69.3 mg, 0.25 mmol) was dissolved in dry THF (3 mL) and cooled 
down to −78 °C. LHMDS (1M in THF, 0.26 mmol, 0.26 mL) was subsequently added 
dropwise and the mixture was left to stir for 45 min. Benzoyl chloride (105 mg, 0.75 mmol, 
0.09 mL) was added in one portion and the reaction was further stir at −78 °C for 3h. When 
the starting material was consumed by TLC the crude was quenched with NH4Cl (5 mL). Both 
layers were separated and the aqueous phase was extracted with EtOAc (3 x 10 mL) and the 
combined organic layers were washed with brine (1 x 15 mL), dried over MgSO4 and 
condensed under reduced pressure. The crude was purified by column chromatography on 
silica gel (Petrol/EtOAc (4:1) to Petrol/EtOAc (2:1) to afford 247 (57.1 mg, 56%) as a white 
solid. m.p. 154 – 155 °C; IR νmax /cm-1 3030, 3012, 1747, 1682, 1437, 1358, 1233, 1182, 933, 
919, 731, 697, 683, 635; 1H NMR (400 MHz, CDCl3) δ 7.84 (m, 2H, H-Ar), 7.66 (m, 1H, H-
Ar), 7.49 (m, 2H, H-Ar), 7.32 – 7.18 (m, 8H, H-Ar), 7.14 (td, J = 7.7, 3.2 Hz, 2H, H-Ar), 5.86 
(s, 1H, H-6), 5.08 – 4.95 (m, 2H, H-7b, H-9b), 4.85 (d, J = 13.9 Hz, 1H, H-9a), 4.29 (d, J = 
14.6 Hz, 1H, H-7a); 13C NMR (101 MHz, CDCl3) δ 190.1 (C-11), 162.6 (C-5), 156.7 (C-3), 
154.6 (C-2), 135.3 (C-13), 134.9 (C-10), 132.9 (C-12), 132.7 (C-8), 129.7 (C-Ar), 129.1 (C-
Ar), 129.0 (C-Ar), 128.8 (C-Ar), 128.6 (C-Ar), 128.5 (C-Ar), 128.1 (C-Ar), 65.1 (C-6), 49.7 
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(C-7), 44.7 (C-9); 1 signal in the C-H aromatic region was not observed due to having 
equivalent resonances; m/z (ES HRMS) C25H20N2O4Na, 435.1321, found [MNa]+ 435.1322. 
 
Synthesis of methyl 1,4-dibenzyl-3,5,6-trioxopiperazine-2-carboxylate 246 
 
Triketopiperazine 242 (252.4 mg, 0.82 mmol) was dissolved in dry THF (4.5 mL) and cooled 
down to −78 °C. LHMDS (1M in THF, 0.90 mmol, 0.90 mL) was subsequently added 
dropwise and the mixture was left to stir for 45 min. Methyl carbonocyanidate (209.2 mg, 
2.46 mmol, 0.20 mL) was added in one go and the reaction is left to stir for 20 min at −78 °C 
and it was let to warm up over 2h to 0 °C. When the starting material was consumed the 
mixture was quenched with NH4Cl (5 mL) and EtOAc (5 mL). Both layers were separated and 
the aqueous phase was extracted with EtOAc (3 x 15 mL) and the combined organic layers 
were washed with brine (1 x 20 mL), dried over MgSO4 and condensed under reduced 
pressure. The crude was purified by column chromatography on silica gel (Petrol/EtOAc (3:1) 
to afford 246 (262.5 mg, 87%) as a yellow solid. m.p. 89 – 91 °C; IR νmax /cm-1 2988, 2903, 
1748, 1732, 1686, 1435, 1239, 1171, 1059, 731, 698; 1H NMR (400 MHz, CDCl3) δ 7.43 – 
7.22 (m, 10H, H-Ar), 5.07 – 4.92 (m, 3H, H-7b, H-11), 4.82 (s, 1H, H-2), 4.40 (d, J = 14.6 
Hz, 1H, H-7a), 3.59 (s, 3H, H-10); 13C NMR (101 MHz, CDCl3) δ 165.1 (C-3), 161.9 (C-9), 
155.9 (C-5), 153.0 (C-6), 134.7 (C-12), 133.1 (C-8), 129.5 (C-Ar), 129.1 (C-Ar), 129.0 (C-
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Ar), 129.0 (C-Ar), 128.7 (C-Ar), 128.3 (C-Ar), 64.0 (C-2), 54.2 (C-10), 49.9 (C-7), 44.8 (C-
11); m/z (ES HRMS) C20H18N2O5Na requires 389.1113, found [MNa]+ 389.1105. 
 
Preparation of Racemic adducts: 
To a solution of triketopiperazine (0.1 mmol) in CH2Cl2 (0.7 mL) at −78 °C, triethylamine (10 
mol%) was added followed by the Michael acceptor (2.5 eq). The mixture was allowed to 
warm to −20 °C and left to react until the starting material was consumed. The crude mixture 
was directly purified by flash chromatography. 
 
General procedure B for enantioselective Michael addition of triketopiperazines to α,β-
unsaturated ketones and aldehydes 
 
To a mixture of triketopiperazine (0.1 mmol) and chiral catalyst (4.0 mg, 10 mol%) dissolved 
in CH2Cl2 (0.7 mL) at −78 °C, the Michael acceptor was added neat over 1 minute. The 
reaction mixture was allowed to warm to –20 °C and left to react. After the starting material 
was completely consumed the crude was directly purified by flash chromatography. 
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Synthesis of methyl (S)-1,4-dibenzyl-3,5,6-trioxo-2-(3-oxobutyl)piperazine-2-carboxylate 250 
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General procedure B using triketopiperazine 246 (37.5 mg) was followed to synthesise this 
product (43.6 mg) as a colourless oil in 99% yield from a reaction catalysed by 201 (10 
mol%) at −20 °C for 1.5 hours. Purification by flash column chromatography (gradient: 
hexane/ethyl acetate = (9:1) to (3:1) gave 250 with 99:1 er as determined by HPLC analysis 
[Phenomenex Lux Cellulose-3, acetonitrile:water, 40:60, 1 mL/min, λ 210 nm, t(major) = 10.0 
min, t(minor) = 11.1 min]. IR νmax /cm-1 2960, 2922, 1768, 1740, 1687, 1415, 1371, 1243, 
1079, 705, 698; 1H NMR (400 MHz, CDCl3) δ 7.41 (m, 2H, H-Ar); 7.36 – 7.26 (m, 8H, H-
Ar); 5.11 (d, J = 13.7 Hz, 1H, H-15b); 5.05 (d, J = 13.7 Hz, 1H, H-15a); 4.71 (d, J = 15.0 Hz, 
1H, H-7b); 4.60 (d, J = 15.0 Hz, 1H, H-7a); 3.33 (s, 3H, H-10); 2. 61 (m, 2H, H-11); 1.91 (m, 
2H, H-12); 1.84 (s, 3H, H-14); 13C NMR (101 MHz, CDCl3) δ 204.9 (C-13), 165.8 (C-9), 
165.5 (C-3), 155.2 (C-5), 154.2 (C-6), 134.8 (C-16), 134.8 (C-8), 129.2 (C-Ar), 129.2 (C-Ar), 
128.7 (C-Ar), 128.7 (C-Ar), 128.4 (C-Ar), 72.3 (C-2), 53.7 (C-10), 47.7 (C-7), 44.8 (C-15), 
36.2 (C-12), 29.6 (C-14), 27.6 (C-11); 1 signal in the C-H aromatic region was not observed 
due to having equivalent resonances; m/z (ES HRMS) C24H24N2O6Na requires 459.1532, 
found [MNa]+ 459.1539; = −25.5 (c 1.5, CHCl3). 
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Synthesis of methyl (S)-1,4-dibenzyl-3,5,6-trioxo-2-(3-oxopropyl)piperazine-2-carboxylate 
251 
 
General procedure B using triketopiperazine 246 (36.3 mg) was followed to synthesise this 
product (41.4 mg) as a colourless oil in 99% yield from a reaction catalysed by 201 (10 
mol%) at −20 °C for 1 hour. Purification by flash column chromatography (gradient: 
hexane/ethyl acetate = (9:1) to (3:1) gave product 251. IR νmax /cm-1 3035, 2956, 1786 1757, 
1689, 1440, 1386, 1282, 1008, 702, 694; 1H NMR (400 MHz, CDCl3) δ 9.36 (s, 1H, H-13), 
7.47 – 7.14 (m, 10H, H-Ar), 5.10 (d, J = 13.7 Hz, 1H, H-14b), 5.05 (d, J = 13.7 Hz, 1H, H-
14a), 4.70 (d, J = 15.0 Hz, 1H, H-7b), 4.64 (d, J = 15.0 Hz, 1H, H-7a), 3.35 (s, 3H, H-10), 
2.71 (m, 2H, H-11), 2.00 (m, 2H, H-12);13C NMR (101 MHz, CDCl3) δ 197.1 (C-13), 164.8 
(C-9), 164.3 (C-3), 154.1 (C-5), 153.2 (C-6), 133.8 (C-15), 133.7 (C-8), 128.1 (C-Ar), 127.7 
(C- Ar), 127.7 (C-Ar), 127.5 (C-Ar), 127.4 (C-Ar), 71.3 (C-2), 52.8 (C-10), 46.8 (C-7), 43.9 
(C-14), 36.0 (C-12), 24.9 (C-11); 1 signal in the C-H aromatic region was not observed due to 
having equivalent resonances; m/z (ES HRMS) C23H22N2O6Na, 445.1376, found [MNa]+ 
445.1365; α = -4.5 (c 0.8, CHCl3). 
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Synthesis of methyl (S)-1,4-dibenzyl-3,5,6-trioxo-2-(3-oxopentyl)piperazine-2-carboxylate 
252 
 
General procedure B using triketopiperazine 246 (28.8 mg) was followed to synthesise this 
product (31.7 mg) as a colourless oil in 90% yield from a reaction catalysed by 201 (10 
mol%) at −20 °C for 2 hours. Purification by flash column chromatography (gradient: 
hexane/ethyl acetate = (9:1) to (3:1) gave 252 with 97:3 er as determined by HPLC analysis 
[Daicel Chiralpak AD, hexanes:IPA, 80:20, 1.0 mL/min, λ 210 nm, t(major) = 17.4 min, 
t(minor) = 22.4 min]. IR νmax /cm-1 3034, 2970, 1743, 1685, 1417, 1367, 1231, 1156, 734, 
701; 1H NMR (400 MHz, CDCl3) δ 7.39 (m, 2H, H-Ar), 7.36 – 7.25 (m, 8H, H-Ar), 5.11 (d, J 
= 13.7 Hz, 1H, H-16b), 5.05 (d, J = 13.7 Hz, 1H, H-16a), 4.73 (d, J = 15.0 Hz, 1H, H-7b), 
4.59 (d, J = 15.0 Hz, 1H, H-7a), 3.33 (s, 3H, H-10), 2.66 (m, 2H, H-11), 2.06 (m, 2H, H-14), 
1.90 (m, 2H, H-12), 0.90 (t, J = 7.3 Hz, 3H, H-15);13C NMR (101 MHz, CDCl3) δ 207.7 (C-
13), 165.9 (C-9), 165.6 (C-3), 155.2 (C-5), 154.2 (C-6), 134.9 (C-17), 134.8 (C-8), 129.2 (C-
Ar), 129.2 (C-Ar), 128.6 (C-Ar), 128.4 (C-Ar), 128.3 (C-Ar), 72.4 (C-2), 53.7 (C-10), 47.7 
(C-7), 44.8 (C-16), 35.7 (C-14), 34.9 (C-12), 27.7 (C-11), 7.6 (C-15); 1 signal in the C-H 
aromatic region was not observed due to having equivalent resonances; m/z (ESI) C25H27N2O6 
requires 451.1857, found [MH]+ 451.1869; = − 30.9 (c 1.3, CHCl3). 
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Synthesis of methyl (S)-1,4-dibenzyl-2-(3-cyclohexyl-3-oxopropyl)-3,5,6-trioxopiperazine-2-
carboxylate 253 
 
General procedure B using triketopiperazine 246 (34.5 mg) was followed to synthesise this 
product (48.6 mg) as a colourless oil in 99% yield from a reaction catalysed by 201 (10 
mol%) at −20 °C for 3 hours. Purification by flash column chromatography (gradient: 
hexane/ethyl acetate = (19:1) to (4:1) gave 253 with 97:3 er as determined by HPLC analysis 
[Daicel Chiralpak AD, hexanes:IPA, 85:15, 0.7 mL/min, λ 210 nm, t(major) = 30.8 min, 
t(minor) = 34.7 min]. IR νmax /cm-1 3035, 2931, 2854, 1743, 1685, 1496, 1417, 1367, 1234, 
1150, 1030, 733, 700; 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.37 (m, 2H, H-Ar), 7.35 – 7.23 
(m, 8H, H-Ar), 5.12 (d, J = 13.6 Hz, 1H, H-20b), 5.04 (d, J = 13.6 Hz, 1H, H-20a), 4.72 (d, J 
= 15.0 Hz, 1H, H-7b), 4.58 (d, J = 15.0 Hz, 1H, H-7a), 3.33 (s, 3H, H-10), 2.65 (m, 2H, H-
11), 1.99 – 1.81 (m, 3H, H-12, H-14), 1.75 – 1.67 (m, 2H, H-16b, H-18b), 1.63 (m, 1H, H-
17b), 1.56 – 1.44 (m, 2H, H-15b, H19b), 1.23 – 0.99 (m, 5H, H-15a, H-16a, H-17a, H-18a, H-
19a);13C NMR (101 MHz, CDCl3) δ 210.3 (C-13), 165.9 (C-9), 165.7 (C-3), 155.2 (C-5), 
154.2 (C-6), 134.9 (C-21, C-8), 129.3 (C-Ar), 129.2 (C-Ar), 128.6 (C-Ar), 128.3 (C-Ar), 
128.3 (C-Ar), 72.4 (C-2), 53.6 (C-10), 50.6 (C-14), 47.8 (C-7), 44.7 (C-20), 33.1 (C-12), 28.3 
(C-15), 28.1 (C-19), 27.9 (C-11), 25.6 (C-16), 25.5 (C-17), 25.4 (C-18); 1 signal in the C-H 
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aromatic region was not observed due to having equivalent resonances; m/z (ESI) C29H33N2O6 
requires 505.2385, found [MH]+ 505.2339; = −39.7 (c 1.3, CHCl3). 
 
Synthesis of methyl (S)-1,4-dibenzyl-3,5,6-trioxo-2-(3-oxo-3-phenylpropyl)piperazine-2-
carboxylate 254 
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General procedure B using triketopiperazine 246 (34.5 mg) was followed to synthesise this 
product (46.0 mg) as a colourless oil in 98% yield from a reaction catalysed by 201 (10 
mol%) at −20 °C for 1 hour. Purification by flash column chromatography (gradient: 
hexane/ethyl acetate = (9:1) to (4:1) gave 254 with 99:1 er as determined by HPLC analysis 
[Daicel Chiralcel OD, hexanes:IPA, 80:20, 1.0 mL/min, λ 210 nm, t(major) = 28.9 min, 
t(minor) = 40.9 min]. IR νmax /cm-1 3065, 2956, 1763, 1743, 1682, 1599, 1496, 1367, 1222, 
1151, 1080, 733, 696; 1H NMR (400 MHz, CDCl3) δ 7.59 – 7.53 (m, 3H, H-15, H-17), 7.47 – 
7.14 (m, 12H, H-24, H-Ar), 5.15 (d, J = 13.6 Hz, 1H, H-18b), 5.09 (d, J = 13.6 Hz, 1H, H-
18a), 4.86 (d, J = 15.0 Hz, 1H, H-7b), 4.57 (d, J = 15.0 Hz, 1H, H-7a), 3.32 (s, 3H, H-10), 
2.87 (dd, J = 9.0, 6.8 Hz, 2H, H-11), 2.56 (m, 1H, H-12b), 2.41 (m, 1H, H-12a); 13C NMR 
(101 MHz, CDCl3) δ 196.6 (C-13), 165.9 (C-9), 165.7 (C-3), 155.2 (C-5), 154.3 (C-6), 135.9 
(C-14), 134.9 (C-19), 134.7 (C-8), 133.4 (C-17), 129.3 (C-Ar), 129.1 (C-Ar), 128.7 (C-Ar), 
128.6 (C-Ar), 128.5 (C-Ar), 128.4 (C-Ar), 128.3 (C-Ar), 127.95 (C-Ar), 72.4 (C-2), 53.7 (C-
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10), 47.7 (C-7), 44.8 (C-18), 31.5 (C-12), 28.1 (C-11); m/z (ESI) C29H27N2O6 requires 
499.1867, found [MH]+ 499.1869; = −39.3 (c 1.8, CHCl3). 
 
Synthesis of methyl (S)-1,4-dibenzyl-2-(3-(4-methoxyphenyl)-3-oxopropyl)-3,5,6-
trioxopiperazine-2-carboxylate 255 
 
General procedure B using triketopiperazine 246 (26.1 mg) was followed to synthesise this 
product (38.5 mg) as a white solid in 87% yield from a reaction catalysed by 201 (10 mol%) 
at −20 °C for 1.5 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (9:1) to (3:1) gave 255 with 99:1 er as determined by HPLC analysis [Daicel 
Chiralcel OD, hexanes:IPA, 80:20, 1.0 mL/min, λ 210 nm, t(major) = 56.1 min, t(minor) = 
86.7 min]. m.p. 167 – 168 °C; IR νmax /cm-1 2957, 1763, 1743, 1684, 1600, 1419, 1369, 1259, 
1233, 1172, 1028, 735, 701; 1H NMR (400 MHz, CDCl3) δ 7.53 (m, 2H, H-15), 7.42 (m, 2H, 
H-Ar), 7.34 – 7.12 (m, 8H, H-Ar), 6.84 (m, 2H, H-16), 5.12 (d, J = 13.6 Hz, 1H, H-19b), 5.06 
(d, J = 13.6 Hz, 1H, H-19a), 4.90 (d, J = 15.0 Hz, 1H, H-7b), 4.48 (d, J = 15.0 Hz, 1H, H-7a), 
3.87 (s, 3H, H-18), 3.26 (s, 3H, H-10), 2.83 (m, 2H, H-11), 2.51 (m, 1H, H-12b), 2.35 (m, 1H, 
H-12a); 13C NMR (101 MHz, CDCl3) δ 195.1 (C-13), 165.9 (C-9), 165.7 (C-3), 163.7 (C-17), 
155.3 (C-5), 154.3 (C-6), 135.0 (C-20), 134.7 (C-8), 130.2 (C-15), 129.3 (C-Ar), 129.2 (C-
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Ar), 129.0 (C-14), 128.7 (C-Ar), 128.6 (C-Ar), 128.4 (C-Ar), 128.9 (C-Ar), 113.7 (C-16), 
72.4 (C-2), 55.5 (C-18), 53.6 (C-10), 47.6 (C-7), 44.7 (C-19), 31.1 (C-12), 28.3 (C-11); m/z 
(ESI) C30H28N2O7Na requires 551.1801, found [MNa]+ 551.1794;  = −28.8 (c 1.3, 
CHCl3). 
 
Synthesis of methyl (S)-1,4-dibenzyl-2-(3-(4-bromophenyl)-3-oxopropyl)-3,5,6-
trioxopiperazine-2-carboxylate 256 
 
General procedure B using triketopiperazine 246 (32.1 mg) was followed to synthesise this 
product (56.4 mg) as a white solid in 98% yield from a reaction catalysed by 201 (10 mol%) 
at −20 °C for 1.5 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (9:1) to (3:1) gave 256 with 99:1 er as determined by HPLC analysis [Daicel 
Chiralpak AD, hexanes:IPA, 80:20, 1.0 mL/min, λ 210 nm, t(major) = 34.0 min, t(minor) = 
47.1 min]. m.p. 124 – 127 °C ; IR νmax /cm-1 3052, 2954, 1764, 1743, 1684, 1585, 1496, 1368, 
1229, 1071, 1009, 734, 700; 1H NMR (400 MHz, CDCl3) δ 7.43 (m, 2H, H-15), 7.35 (m, 2H, 
H-Ar), 7.30 (m, 2H, H-16), 7.25 – 7.18 (m, 5H, H-Ar), 7.16 – 7.04 (m, 3H, H-Ar), 5.05 (d, J = 
13.6 Hz, 1H, H-18b), 4.99 (d, J = 13.6 Hz, 1H, H-18a), 4.69 (d, J = 15.0 Hz, 1H, H-7b), 4.52 
(d, J = 15.0 Hz, 1H, H-7a), 3.25 (s, 3H, H-10), 2.75 (m, 2H, H-11), 2.35 (m, 2H, H-12); 13C 
NMR (101 MHz, CDCl3) δ 195.6 (C-13), 165.9 (C-9), 165.6 (C-3), 155.2 (C-5), 154.3 (C-6), 
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134.9 (C-19), 134.8 (C-8), 134.6 (C-14), 131.8 (C-16), 129.4 (C-Ar), 129.1 (C-Ar), 128.7 (C-
Ar), 128.7 (C-Ar), 128.4 (C-Ar), 128.3 (C-Ar), 72.4 (C-2), 53.7 (C-10), 47.8 (C-7), 44.8 (C-
18), 31.5 (C-12), 28.1 (C-11); 2 signals in the C-H aromatic region were not observed due to 
having equivalent resonances; m/z (ESI) C29H26N2O679Br requires 577.0968, found [MH]+ 
577.0974; = −17.4 (c 2.0, CHCl3).  
 
Synthesis of methyl (2S)-1,4-dibenzyl-2-((R)1-methoxy-1,4-dioxopentan-2-yl)-3,5,6-
trioxopiperazine-2-carboxylate 263 
 
General procedure B using triketopiperazine 246 (32.0 mg) was followed to synthesise this 
product (27.8 mg) as a white solid in 67% yield from a reaction catalysed by 201 (10 mol%) 
at 0 °C for 48 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (4:1) to (7:3) gave 263 with 92:8 er as determined by HPLC analysis [Daicel 
Chiralpak IC, Heptane:Ethanol, 60:40, 2 mL/min, λ 210 nm, t(major) = 7.1 min, t(minor) = 
11.8 min]. m.p. 93 – 95 °C; IR νmax /cm-1 3035, 2956, 1741, 1687, 1497, 1434, 1367, 1235, 
1172, 1080, 1030, 910, 728, 698; 1H NMR (400 MHz, CDCl3) δ 7.37 (m, 2H, H-Ar), 7.30 – 
7.13 (m, 6H, H-Ar), 7.10 (m, 2H, H-Ar), 5.03 (d, J = 13.7 Hz, 1H, H-17b), 4.99 (d, J = 13.7 
Hz, 1H, H-17a), 4.87 (d, J = 15.8 Hz, 1H, H-7b), 4.61 (d, J = 15.8 Hz, 1H, H-7a), 4.36 (dd, J 
= 10.5, 1.9 Hz, 1H, H-11), 3.46 (s, 3H, H-13), 3.41 (s, 3H, H-10), 2.57 (dd, J = 17.3, 10.5 Hz, 
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1H, H-14b), 2.26 (dd, J = 17.3, 1.9 Hz, 1H, H-14a), 1.82 (s, 3H, H-16); 13C NMR (101 MHz, 
CDCl3) δ 203.2 (C-15), 169.9 (C-12), 165.3 (C-9), 164.8 (C-3), 154.7 (C-5), 154.6 (C-6), 
134.8 (C-8), 134.6 (C-18), 129.5 (C-Ar), 128.8 (C-Ar), 128.6 (C-Ar), 128.3 (C-Ar), 128.0 (C-
Ar), 127.8 (C-Ar), 73.7 (C-2), 53.8 (C-10), 52.9 (C-13), 48.8 (C-7), 45.2 (C-17), 44.9 (C-11), 
40.0 (C-14), 29.5 (C-16); m/z (ES HRMS) C26H27N2O8 requires 495.1767, found [MH]+ 
495.1770; = 11.0 (c 1.5, CHCl3). 
 
Synthesis of methyl (S)-1,4-dibenzyl-2-((R)-1-cyano-3-ethoxy-3-oxopropyl)-3,5,6-
trioxopiperazine-2-carboxylate 264 
 
General achiral procedure B using triketopiperazine 246 (35.6 mg) was followed to synthesise 
this product (22.3 mg) as a white solid in 97% yield from a reaction at 0 °C for 48 hours. 
Purification by flash column chromatography (gradient: hexane/ethyl acetate = (4:1) to (3:2) 
gave compound 264. m.p. 148 – 149 °C; IR νmax /cm-1 2957, 1745, 1690, 1497, 1433, 1373, 
1253, 1080, 1009, 734, 699; 1H NMR (400 MHz, CDCl3) δ 7.37 (m, 2H, H-Ar), 7.30 – 7.15 
(m, 8H, H-Ar), 5.08 (d, J = 13.5 Hz, 1H, H-17b), 5.01 (d, J = 13.5 Hz, 1H, H-17a), 4.59 (s, 
2H, H-7), 4.00 – 3.91 (m, 3H, H-11, H-15), 3.34 (s, 3H, H-10), 2.19 (dd, J = 16.5, 9.4 Hz, 1H, 
H-13b), 2.01 (dd, J = 16.5, 4.7 Hz, 1H, H-13a), 1.12 (t, J = 7.2 Hz, 3H, H-16); 13C NMR (101 
MHz, CDCl3) δ 167.5 (C-14), 163.8 (C-9), 162.8 (C-3), 154.0 (C-5), 153.5 (C-6), 134.1 (C-
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18), 133.8 (C-8), 129.5 (C-Ar), 129.0 (C-Ar), 128.8 (C-Ar), 128.7 (C-Ar), 128.6 (C-Ar), 
128.4 (C-Ar), 116.1 (C-12), 71.8 (C-2), 62.2 (C-15), 54.4 (C-10), 48.1 (C-7), 45.1 (C-17), 
32.3 (C-11), 31.8 (C-13), 13.9 (C-16); m/z (ES HRMS) C26H25N3O7Na requires 514.1590, 
found [MNa]+ 514.1599. 
 
Synthesis of methyl (R)-1,4-dibenzyl-2-((R)-2-chloro-2-cyanoethyl)-3,5,6-trioxopiperazine-2-
carboxylate 267 
 
General procedure B using triketopiperazine 246 (36.6 mg) was followed to synthesise this 
product (32.0 mg) as a white solid in 71% yield from a reaction catalysed by 210 (10 mol%) 
at −20 °C for 0.5 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (9:1) to (3:1) gave 267 with 96:4 er as determined by HPLC analysis [Daicel 
Chiralpak AD, hexanes:IPA, 85:15, 0.9 mL/min, λ 210 nm, t(minor) = 44.3 min, t(major) = 
56.7 min]. m.p. 154 – 155. °C; IR νmax /cm-1 2981, 2954, 1744, 1687, 1498, 1449, 1349, 1232, 
1208, 1159, 1074, 698; 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.34 (m, 7H, H-Ar), 7.34 – 7.28 
(m, 3H, H-Ar), 5.13 (d, J = 13.8 Hz, 1H, H-14b), 5.08 (d, J = 13.8 Hz, 1H, H-14a), 4.75 (d, J 
= 15.1 Hz, 1H, H-7b), 4.68 (d, J = 15.1 Hz, 1H, H-7a), 3.96 (dd, J = 8.6, 6.4 Hz, 1H, H-12), 
3.32 (dd, J = 15.5, 8.6 Hz, 1H, H-11b), 3.32 (s, 3H, H-10), 3.06 (dd, J = 15.5, 6.4 Hz, 1H, H-
11a); 13C NMR (101 MHz, CDCl3) δ 164.8 (C-9), 164.1 (C-3), 154.4 (C-5), 153.7 (C-6), 
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134.3 (C-8), 134.2 (C-15), 129.1 (C-Ar), 129.1 (C-Ar), 129.0 (C-Ar), 128.6 (C-Ar), 128.4 (C-
Ar), 115.2 (C-13), 71.0 (C-2), 54.2 (C-10), 48.6 (C-7), 45.3 (C-14), 38.5 (C-11), 36.7 (C-12); 
1 signal in the C-H aromatic region was not observed due to having equivalent resonances; 
m/z (ES) C23H20N3O535ClNa requires 476.0989 found [MNa]+ 476.0977; = 30.2 (c 1.2, 
CHCl3). 
 
Synthesis of methyl (R)-1,4-dibenzyl-2-(2,2-bis(phenylsulfonyl)ethyl)-3,5,6-trioxopiperazine-
2-carboxylate 269a 
 
General procedure B using triketopiperazine 246 (31.5 mg) was followed to synthesise this 
product (56.0 mg) as a white solid in 97% yield from a reaction catalysed by 210 (10 mol%) 
at 0 °C for 30 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (4:1) to (3:2) gave 269a with 36:64 er as determined by HPLC analysis [Daicel 
Chiralpak ID-3, Heptane:Ethanol-Methanol, 70:30, 2 mL/min, λ 220 nm, t(minor) = 11.1 min, 
t(major) = 15.1 min]. m.p. 158 – 161 °C; IR νmax /cm-1 3070, 2925, 1765, 1744, 1685, 1498, 
1446, 1376, 1313, 1226, 1149, 1080, 734, 683; 1H NMR (400 MHz, CDCl3) δ 7.98 – 7.91 (m, 
3H, H-Ar), 7.88 (dd, J = 8.4, 1.1 Hz, 2H, H-Ar), 7.77 (m, 2H, H-Ar), 7.69 – 7.59 (m, 5H, H-
Ar), 7.37 (m, 2H, H-Ar), 7.33 – 7.21 (m, 6H, H-Ar), 5.63 (d, J = 15.0 Hz, 1H, H-7b), 5.10 (s, 
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2H, H-17), 4.38 (dd, J = 9.4, 2.9 Hz, 1H, H-12), 3.87 – 3.76 (m, 2H, H-7a, H-11b), 3.27 (dd, J 
= 17.0, 9.4 Hz, 1H, H-11a), 2.87 (s, 3H, H-10); 13C NMR (101 MHz, CDCl3) δ 165.7 (C-3), 
165.4 (C-9), 154.9 (C-5), 154.3 (C-6), 136.5 (C-13), 136.1 (C-15), 135.3 (C-14), 135.2 (C-
16), 134.8 (C-18), 133.8 (C-8), 130.2 (C-Ar), 129.9 (C-Ar), 129.9 (C-Ar), 129.5 (C-Ar), 129.3 
(C-Ar), 129.0 (C-Ar), 128.5 (C-Ar), 128.5 (C-Ar), 128.4 (C-Ar), 128.0 (C-Ar), 79.3 (C-12), 
70.0 (C-2), 53.4 (C-10), 47.1 (C-7), 44.9 (C-17), 29.0 (C-11); m/z (ES HRMS) C34H31N2O9S2 
requires 675.1471, found [MH]+ 675.1484; = −2.5 (c 1.1, CHCl3). 
 
Synthesis of methyl (R)-1,4-dibenzyl-2-((R)-1,2-bis(phenylsulfonyl)ethyl)-3,5,6-
trioxopiperazine-2-carboxylate 269b 
 
General procedure B using triketopiperazine 246 (36.6 mg) was followed to synthesise this 
product (35.0 mg) as a white solid in 52% yield from a reaction catalysed by 210 (10 mol%) 
at 0 °C for 20 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (4:1) to (3:2) gave compound 269b. m.p. 126 – 128 °C; IR νmax /cm-1 3069, 1765, 
1745, 1686, 1496, 1448, 1383, 1309, 1226, 1152, 1077, 1023, 910, 741, 699; 1H NMR (400 
MHz, CDCl3) δ 7.91 (m, 2H, H-Ar), 7.83 (m, 2H, H-Ar), 7.75 (m, 2H, H-Ar), 7.67 – 7.57 (m, 
4H, H-Ar), 7.32 (m, 2H, H-Ar), 7.29 – 7.21 (m, 6H, H-Ar), 7.17 (m, 2H, H-Ar), 5.61 (d, J = 
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15.0 Hz, 1H, H-7b), 5.10 (d, J = 14.0 Hz, 1H, H-17b), 5.06 (d, J = 14.0 Hz, 1H, H-17a), 4.42 
(dd, J = 9.4, 2.8 Hz, 1H, H-11), 3.79 (d, J = 15.0 Hz, 1H, H-7a), 3.77 (dd, J = 17.1, 3.2 Hz, 
1H, H-14b), 3.26 (m, 1H, H-14a), 2.85 (s, 3H, H-10); 13C NMR (101 MHz, CDCl3) δ 165.7 
(C-3), 165.4 (C-9), 155.0 (C-5), 154.4 (C-6), 136.4 (C-12), 136.0 (C-15), 135.3 (C-13), 135.3 
(C-16), 134.8 (C-18), 133.7 (C-8), 130.2 (C-Ar), 129.9 (C-Ar), 129.5 (C-Ar), 129.3 (C-Ar), 
129.0 (C-Ar), 128.5 (C-Ar), 128.5 (C-Ar), 128.4 (C-Ar), 128.0 (C-Ar), 79.1 (C-11), 69.9 (C-
2), 53.5 (C-10), 47.1 (C-7), 44.9 (C-17), 28.9 (C-14); 1 signal in the C-H aromatic region was 
not observed due to having equivalent resonances; m/z (ES HRMS) C34H31N2O9S2 requires 
675.1471, found [MH]+ 675.1487; = 8.4 (c 1.0, CHCl3). 
 
Synthesis of methyl (S)-1,4-dibenzyl-2-((S)-2-nitro-1-phenylethyl)-3,5,6-trioxopiperazine-2-
carboxylate 271a 
 
General procedure B using triketopiperazine 246 (35.2 mg) was followed to synthesise this 
product (38.1 mg) as a white solid in 78% yield from a reaction catalysed by 201 (10 mol%) 
at −20 °C for 1.0 hour. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (9:1) to (3:1) gave 271a with 61:39 er as determined by HPLC analysis 
[Phenomenex Lux Cellulose-3, acetonitrile:water, 35:65, 1 mL/min, λ 210 nm, t(minor) = 
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19.1 min, t(major) = 22.1 min]. m.p. 168 – 169 °C; IR νmax /cm-1 2955, 1749, 1685, 1550, 
1496, 1433, 1369, 1242, 1208, 1190, 1079, 1030, 750, 700; 1H NMR (400 MHz, CDCl3) δ 
7.55 (m, 2H, H-Ar), 7.48 – 7.42 (m, 3H, H-Ar), 7.36 – 7.28 (m, 3H, H-Ar), 7.27 – 7.20 (m, 
3H, H-Ar), 6.99 (t, J = 7.3 Hz, 2H, H-Ar), 6.63 (d, J = 7.3 Hz, 2H, H-Ar), 5.49 (d, J = 15.2 
Hz, 1H, H-7b), 5.27 (dd, J = 13.6, 2.4 Hz, 1H, H-13b), 5.02 (d, J = 13.4 Hz, 1H, H-14b), 4.91 
(d, J = 13.4 Hz, 1H, H-14a), 4.84 – 4.69 (m, 2H, H-11, H-13a), 4.16 (d, J = 15.2 Hz, 1H, H-
7a), 3.08 (s, 3H, H-10); 13C NMR (101 MHz, CDCl3) δ 165.2 (C-3, C-9), 154.0 (C-5), 152.6 
(C-6), 134.2 (C-8), 133.6 (C-15), 131.2 (C-12), 130.6 (C-Ar), 129.9 (C-Ar), 129.6 (C-Ar), 
128.9 (C-Ar), 128.8 (C-Ar), 128.5 (C-Ar), 128.2 (C-Ar), 75.3 (C-13), 73.1 (C-2), 53.4 (C-10), 
47.0 (C-7), 46.4 (C-11), 45.1 (C-14); 2 signals in the C-H aromatic region were not observed 
due to having equivalent resonances; m/z (ESI) C28H25N3O7Na requires 538.1590, found 
[MNa]+ 538.1574; = 29.9 (c 0.9, CHCl3). 
 
Synthesis of methyl (S)-1,4-dibenzyl-2-((S)-1-(4-fluorophenyl)-2-nitroethyl)-3,5,6-
trioxopiperazine-2-carboxylate 271b 
 
General procedure B using triketopiperazine 246 (36.6 mg) was followed to synthesise this 
product (32.4 mg) as a white solid in 61% yield from a reaction catalysed by 201 (10 mol%) 
at −20 °C for 1.0 hour. Purification by flash column chromatography (gradient: hexane/ethyl 
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acetate = (9:1) to (3:1) gave compound 271b. m.p. 139 – 141 °C; IR νmax /cm-1 2962, 1752, 
1687, 1606, 1550, 1512, 1431, 1375, 1234, 1207, 1072, 1031, 844, 757, 737, 703; 1H NMR 
(400 MHz, CDCl3) δ 7.57 (m, 2H, H-Ar), 7.51 – 7.44 (m, 3H, H-Ar), 7.37 – 7.29 (m, 3H, H-
Ar), 7.25 (m, 2H, H-Ar), 6.62 (t, J = 8.5 Hz, 2H, H-Ar), 6.55 (dd, J = 8.5 Hz, 5.1, 2H, H-Ar), 
5.46 (d, J = 15.2 Hz, 1H, H-7b), 5.25 (m, 1H, H-16b), 5.03 (d, J = 13.3 Hz, 1H, H-17b), 4.92 
(d, J = 13.3 Hz, 1H, H-17a), 4.78 – 4.67 (m, 2H, H-11, H-16a), 4.16 (d, J = 15.2 Hz, 1H, H-
7a), 3.10 (s, 3H, H-10); 13C NMR (101 MHz, CDCl3) δ 165.1 (C-9), 165.1 (C-3), 162.9 (d, J = 
251.3 Hz, C-15), 153.9 (C-5), 152.6 (C-6), 134.0 (C-8), 133.6 (C-18), 130.7 (C-Ar), 130.1 (d, 
J = 8.4 Hz, C-13), 129.1 (C-Ar), 128.9 (C-Ar), 128.6 (C-Ar), 128.6 (C-Ar), 128.4 (C-Ar), 
127.0 (d, J = 3.1 Hz, C-12), 116.8 (d, J = 21.9 Hz, C-14), 75.4 (C-16), 73.0 (C-2), 53.5 (C-
10), 47.0 (C-7), 45.8 (C-11), 45.2 (C-17); m/z (ESI) C28H24N3O7NaF requires 556.1496, found 
[MNa]+ 556.1500; = 66.8 (c 1.3, CHCl3). 
 
Synthesis of (S)-1,4-dibenzyl-6-(3-oxobutyl)piperazine-2,3,5-trione 276 
 
General procedure B using triketopiperazine 242 (29.5 mg) was followed to synthesise this 
product (28.9 mg) as a colourless oil in 80% yield from a reaction catalysed by 201 (10 
mol%) at −20 °C for 4 hours. Purification by flash column chromatography (gradient: 
hexane/ethyl acetate = (4:1) to (1:1) gave 276 with 93:7 er as determined by HPLC analysis 
Chapter 5   Experimental
  
 
187 
[Daicel Chiralcel OD, hexanes:IPA, 80:20, 2.0 mL/min, λ 210 nm, t(major) = 17.7 min, 
t(minor) = 44.6 min]. IR νmax /cm-1 3034, 2958, 1743, 1685, 1497, 1429, 1361, 1322, 1261, 
1211, 1164, 1077, 1030, 745, 702; 1H NMR (400 MHz, CDCl3) δ 7.43 (m, 2H, H-Ar), 7.39 – 
7.35 (m, 5H, H-Ar), 7.34 – 7.29 (m, 3H, H-Ar), 5.35 (d, J = 14.5 Hz, 1H, H-7b), 4.99 (s, 2H, 
H-9), 4.20 (d, J = 14.5 Hz, 1H, H-7a) 4.19 (dd, J = 8.5 Hz, 3.1 Hz, 1H, H-6) 2.34 (m, 1H, H-
11b), 2.24 (t, J = 6.7 Hz, 2H, H-12), 2.03 (s, 3H, H-14), 1.91 (m, 1H, H-11a); 13C NMR (101 
MHz, CDCl3) δ 206.0 (C-13), 168.0 (C-5), 156.5 (C-3), 152.9 (C-2), 135.2 (C-10), 134.5 (C-
8), 129.4 (C-Ar), 129.1 (C-Ar), 129.0 (C-Ar), 128.7 (C-Ar), 128.6 (C-Ar), 128.3 (C-Ar), 58.6 
(C-6), 48.0 (C-7), 44.3 (C-9), 36.8 (C-12), 29.9 (C-14), 27.3 (C-11); m/z (ESI) C22H22N2O4Na 
requires 401.1481, found [MNa]+ 401.1477; = −157.1 (c 1.0, CHCl3). 
 
Synthesis of (S)-1,4-dibenzyl-6-(3-oxopropyl)piperazine-2,3,5-trione 289 
 
General procedure B using triketopiperazine 242 (30.6 mg) was followed to synthesise this 
product (26.9 mg) as a colourless oil in 74% yield from a reaction catalysed by 201 (10 
mol%) at −20 °C for 3 hours. Purification by flash column chromatography (gradient: 
Hexane/Ethyl acetate = (4:1) to (2:1) gave compound 289. IR νmax /cm-1 3064, 2927, 2847, 
1743, 1721, 1680, 1496, 1431, 1386, 1361, 1322, 1262, 1210, 1161, 1078, 1030, 976, 731, 
700; 1H NMR (400 MHz, CDCl3) δ 9.61 (s, 1H, H-13), 7.42 (m, 2H, H-Ar), 7.39 – 7.34 (m, 
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5H, H-Ar), 7.34 – 7.29 (m, 3H, H-Ar), 5.33 (d, J = 14.6 Hz, 1H, H-7b), 4.99 (m, 2H, H-9), 
4.28 – 4.19 (m, 2H, H-7a, H-6), 2.47 – 2.33 (m, 3H, H-12, H-11b), 1.95 (m, 1H, H-11a); 13C 
NMR (101 MHz, CDCl3) δ 199.2 (C-13), 167.8 (C-5), 156.4 (C-3), 152.8 (C-2), 135.2 (C-
10), 134.4 (C-8), 129.3 (C-Ar), 129.2 (C-Ar), 128.9 (C-Ar), 128.7 (C-Ar), 128.3 (C-Ar), 
58.6 (C-6), 48.1 (C-7), 44.4 (C-9), 37.7 (C-12), 25.8 (C-11); 1 signal in the C-H aromatic 
region was not observed due to having equivalent resonances; m/z (ESI) C21H21N2O4 
requires 365.1505, found [MH]+ 365.1501; = −25.7 (c 1.06, CHCl3). 
 
Synthesis of (S)-1,4-dibenzyl-6-(3-oxopentyl)piperazine-2,3,5-trione 290 
 
General procedure B using triketopiperazine 242 (30.9 mg) was followed to synthesise this 
product (34.0 mg) as a colourless oil in 86% yield from a reaction catalysed by 201 (10 
mol%) at −20 °C for 4 hours. Purification by flash column chromatography (gradient: 
hexane/ethyl acetate = (4:1) to (2:1) gave 290 with 96:4 er as determined by HPLC analysis 
[Daicel Chiralcel OD, hexanes:IPA, 80:20, 2.0 mL/min, λ 210 nm, t(major) = 13.3 min, 
t(minor) = 41.3 min]. IR νmax /cm-1 3065, 3034, 2976, 2940, 1744, 1683, 1497, 1454, 1431, 
1361, 1260, 1158, 728, 701; 1H NMR (400 MHz, CDCl3) δ 7.43 (m, 2H, H-Ar), 7.39 – 7.34 
(m, 5H, H-Ar), 7.34 – 7.29 (m, 3H, H-Ar), 5.35 (d, J = 14.6 Hz, 1H, H-7b), 4.99 (s, 2H, H-9), 
4.21 (d, J = 14.6 Hz, 1H, H-7a), 4.19 (dd, J = 8.3 Hz, 3.2 Hz, 1H, H-6), 2.35 (m, 1H, H-11b), 
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2.26 (m, 2H, H-14), 2.20 (m, 2H, H-12), 21.96 (m, 1H, H-11a), 1.01 (t, J = 7.3 Hz, 3H, H-
15);13C NMR (101 MHz, CDCl3) δ 208.8 (C-13), 168.0 (C-5), 156.5 (C-3), 152.9 (C-2), 135.3 
(C-10), 134.5 (C-8), 129.4 (C-Ar), 129.1 (C-Ar), 128.9 (C-Ar), 128.7 (C-Ar), 128.6 (C-Ar), 
128.3 (C-Ar), 58.7 (C-6), 48.0 (C-7), 44.3 (C-9), 36.0 (C-14), 35.4 (C-12), 27.4 (C-11), 7.67 
(C-15); m/z (ESI) C23H25N2O4 requires 393.1812, found [MH]+ 393.1814; = −77.1 (c 
1.5, CHCl3). 
 
Synthesis of (S)-1,4-dibenzyl-6-(3-cyclohexyl-3-oxopropyl)piperazine-2,3,5-trione 201 
 
General procedure B using triketopiperazine 242 (29.6 mg) was followed to synthesise this 
product (42.6 mg) as a white solid in 99% yield from a reaction catalysed by 201 (10 mol%) 
at −20 °C for 6 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (9:1) to (2:1) gave 291 with 89:11 er as determined by HPLC analysis [Phenomenex 
Lux Cellulose-3, acetonitrile:water, 40:60, 1 mL/min, λ 220 nm, t(minor) = 34.5 min, t(major) 
= 39.3 min]. m.p. 117 – 119 °C; IR νmax /cm-1 3004, 2928, 2853, 1744, 1675, 1496, 1432, 
1363, 1321, 1252, 1209, 1145, 740, 718, 699; 1H NMR (400 MHz, CDCl3) δ 7.44 (m, 2H, H-
Ar), 7.39 – 7.33 (m, 5H, H-Ar), 7.33 – 7.29 (m, 3H, H-Ar), 5.34 (d, J = 14.6 Hz, 1H, H-7b), 
4.99 (s, 2H, H-9), 4.26 – 4.15 (m, 2H, H-7a, H-6), 2.31 (m, 1H, H-11b), 2.20 (m, 2H, H-12), 
2.12 (ddd, J = 10.5, 7.4, 2.8 Hz, 1H, H-14), 1.97 (m, 1H, H-11a), 1.83 – 1.72 (m, 2H, H-16b, 
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H-18b), 1.70 – 1.60 (m, 3H, H-15b, H-17b, H-19b), 1.32 – 1.09 (m, 5H, H-15a, H-16a, H-17a, 
H-18a, H-19a); 13C NMR (101 MHz, CDCl3) δ 211.4 (C-13), 168.0 (C-5), 156.5 (C-3), 152.9 
(C-2), 135.3 (C-10), 134.5 (C-8), 129.5 (C-Ar), 129.1 (C-Ar), 128.9 (C-Ar), 128.7 (C-Ar), 
128.6 (C-Ar), 128.3 (C-Ar), 58.9 (C-6), 50.7 (C-14), 47.9 (C-7), 44.2 (C-9), 33.7 (C-12), 28.4 
(C-15), 28.2 (C-19), 27.3 (C-11), 25.7 (C-16), 25.5 (C-17), 25.5 (C-18); m/z (ESI) 
C27H31N2O4 requires 447.2285, found [MH]+ 447.2284; = −76.4 (c 0.9, CHCl3). 
 
Synthesis of (S)-1,4-dibenzyl-6-(3-oxo-3-phenylpropyl)piperazine-2,3,5-trione 292 
 
General procedure B using triketopiperazine 242 (36.5 mg) was followed to synthesise this 
product (34.6 mg) as a white solid in 79% yield from a reaction catalysed by 201 (10 mol%) 
at −20 °C for 2 hours. Purification by flash column chromatography (gradient: Hexane/Ethyl 
acetate = (4:1) to (2:1) gave compound 292. m.p. 146 – 148 °C; IR νmax /cm-1 3063, 2921, 
2851, 1748, 1673, 1598, 1497, 1435, 1363, 1339, 1324, 1286, 1215, 1161, 1081, 1030, 739, 
718, 692; 1H NMR (400 MHz, CDCl3) δ 7.73 (dd, J = 8.3, 1.1 Hz, 2H, H-15), 7.60 (m, 1H, H-
16), 7.49 – 7.44 (m, 4H, H-Ar), 7.44 – 7.33 (m, 5H, H-Ar), 7.32 – 7.27 (m, 3H, H-Ar), 5.44 
(d, J = 14.5 Hz, 1H, H-7b), 5.03 (s, 2H, H-9), 4.31 (dd, J = 8.1, 3.3 Hz, 1H, H-6), 4.26 (d, J = 
14.5 Hz, 1H, H-7a), 2.79 (m, 2H, H-12), 2.54 (dtd, J = 11.0, 7.7, 3.3 Hz, 1H, H-11b), 2.18 (m, 
1H, H-11a); 13C NMR (101 MHz, CDCl3) δ 197.5 (C-13), 168.1 (C-5), 156.5 (C-3), 152.9 (C-
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2), 136.1 (C-14), 135.3 (C-10), 134.5 (C-8), 133.6 (C-16), 129.5 (C-Ar), 129.1 (C-Ar), 129.0 
(C-Ar), 128.7 (C-Ar), 128.7 (C-Ar), 128.6 (C-Ar), 128.3 (C-Ar), 127.9 (C-Ar), 58.8 (C-6), 
47.9 (C-7), 44.3 (C-9), 32.0 (C-12), 27.7 (C-11); m/z (ESI) C27H25N2O4 requires 441.1841, 
found [MH]+ 441.1814; = −57.1 (c 1.5, CHCl3). 
 
Synthesis of (S)-1,4-dibenzyl-6-(3-(4-methoxyphenyl)-3-oxopropyl)piperazine-2,3,5-trione 
293 
 
General procedure B using triketopiperazine 242 (30.5 mg) was followed to synthesise this 
product (43.2 mg) as a white solid in 93% yield from a reaction catalysed by 201 (10 mol%) 
at −20 °C for 2.5 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (4:1) to (2:1) gave 293 with 88:12 er as determined by HPLC analysis [Daicel 
Chiralpak AD, hexanes:IPA, 80:20, 1.0 mL/min, λ 210 nm, t(minor) = 43.8 min, t(major) = 
49.4 min]. m.p. 153 – 154 °C; IR νmax /cm-1 3018, 2956, 1744, 1672, 1598, 1575, 1455, 1434, 
1365, 1318, 1250, 1212, 1172, 1082, 1030, 992, 844, 738, 699; 1H NMR (400 MHz, CDCl3) δ 
7.70 (m, 2H, H-15), 7.48 (m, 2H, H-Ar), 7.42 – 7.27 (m, 8H, H-Ar), 6.93 (m, 2H, H-16), 5.43 
(d, J = 14.6 Hz, 1H, H-7b), 5.01 (s, 2H, H-9), 4.30 (dd, J = 8.0, 3.2 Hz, 1H, H-6), 4.24 (d, J = 
14.6 Hz, 1H, H-7a), 3.90 (s, 3H, H-18) 2.72 (m, 2H, H-12), 2.52 (m, 1H, H-11b), 2.18 (m, 1H, 
H-11a); 13C NMR (101 MHz, CDCl3) δ 195.9 (C-13), 168.2 (C-5), 163.8 (C-27), 156.6 (C-3), 
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152.9 (C-2), 135.3 (C-10), 134.5 (C-8), 130.3 (C-15), 129.5 (C-Ar), 129.2 (C-14), 129.1 (C-
Ar), 129.0 (C-Ar), 128.7 (C-Ar), 128.6 (C-Ar), 128.3 (C-Ar), 113.8 (C-16), 58.8 (C-6), 55.5 
(C-18), 47.8 (C-7), 44.3 (C-9), 31.5 (C-12), 27.8 (C-11); m/z (ESI HRMS) C28H26N2O5Na 
requires 493.1730, found [MNa]+ 493.1739; = −34.7 (c 1.3, CHCl3). 
 
Synthesis of (S)-1,4-dibenzyl-6-(3-(4-bromophenyl)-3-oxopropyl)piperazine-2,3,5-trione 294 
 
General procedure B using triketopiperazine 242 (30.4 mg) was followed to synthesise this 
product (50.3 mg) as a white solid in 97% yield from a reaction catalysed by 201 (10 mol%) 
at −20 °C for 2 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (4:1) to (2:1) gave 294 with 79:21 er as determined by HPLC analysis [Daicel 
Chiralcel OD, hexanes:IPA, 91.6:8.4, 0.4 mL/min, λ 210 nm, t(minor) = 179.2 min, t(major) = 
192.2 min]. m.p. 173 – 176 °C; IR νmax /cm-1 3006, 1744, 1675, 1586, 1433, 1391, 1368, 
1252, 1214, 1199, 1070, 993, 833, 744, 717, 699; 1H NMR (300 MHz, CDCl3) δ 7.62 – 7.51 
(m, 4H, H-15, H-16), 7.47 (m, 2H, H-Ar), 7.41 – 7.26 (m, 8H, H-Ar), 5.41 (d, J = 14.6 Hz, 
1H, H-7b), 5.01 (s, 2H, H-9), 4.34 – 4.21 (m, 2H, H-7a, H-6), 2.73 (m, 2H, H-12), 2.51 (m, 
1H, H-11b), 2.16 (dt, J = 14.3, 7.4 Hz, 1H, H-11a); 13C NMR (101 MHz, CDCl3) δ 196.4 (C-
13), 168.1 (C-5), 156.5 (C-3), 152.9 (C-2), 135.3 (C-10), 134.8 (C-14), 134.5 (C-8), 132.0 (C-
16), 129.5 (C-Ar), 129.4 (C-Ar), 129.2 (C-Ar), 129.0 (C-Ar), 128.8 (C-17), 128.7 (C-Ar), 
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128.7 (C-Ar), 128.4 (C-Ar), 58.7 (C-6), 48.0 (C-7), 44.3 (C-9), 32.0 (C-12), 27.5 (C-11); m/z 
(ESI) C27H23N2O4Na79Br requires 541.0739, found [MNa]+ 541.0733; = −17.4 (c 2.1, 
CHCl3). 
 
Synthesis of (S)-1,4-dibenzyl-6-((S)-3-oxo-1,3-diphenylpropyl)piperazine-2,3,5-trione 295 
 
General procedure B using triketopiperazine 242 (28.7 mg) was followed to synthesise this 
product (47.8 mg) as a white solid in 98% yield from a reaction catalysed by 201 (10 mol%) 
at −20 °C for 6 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (9:1) to (3:1) gave 295 with 99:1 er as determined by HPLC analysis [Daicel 
Chiralpak AD, hexanes:IPA, 80:20, 1.0 mL/min, λ 210 nm, t(major) = 32.8 min, t(minor) = 
45.4 min]. m.p. 144 – 147 °C; IR νmax /cm-1 3063, 3034, 2955, 1743, 1692, 1682, 1593, 1495, 
1449, 1425, 1378, 1356, 1345, 1255, 1215, 1191, 1001, 985, 759, 736, 693; 1H NMR (300 
MHz, CDCl3) δ 7.75 (m, 2H, H-16), 7.59 (m, 1H, H-17), 7.51 – 7.35 (m, 4H, H-Ar), 7.34 – 
7.19 (m, 9H, H-Ar), 7.13 – 7.01 (m, 4H, H-Ar), 5.41 (d, J = 14.9 Hz, 1H, H-7b), 4.80 (s, 2H, 
H-9), 4.54 (d, J = 5.6 Hz, 1H, H-6), 3.95 (dd, J = 15.2, 5.6 Hz, 1H, H-11), 3.58 (d, J = 14.9 
Hz, 1H, H-7a), 3.37 (dd, J = 17.9, 7.0 Hz, 1H, H-13b), 3.23 (dd, J = 17.9, 7.0 Hz, 1H, H-13a); 
13C NMR (101 MHz, CDCl3) δ 196.3 (C-14), 167.8 (C-5), 156.5 (C-3), 154.3 (C-2), 137.9 (C-
12), 136.1 (C-15), 135.1 (C-10), 134.5 (C-8), 133.6 (C-Ar), 129.7 (C-Ar), 129.3 (C-Ar), 129.2 
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(C-Ar), 128.7 (C-Ar), 128.6 (C-Ar), 128.5 (C-Ar), 128.4 (C-Ar), 128.3 (C-Ar), 128.2 (C-Ar), 
128.0 (C-Ar), 64.3 (C-6), 49.8 (C-7), 47.1 (C-11), 44.4 (C-9), 40.1 (C-13); 1 signal in the C-H 
aromatic region was not observed due to having equivalent resonances; m/z (ESI) 
C33H28N2O4Na requires 539.1968, found [MNa]+ 539.1947; = −101.3 (c 1.1, CHCl3). 
 
Synthesis of (S)-1,4-dibenzyl-6-((S)-3-(2-bromophenyl)-3-oxo-1-phenylpropyl)piperazine-
2,3,5-trione 296 
 
General procedure B using triketopiperazine 242 (30.8 mg) was followed to synthesise this 
product (53.9 mg) as a white solid in 91% yield from a reaction catalysed by 201 (10 mol%) 
at −20 °C for 7 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (9:1) to (3:1) gave 296 with 88:12 er as determined by HPLC analysis [Daicel 
Chiralpak AD, hexanes:IPA, 84:16, 0.75 mL/min, λ 210 nm, t(major) = 61.7 min, t(minor) = 
69.2 min]. m.p. 124 – 125 °C; IR νmax /cm-1 2971, 2902, 1742, 1680, 1585, 1496, 1408, 1384, 
1354, 1294, 1231, 1068, 981, 751, 742, 697; 1H NMR (400 MHz, CDCl3) δ 7.59 (m, 1H, H-
17), 7.39 (m, 2H, H-Ar), 7.34 – 7.21 (m, 11H, H-Ar), 7.13 (dt, J = 4.3, 3.2 Hz, 2H, H-Ar), 
7.07 (m, 1H, H-Ar), 6.96 (m, 2H, H-Ar), 5.44 (d, J = 14.9 Hz, 1H, H-7b), 4.84 (d, J = 13.8 
Hz, 1H, H-9b), 4.80 (d, J = 13.8 Hz, 1H, H-9a), 4.45 (d, J = 5.7 Hz, 1H, H-6), 3.85 (dt, J = 
8.4, 5.7 Hz, 1H, H-11), 3.56 (d, J = 14.9 Hz, 1H, H-7a), 3.41 (dd, J = 17.5, 8.4 Hz, 1H, H-
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13b), 3.27 (dd, J = 17.5, 5.7 Hz, 1H, H-13a); 13C NMR (101 MHz, CDCl3) δ 200.0 (C-14), 
167.6 (C-5), 156.4 (C-3), 154.2 (C-2), 140.5 (C-12), 136.7 (C-15), 135.0 (C-10), 134.4 (C-8), 
133.8 (C-Ar), 132.1 (C-Ar), 129.6 (C-Ar), 129.3 (C-Ar), 129.2 (C-Ar), 128.8 (C-Ar), 128.6 
(C-Ar), 128.5 (C-Ar), 128.4 (C-Ar), 128.2 (C-Ar), 127.5 (C-Ar), 118.7 (C-16), 64.4 (C-6), 
49.8 (C-7), 47.6 (C-11), 44.5 (C-9), 44.4 (C-13); 2 signals in the C-H aromatic region were 
not observed due to having equivalent resonances; m/z (ESI) C33H28N2O479Br requires 
595.1245, found [MH]+ 595.1232; = −83.9 (c 1.5, CHCl3). 
 
Synthesis of (R)-1,4-dibenzyl-6-(2,2-bis(phenylsulfonyl)ethyl)piperazine-2,3,5-trione 298 
 
General procedure B using triketopiperazine 242 (31.7 mg) was followed to synthesise this 
product (50.6 mg) as a white solid in 82% yield from a reaction catalysed by 210 (10 mol%) 
at 0 °C for 20 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (3:1) to (1:2) gave 298 with 61:39 er as determined by HPLC analysis [Daicel 
Chiralcel OD, heptane:EtOH, 60:40, 2 mL/min, λ 210 nm, t(minor) = 8.2 min, t(major) = 13.7 
min]. m.p. 165 – 166 °C; IR νmax /cm-1 3066, 1746, 1687, 1672, 1496, 1447, 1392, 1330, 
1182, 1147, 1078, 724, 685; 1H NMR (400 MHz, CDCl3) δ 7.94 (m, 2H, H-Ar), 7.79 (m, 2H, 
H-Ar), 7.71 (m, 2H, H-Ar), 7.64 – 7.51 (m, 5H, H-Ar), 7.48 – 7.36 (m, 4H, H-Ar), 7.36 – 7.27 
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(m, 5H, H-Ar), 5.28 – 5.18 (m, 2H, H-12, H-7b), 5.00 (d, J = 13.9 Hz, 1H, H-9b), 4.85 (dd, J 
= 11.3, 3.2 Hz, 1H, H-6), 4.67 (d, J = 13.9 Hz, 1H, H-9a), 4.32 (dd, J = 14.5, 2.2 Hz, 1H, H-
7a), 2.96 (ddd, J = 15.3, 9.5, 3.2 Hz, 1H, H-11b), 2.57 (m, 1H, H-11a); 13C NMR (101 MHz, 
CDCl3) δ 167.6 (C-5), 155.9 (C-3), 152.4 (C-2), 137.8 (C-15), 136.4 (C-13), 135.0 (C-8), 
134.9 (C-16), 134.7 (C-14, C-10), 129.8 (C-Ar), 129.3 (C-Ar), 129.3 (C-Ar), 129.2 (C-Ar), 
129.2 (C-Ar), 129.1 (C-Ar), 128.7 (C-Ar), 128.7 (C-Ar), 128.3 (C-Ar), 77.9 (C-12), 58.4 (C-
6), 48.6 (C-7), 44.7 (C-9), 29.8 (C-11); 1 signal in the C-H aromatic region was not observed 
due to having equivalent resonances; m/z (ES HRMS) C32H29N2O7S2, 617.1416, found [MH]+ 
617.1413; = 8.0 (c 0.95, CHCl3). 
 
General procedure C for the alkylation of triketopiperazines  
To a suspension of NaH (1.05 eq) in dry DMF (0.25 M) at −10 °C, triketopiperazine 242 (1.0 
eq) was added and left to stir for 5 minutes. Alkyl halide (3.0 eq) was subsequently added and 
the mixture was left to react at that temperature until the starting material was observed to be 
consumed by TLC. The crude mixture was quenched with water, extracted with AcOEt
 
(3 x 
30 mL) and washed with water (4 x 30 mL) and brine (1 x 30 mL), dried over MgSO4 and 
condensed under reduced pressure. The crude was purified by flash column chromatography. 
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Synthesis of 6-allyl-1,4-dibenzylpiperazine-2,3,5-trione 299 
 
General procedure C using compound 242 (308.4 mg) was followed to synthesise TKP 299 
(284.7 mg) in 3 hours as a colourless oil that solidifies on standing in 82% yield after being 
purified by flash column chromatography (gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 
73 – 74 °C; IR νmax /cm-1 3033, 2928, 1744, 1682, 1496, 1431, 1385, 1358, 1261, 1192, 1080, 
723, 699; 1H NMR (300 MHz, CDCl3) δ 7.42 (m, 2H, H-Ar), 7.38 – 7.24 (m, 8H, H-Ar), 5.32 
(d, J = 14.7 Hz, 1H, H-7b), 5.24 (m, 1H, H-12), 4.98 (dd, J = 10.2, 1.3 Hz, 1H, H-13cis), 4.94 
(s, 2H, H-9), 4.85 (dd, J = 17.0, 1.3 Hz, 1H, H-13trans), 4.28 (dd, J = 4.9, 3.6 Hz, 1H, H-6), 
4.17 (d, J = 14.7 Hz, 1H, H-7a), 2.64 (m, 2H, H-11); 13C NMR (101 MHz, CDCl3) δ 168.0 (C-
5), 156.7 (C-3), 153.3 (C-2), 135.1 (C-10), 134.3 (C-8), 129.7 (C-Ar), 129.2 (C-Ar), 128.9 (C-
Ar), 128.7 (C-12), 128.5 (C-Ar), 128.3 (C-Ar), 128.2 (C-Ar), 122.8 (C-13), 59.6 (C-6), 48.1 
(C-7), 44.3 (C-9), 36.6 (C-11); m/z (ES HRMS) C21H21N2O3 requires 349.1552, found [MH]+ 
349.1394. 
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Synthesis of 1,4,6-tribenzylpiperazine-2,3,5-trione 300 
 
General procedure C using compound 242 (326.0 mg) was followed to synthesise TKP 300 
(339.1 mg) in 3.5 hours as an oil that solidifies on standing in 83% yield after being purified 
by flash column chromatography (gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 78 – 81 
°C; IR νmax /cm-1 3032, 1743, 1677, 1494, 1455, 1427, 1364, 1321, 1258, 1215, 1176, 979, 
743, 699; 1H NMR (400 MHz, CDCl3) δ 7.46 – 7.25 (m, 10H, H-Ar), 7.22 (t, J = 7.5 Hz, 1H, 
H-15), 7.09 (t, J = 7.5 Hz, 2H, H-14), 6.78 (m, 2H, H-13), 5.59 (d, J = 14.6 Hz, 1H, H-7b), 
4.75 (d, J = 13.5 Hz, 1H, H-9b), 4.71 (d, J = 13.5 Hz, 1H, H-9a), 4.49 (dd, J = 4.6, 3.6 Hz, 
1H, H-6), 4.13 (d, J = 14.6 Hz, 1H, H-7a), 3.28 (dd, J = 14.0, 4.6 Hz, 1H, H-11b), 3.20 (dd, J 
= 14.0, 3.6 Hz, 1H, H-11a); 13C NMR (101 MHz, CDCl3) δ 168.0 (C-5), 155.8 (C-3), 153.3 
(C-2), 134.8 (C-10), 134.1 (C-8), 132.2 (C-12), 130.0 (C-Ar), 129.4 (C-Ar), 129.3 (C-Ar), 
129.0 (C-Ar), 129.0 (C-Ar), 128.8 (C-Ar), 128.5 (C-Ar), 128.2 (C-Ar), 128.2 (C-Ar), 60.4 (C-
6), 47.9 (C-7), 44.2 (C-9), 38.3 (C-11); m/z (ES HRMS) C25H22N2O3Na requires 421.1528, 
found [MNa]+ 421.1522. 
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Synthesis of 1,4-dibenzyl-6-propylpiperazine-2,3,5-trione 301 
 
General procedure C using compound 242 (616.0 mg) was followed to synthesise TKP 301 
(567.1 mg) in 3 hours as a colourless oil that solidifies on standing in 81% yield after being 
purified by flash column chromatography (gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 
75 – 77 °C; IR νmax /cm-1 3032, 2976, 2955, 2872, 1747, 1684, 1671, 1495, 1436, 1375, 1323, 
1243, 1190, 1083, 745, 701; 1H NMR (400 MHz, CDCl3) δ 7.44 (m, 2H, H-Ar), 7.40 – 7.34 
(m, 3H, H-Ar), 7.34 – 7.27 (m, 5H, H-Ar), 5.35 (d, J = 14.7 Hz, 1H, H-7b), 5.04 (d, J = 13.6 
Hz, 1H, H-9b), 4.99 (d, J = 13.6 Hz, 1H, H-9a), 4.21 (dd, J = 6.1, 3.3 Hz, 1H, H-6), 4.15 (d, J 
= 14.7 Hz, 1H, H-7a), 1.94 (m, 1H, H-11b), 1.82 (m, 1H, H-11a), 1.15 (m, 1H, H-12b), 0.92 
(m, 1H, H-12a), 0.77 (t, J = 7.2 Hz, 3H, H-13); 13C NMR (101 MHz, CDCl3) δ 168.4 (C-5), 
156.7 (C-3), 153.2 (C-2), 135.2 (C-10), 134.3 (C-8), 129.5 (C-Ar), 129.2 (C-Ar), 128.7 (C-
Ar), 128.6 (C-Ar), 128.6 (C-Ar), 128.2 (C-Ar), 59.8 (C-6), 48.0 (C-7), 44.3 (C-9), 34.9 (C-
11), 16.5 (C-12), 13.3 (C-13); m/z (ES HRMS) C21H22N2O3Na requires 373.1528, found 
[MNa]+ 373.1519. 
 
General procedure D for the preparation of Racemic Alkyl-TKP adducts: 
To a solution of alkyl triketopiperazine (0.1 mmol) in CH2Cl2 (0.7 mL) at room temperature, 
triethylamine (10 mol%) was added followed by the Michael acceptor (2.5 eq). The mixture 
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was left to react until the starting material was consumed. The crude mixture was directly 
purified by flash chromatography. 
 
Synthesis of 6-allyl-1,4-dibenzyl-6-(3-oxobutyl)piperazine-2,3,5-trione 303 
1
2 3
4
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7
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9
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General procedure D using triketopiperazine 299 (35.3 mg) was followed to synthesise 303 
(31.1 mg) in 15 hours as a white solid in 73% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 137 – 138 °C; IR νmax 
/cm-1 3071, 2972, 1738, 1711, 1673, 1496, 1456, 1427, 1356, 1309, 1269, 1257, 1172, 1130, 
1080, 934, 756, 703; 1H NMR (400 MHz, CDCl3) δ 7.49 – 7.38 (m, 4H, H-Ar), 7.35 – 7.22 
(m, 6H, H-Ar), 5.21 (d, J = 14.7 Hz, 1H, H-7b), 5.20 (m, 1H, H-12), 5.06 (d, J = 13.4 Hz, 1H, 
H-9b), 5.02 (d, J = 13.4 Hz, 1H, H-9a), 4.95 (dd, J = 10.2, 1.1 Hz, 1H, H-13cis), 4.85 (dd, J = 
17.0, 1.1 Hz, 1H, H-13trans), 4.28 (d, J = 14.7 Hz, 1H, H-7a), 2.70 (qd, J = 14.2, 7.5 Hz, 2H, 
H-11), 2.33 (m, 1H, H-14b), 2.18 (m, 1H, H-14a), 1.86 (m, 1H, H-15b), 1.73 (m, 1H, H-15a), 
1.67 (s, 3H, H-17); 13C NMR (101 MHz, CDCl3) δ 205.3 (C-16), 169.9 (C-5), 155.9 (C-3), 
155.2 (C-2), 136.6 (C-8), 135.1 (C-10), 129.7 (C-Ar), 129.0 (C-Ar), 128.9 (C-Ar), 128.6 (C-
12), 128.5 (C-Ar), 128.3 (C-Ar), 128.2 (C-Ar), 122.7 (C-13), 70.8 (C-6), 46.5 (C-7), 44.5 (C-
9), 43.5 (C-11), 37.1 (C-15), 31.7 (C-14), 29.3 (C-17); m/z (ES HRMS) C25H27N2O4 requires 
419.1971, found [MH]+ 419.1955. 
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Synthesis of 1,4-dibenzyl-6-(3-oxobutyl)-6-propylpiperazine-2,3,5-trione 304 
 
General procedure D using triketopiperazine 301 (35.0 mg) was followed to synthesise 304 
(38.1 mg) in 15 hours as a white solid in 89% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 129 – 131 °C; IR νmax 
/cm-1 2962, 1742, 1708, 1678, 1495, 1455, 1421, 1365, 1316, 1267, 1216, 1173, 1077, 745, 
701; 1H NMR (400 MHz, CDCl3) δ 7.46 – 7.38 (m, 4H, H-Ar), 7.34 – 7.24 (m, 6H, H-Ar), 
5.11 (d, J = 13.4 Hz, 1H, H-9b), 5.05 (d, J = 13.4 Hz, 1H, H-9a), 4.92 (d, J = 14.8 Hz, 1H, H-
7b), 4.51 (d, J = 14.8 Hz, 1H, H-7a), 2.21 (m, 2H, H-14), 2.00 (m, 1H, H-11b), 1.86 (m, 1H, 
H-11a), 1.75 (m, 2H, H-15), 1.72 (s, 3H, H-17), 0.93 (m, 1H, H-12b), 0.79 (m, 1H, H-12a), 
0.61 (t, J = 7.2 Hz, 3H, H-13); 13C NMR (101 MHz, CDCl3) δ 205.3 (C-16), 170.5 (C-5), 
155.9 (C-3), 155.0 (C-2), 136.6 (C-8), 135.2 (C-10), 129.5 (C-Ar), 128.9 (C-Ar), 128.8 (C-
Ar), 128.6 (C-Ar), 128.3 (C-Ar), 128.1 (C-Ar), 71.0 (C-6), 46.3 (C-7), 44.4 (C-9), 41.4 (C-
11), 36.9 (C-15), 32.7 (C-14), 29.5 (C-17), 17.1 (C-12), 13.1 (C-13); m/z (ES HRMS) 
C25H29N2O4 requires 421.2127, found [MH]+ 421.2120. 
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Synthesis of 1,4,6-tribenzyl-6-(3-oxobutyl)piperazine-2,3,5-trione 305 
 
General procedure D using triketopiperazine 300 (38.6 mg) was followed to synthesise 305 
(42.9 mg) in 15 hours as a white solid in 93% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 171 – 173 °C; IR νmax 
/cm-1 3062, 2960, 1743, 1703, 1678, 1497, 1455, 1419, 1372, 1326, 1255, 1171, 1079, 736, 
700; 1H NMR (400 MHz, CDCl3) δ 7.43 (m, 2H, H-Ar), 7.37 (m, 2H, H-Ar), 7.35 – 7.26 (m, 
6H, H-Ar), 7.19 (m, 1H, H-15), 7.05 (t, J = 7.7 Hz, 2H, H-14), 6.74 (m, 2H, H-13), 5.63 (d, J 
= 14.7 Hz, 1H, H-7b), 4.86 (d, J = 13.4 Hz, 1H, H-9b), 4.75 (d, J = 13.4 Hz, 1H, H-9a), 4.16 
(d, J = 14.7 Hz, 1H, H-7a), 3.34 (d, J = 13.9 Hz, 1H, H-11b), 3.22 (d, J = 13.9 Hz, 1H, H-
11a), 2.53 (ddd, J = 14.9, 12.0, 5.4 Hz, 1H, H-16b), 2.31 (ddd, J = 14.9, 11.8, 3.0 Hz, 1H, H-
16a), 1.84 (ddd, J = 17.4, 11.8, 5.4 Hz, 1H, H-17b), 1.59 (m, 1H, H-17a), 1.58 (s, 3H, H-19); 
13C NMR (101 MHz, CDCl3) δ 205.5 (C-18), 170.0 (C-5), 155.3 (C-2), 155.1 (C-3), 136.8 (C-
8), 134.8 (C-10), 132.5 (C-12), 130.0 (C-Ar), 129.4 (C-Ar), 129.0 (C-Ar), 128.5 (C-Ar), 128.3 
(C-Ar), 128.2 (C-Ar), 128.2 (C-Ar), 72.1 (C-6), 47.0 (C-7), 45.4 (C-11), 44.4 (C-9), 37.3 (C-
17), 31.7 (C-16), 29.2 (C-19); 2 signals in the C-H aromatic region were not observed due to 
having equivalent resonances; m/z (ES HRMS) C29H28N2O4Na requires 491.1947, found 
[MNa]+ 491.1945. 
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Synthesis of 6-allyl-1,4-dibenzyl-6-(3-oxopropyl)piperazine-2,3,5-trione 306 
 
General procedure D using triketopiperazine 299 (17.3 mg) was followed to synthesise 306 
(20.2 mg) in 25 hours as a colourless oil in 98% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (4:1) to (2:1). IR νmax /cm-1 3062, 2960, 
1743, 1703, 1678, 1497, 1455, 1419, 1372, 1326, 1255, 1171, 1079, 736, 700; 1H NMR (400 
MHz, CDCl3) δ 9.16 (s, 1H, H-16), 7.48 – 7.38 (m, 4H, H-Ar), 7.36 – 7.26 (m, 6H, H-Ar), 
5.25 (d, J = 14.9 Hz, 1H, H-7b), 5.20 (m, 1H, H-12), 5.07 (d, J = 13.4 Hz, 1H, H-9b), 5.01 (d, 
J = 13.4 Hz, 1H, H-9a), 4.97 (dd, J = 10.1, 1.0 Hz, 1H, H-13cis), 4.86 (dd, J = 17.0, 1.0 Hz, 
1H, H-13trans), 4.29 (d, J = 14.9 Hz, 1H, H-7a), 2.75 (dd, J = 14.2, 7.2 Hz, 1H, H-11b), 2.67 
(dd, J = 14.2, 7.2 Hz, 1H, H-11a), 2.39 (ddd, J = 15.0, 11.3, 5.5 Hz, 1H, H-14b), 2.23 (ddd, J 
= 15.0, 11.1, 3.6 Hz, 1H, H-14a), 1.94 (ddd, J = 18.0, 11.1, 5.5 Hz, 1H, H-15b), 1.75 (ddd, J = 
18.0, 11.3, 3.6 Hz, 1H, H-15a); 13C NMR (101 MHz, CDCl3) δ 198.4 (C-16), 169.8 (C-5), 
155.8 (C-3), 155.2 (C-2), 136.5 (C-8), 135.0 (C-10), 129.6 (C-Ar), 128.9 (C-Ar), 128.9 (C-
Ar), 128.6 (C-12), 128.5 (C-Ar), 128.3 (C-Ar), 122.9 (C-13), 70.8 (C-6), 46.5 (C-7), 44.5 (C-
9), 43.5 (C-11), 38.0 (C-15), 30.0 (C-14); 1 signal in the C-H aromatic region was not 
observed due to having equivalent resonances; m/z (ES HRMS) C24H25N2O4 requires 
405.1814, found [MH]+ 405.1909. 
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Synthesis of 1,4-dibenzyl-6-(3-oxopropyl)-6-propylpiperazine-2,3,5-trione 307 
 
General procedure D using triketopiperazine 301 (33.6 mg) was followed to synthesise 307 
(34.5 mg) in 22 hours as a white solid in 85% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 116 – 117 °C; IR νmax 
/cm-1 2739, 1742, 1718, 1675, 1496, 1455, 1413, 1378, 1360, 1322, 1256, 1221, 1158, 1076, 
737, 698; 1H NMR (400 MHz, CDCl3) δ 9.21 (s, 1H, H-16), 7.42 (m, 4H, H-Ar), 7.35 – 7.25 
(m, 6H, H-Ar), 5.07 (s, 2H, H-9), 4.98 (d, J = 14.9 Hz, 1H, H-7b), 4.49 (d, J = 14.9 Hz, 1H, 
H-7a), 2.33 (m, 1H, H-14b), 2.20 (ddd, J = 21.9, 11.1, 5.9 Hz, 1H, H-14a), 2.01 (m, 1H, H-
11b), 1.94 – 1.76 (m, 3H, H-11a, H-15), 0.95 (m, 1H, H-12b), 0.79 (m, 1H, H-12a), 0.63 (t, J 
= 7.2 Hz, 3H, H-13);13C NMR (101 MHz, CDCl3) δ 198.4 (C-16), 170.4 (C-5), 155.8 (C-3), 
155.0 (C-2), 136.5 (C-8), 135.1 (C-10), 129.4 (C-Ar), 128.9 (C-Ar), 128.8 (C-Ar), 128.6 (C-
Ar), 128.3 (C-Ar), 128.3 (C-Ar), 70.9 (C-6), 46.3 (C-7), 44.5 (C-9), 41.6 (C-11), 37.8 (C-15), 
30.9 (C-14), 17.0 (C-12), 13.1 (C-13); m/z (ES HRMS) C24H27N2O4 requires 407.1971, found 
[MH]+ 407.1975. 
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Synthesis of 1,4,6-tribenzyl-6-(3-oxopropyl)piperazine-2,3,5-trione 308 
 
General procedure D using triketopiperazine 300 (41.5 mg) was followed to synthesise 308 
(41.4 mg) in 15 hours as a white solid in 93% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 166 – 167 °C; IR νmax 
/cm-1 3303, 3069, 2977, 2836, 1742, 1705, 1675, 1497, 1454, 1420, 1370, 1326, 1266, 1143, 
1079, 982, 737, 698; 1H NMR (400 MHz, CDCl3) δ 9.05 (s, 1H, H-18), 7.42 (dd, J = 7.2, 2.0 
Hz, 2H, H-Ar), 7.39 – 7.25 (m, 8H, H-Ar), 7.21 (t, J = 7.5 Hz, 1H, H-15), 7.07 (t, J = 7.5 Hz, 
2H, H-14), 6.76 (m, 2H, H-13), 5.66 (d, J = 14.7 Hz, 1H, H-7b), 4.86 (d, J = 13.4 Hz, 1H, H-
9b), 4.73 (d, J = 13.4 Hz, 1H, H-9a), 4.19 (d, J = 14.7 Hz, 1H, H-7a), 3.37 (d, J = 13.9 Hz, 
1H, H-11b), 3.22 (d, J = 13.9 Hz, 1H, H-11a), 2.57 (ddd, J = 15.0, 11.5, 5.4 Hz, 1H, H-16b), 
2.37 (ddd, J = 15.0, 11.3, 3.3 Hz, 1H, H-16a), 1.91(m, 1H, H-17b), 1.58 (ddd, J = 18.3, 11.5, 
3.3 Hz, 1H, H-17a); 13C NMR (101 MHz, CDCl3) δ 198.5 (C-18), 169.9 (C-5), 155.3 (C-2), 
155.0 (C-3), 136.6 (C-8), 134.7 (C-10), 132.4 (C-12), 129.9 (C-Ar), 129.6 (C-Ar), 129.0 (C-
Ar), 129.0 (C-Ar), 128.8 (C-Ar), 128.6 (C-Ar), 128.4 (C-Ar), 128.3 (C-Ar), 128.2 (C-Ar), 
72.1 (C-6), 47.1 (C-7), 45.4 (C-11), 44.4 (C-9), 38.2 (C-17), 30.1 (C-16); m/z (ES HRMS) 
C28H26N2O4Na requires 477.1790, found [MNa]+ 477.1799. 
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Synthesis of 1,4-dibenzyl-6-(3-oxopentyl)-6-propylpiperazine-2,3,5-trione 309 
 
General procedure D using triketopiperazine 301 (250 mg) was followed to synthesise 309 
(330 mg) in 15 hours as a white solid in 76% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 147 – 148 °C; IR νmax 
/cm-1 3069, 2971, 2938, 2876, 1742, 1709, 1671, 1499, 1452, 1420, 1355, 1328, 1265, 1221, 
1156, 1080, 979, 723, 702; 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.29 (m, 4H, H-Ar), 7.27 – 
7.14 (m, 6H, H-Ar), 5.02 (d, J = 13.4 Hz, 1H, H-9b), 4.97 (d, J = 13.4 Hz, 1H, H-9a), 4.82 (d, 
J = 14.8 Hz, 1H, H-7b), 4.44 (d, J = 14.8 Hz, 1H, H-7a), 2.14 (m, 2H, H-14), 1.98 – 1.71 (m, 
4H, H-11, H-17), 1.66 (t, J = 8.1 Hz, 2H, H-15), 0.83 (m, 2H, H-12), 0.75 (t, J = 7.3 Hz, 3H, 
H-18), 0.52 (t, J = 7.2 Hz, 3H, H-13); 13C NMR (101 MHz, CDCl3) δ 208.1 (C-16), 170.5 (C-
5), 156.0 (C-3), 155.0 (C-2), 136.6 (C-8), 135.2 (C-10), 129.5 (C-Ar), 129.0 (C-Ar), 128.8 (C-
Ar), 128.6 (C-Ar), 128.3 (C-Ar), 128.1 (C-Ar), 71.1 (C-6), 46.3 (C-7), 44.4 (C-9), 41.5 (C-
11), 35.6 (C-15), 35.5 (C-17), 32.7 (C-14), 17.1 (C-12), 13.1 (C-13), 7.6 (C-18); m/z (ES 
HRMS) C26H30N2O4Na requires 457.2103, found [MNa]+ 457.2104. 
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Synthesis of 1,4-dibenzyl-6-(3-oxo-3-phenylpropyl)-6-propylpiperazine-2,3,5-trione 310 
 
General procedure D using triketopiperazine 301 (35.6 mg) was followed to synthesise 310 
(29.7 mg) in 23 hours as a white solid in 61% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 162 – 163 °C; IR νmax 
/cm-1 2957, 1744, 1675, 1495, 1446, 1416, 1359, 1262, 1148, 1079, 975, 731, 691; 1H NMR 
(400 MHz, CDCl3) δ 7.53 (m, 1H, H-Ar), 7.51 – 7.44 (m, 4H, H-Ar), 7.44 – 7.33 (m, 4H, H-
Ar), 7.32 – 7.23 (m, 3H, H-Ar), 7.17 (t, J = 7.4 Hz, 2H, H-Ar), 7.10 (m, 1H, H-Ar), 5.15 (d, J 
= 13.4 Hz, 1H, H-9b), 5.10 (d, J = 13.4 Hz, 1H, H-9a), 4.90 (d, J = 14.8 Hz, 1H, H-7b), 4.63 
(d, J = 14.8 Hz, 1H, H-7a), 2.45 (m, 2H, H-14), 2.32 (m, 2H, H-15), 2.07 (ddd, J = 14.4, 12.1, 
5.1 Hz, 1H, H-11b), 1.90 (m, 1H, H-11a), 0.92 (m, 2H, H-12), 0.63 (t, J = 7.2 Hz, 3H, H-13); 
13C NMR (101 MHz, CDCl3) δ 197.0 (C-16), 170.6 (C-5), 156.0 (C-3), 155.0 (C-2), 136.5 (C-
17), 135.9 (C-8), 135.3 (C-10), 133.3 (C-Ar), 129.6 (C-Ar), 128.8 (C-Ar), 128.7 (C-Ar), 128.4 
(C-Ar), 128.3 (C-Ar), 128.1 (C-Ar), 127.7 (C-Ar), 71.2 (C-6), 46.4 (C-7), 44.4 (C-9), 41.5 (C-
11), 33.1 (C-14), 32.1 (C-15), 17.2 (C-12), 13.1 (C-13); 1 signal in the C-H aromatic region 
was not observed due to having equivalent resonances; m/z (ES HRMS) C30H31N2O4 requires 
483.2284, found [MH]+ 483.2282. 
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Synthesis of 1,4,6-tribenzyl-6-(3-oxo-3-phenylpropyl)piperazine-2,3,5-trione 311 
 
General procedure D using triketopiperazine 300 (38.0 mg) was followed to synthesise 311 
(26.6 mg) in 24 hours as a white solid in 52% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 151 – 153 °C; IR νmax-1 
/cm-3032, 1742, 1687, 1673, 1662, 1597, 1495, 1450, 1424, 1361, 1304, 1266, 1189, 1085, 
968, 742, 694; 1H NMR (400 MHz, CDCl3) δ 7.50 (m, 1H, H-Ar), 7.44 – 7.36 (m, 6H, H-Ar), 
7.36 – 7.27 (m, 5H, H-Ar), 7.22 (m, 1H, H-Ar), 7.14 – 7.06 (m, 4H, H-Ar), 6.92 (t, J = 7.4 
Hz, 1H, H-Ar), 6.82 (m, 2H, H-Ar), 5.64 (d, J = 14.6 Hz, 1H, H-7b), 4.90 (d, J = 13.4 Hz, 1H, 
H-9b), 4.80 (d, J = 13.4 Hz, 1H, H-9a), 4.24 (d, J = 14.6 Hz, 1H, H-7a), 3.41 (d, J = 13.9 Hz, 
1H, H-11b), 3.31 (d, J = 13.9 Hz, 1H, H-11a), 2.74 (ddd, J = 14.8, 11.7, 5.2 Hz, 1H, H-13b), 
2.52 (ddd, J = 14.8, 11.5, 3.1 Hz, 1H, H-13a), 2.33 (ddd, J = 16.8, 11.5, 5.2 Hz, 1H, H-14b), 
2.20 – 2.05 (ddd, J = 16.8, 11.7, 3.1 Hz, 1H, H-14a); 13C NMR (101 MHz, CDCl3) δ 197.1 
(C-15), 170.1 (C-5), 155.3 (C-2), 155.2 (C-3), 136.5 (C-16), 136.0 (C-8), 135.0 (C-10), 133.0 
(C-Ar), 132.6 (C-12), 129.9 (C-Ar), 129.4 (C-Ar), 129.0 (C-Ar), 128.9 (C-Ar), 128.8 (C-Ar), 
128.6 (C-Ar), 128.4 (C-Ar), 128.2 (C-Ar), 128.0 (C-Ar), 127.6 (C-Ar), 72.4 (C-6), 47.1 (C-7), 
45.5 (C-11), 44.2 (C-9), 32.6 (C-14), 32.2 (C-13); 1 signal in the C-H aromatic region was not 
observed due to having equivalent resonances; m/z (ES HRMS) C34H31N2O4 requires 
531.2284, found [MH]+ 531.2280. 
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Synthesis of 1,4-dibenzyl-6-(3-cyclohexyl-3-oxopropyl)-6-propylpiperazine-2,3,5-trione 312 
 
General procedure D using triketopiperazine 301 (33.2 mg) was followed to synthesise 312 
(38.1 mg) in 48 hours as a white solid in 82% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 130 – 131 °C; IR νmax 
/cm-1 2930, 2853 1740, 1705, 1674, 1497, 1447, 1427, 1372, 1319, 1261, 1219, 1149, 1075, 
741, 700; 1H NMR (400 MHz, CDCl3) δ 7.47 (m, 2H, H-Ar), 7.40 (m, 2H, H-Ar), 7.35 – 7.22 
(m, 6H, H-Ar), 5.13 (d, J = 13.4 Hz, 1H, H-9b), 5.05 (d, J = 13.4 Hz, 1H, H-9a), 4.89 (d, J = 
14.8 Hz, 1H, H-7b), 4.52 (d, J = 14.8 Hz, 1H, H-7a), 2.19 (m, 2H, H-14), 2.02 (ddd, J = 14.4, 
12.1, 5.1 Hz, 1H, H-11b), 1.87 (ddd, J = 14.4, 12.1, 4.3 Hz, 1H, H-11a), 1.81 – 1.71 (m, 3H, 
H-15, H-17), 1.71 – 1.65 (m, 2H, H-21b, H-19b), 1.60 (m, 1H, H-20b), 1.49 – 1.35 (m, 2H, H-
22b, H-18b), 1.19 – 1.05 (m, 3H, H-21a, H-20a, H-19a), 1.04 – 0.91 (m, 3H, H-12b, H-22a, 
H-18a), 0.83 (m, 1H, H-12a), 0.62 (t, J = 7.2 Hz, 3H, H-13); 13C NMR (101 MHz, CDCl3) δ 
210.7 (C-16), 170.6 (C-5), 156.0 (C-3), 155.0 (C-2), 136.6 (C-8), 135.3 (C-10), 129.6 (C-Ar), 
128.9 (C-Ar), 128.8 (C-Ar), 128.6 (C-Ar), 128.3 (C-Ar), 128.1 (C-Ar), 71.1 (C-6), 50.5 (C-
17), 46.3 (C-7), 44.3 (C-9), 41.4 (C-11), 33.8 (C-15), 32.9 (C-14), 28.4 (C-22), 28.1 (C-18), 
25.6 (C-21), 25.5 (C-19), 25.4 (C-20), 17.1 (C-12), 13.1 (C-13); m/z (ES HRMS) C30H37N2O4 
requires 489.2753, found [MH]+ 489.2772. 
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Synthesis of 1,4,6-tribenzyl-6-(3-cyclohexyl-3-oxopropyl)piperazine-2,3,5-trione 313 
1
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General procedure D using triketopiperazine 300 (37.8 mg) was followed to synthesise 313 
(44.2 mg) in 40 hours as a white solid in 86% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 168 – 169 °C; IR νmax 
/cm-1 3065, 2929, 1740, 1671, 1497, 1452, 1427, 1373, 1306, 1253, 1139, 1080, 1031, 741, 
699; 1H NMR (400 MHz, CDCl3) δ 7.43 (m, 2H, H-Ar), 7.37 (m, 2H, H-Ar), 7.34 – 7.25 (m, 
6H, H-Ar), 7.19 (m, 1H, H-15), 7.08 (t, J = 7.6 Hz, 2H, H-14), 6.78 (d, J = 7.6 Hz, 1H, H-13), 
5.58 (d, J = 14.7 Hz, 1H, H-7b), 4.87 (d, J = 13.4 Hz, 1H, H-9b), 4.80 (d, J = 13.4 Hz, 1H, H-
9a), 4.19 (d, J = 14.7 Hz, 1H, H-7a), 3.35 (d, J = 13.9 Hz, 1H, H-11b), 3.25 (d, J = 13.9 Hz, 
1H, H-11a), 2.49 (ddd, J = 14.9, 12.0, 4.9 Hz, 1H, H-16b), 2.32 (ddd, J = 14.9, 11.9, 3.4 Hz, 
1H, H-16a), 1.81 (ddd, J = 17.1, 11.9, 4.9 Hz, 1H, H-17b), 1.68 – 1.52 (m, 5H, H-17a, H-19, 
H-23b, H-22b, H-21b), 1.43 (d, J = 13.0 Hz, 1H, H-24b), 1.26 (m, 1H, H-20b), 1.16 – 1.02 
(m, 3H, H-23a, H-22a, H-21a), 1.00 – 0.80 (m, 2H, H-24a, H-20a); 13C NMR (101 MHz, 
CDCl3) δ 210.7 (C-18) , 170.1 (C-5), 155.2 (C-3), 155.1 (C-2), 136.7 (C-8), 134.9 (C-10), 
132.6 (C-12), 129.9 (C-Ar), 129.4 (C-Ar), 129.0 (C-Ar), 128.9 (C-Ar), 128.5 (C-Ar), 128.3 
(C-Ar), 128.2 (C-Ar), 128.1 (C-Ar), 72.3 (C-6), 50.3 (C-19), 47.1 (C-7), 45.3 (C-11), 44.2 (C-
9), 34.2 (C-17), 31.9 (C-16), 28.4 (C-24), 28.0 (C-20), 25.6 (C-23), 25.5 (C-21), 25.3 (C-22); 
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1 signal in the C-H aromatic region was not observed due to having equivalent resonances; 
m/z (ES HRMS) C34H37N2O4 requires 537.2753, found [MH]+ 531.2738. 
 
Synthesis of (R)-1,4-dibenzyl-6-(3-oxopentyl)-6-(3-oxopropyl)piperazine-2,3,5-trione 317a 
 
To a mixture of triketopiperazine 242 (0.1 mmol, 30.8 mg) and catalyst 201 (4.0 mg, 10 
mol%) dissolved in CH2Cl2 (0.7 mL) at −78 °C, ethyl vinyl ketone (0.1 mmol, 10 µL, 1.05 eq) 
was added neat over 1 minute. The reaction mixture was allowed to warm to –30 °C and left 
to react. After the starting material was completely consumed, acrolein (33 µL, 0.5 mmol, 5 
eq) was added. The temperature was raised to 0 °C and the mixture was left to react until 
complete consumption of the reactive intermediate, 48 hours. Product 317a (38.0 mg) was 
obtained as a white solid in 85% yield after being purified by flash column chromatography 
(gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 127 – 128 °C; IR νmax /cm-1 2976, 2827, 
2726, 1725, 1713, 1675, 1493, 1422, 1364, 1314, 1269, 1146, 1080, 1034, 727, 702; 1H NMR 
(400 MHz, CDCl3) δ 9.25 (s, 1H, H-13), 7.45 (m, 2H, H-Ar), 7.40 (dt, J = 5.0, 3.0 Hz, 2H, H-
Ar), 7.36 – 7.23 (m, 6H, H-Ar), 5.10 (d, J = 13.4 Hz, 1H, H-9b), 5.05 (d, J = 13.4 Hz, 1H, H-
9a), 4.78 (d, J = 14.9 Hz, 1H, H-7b), 4.64 (d, J = 14.9 Hz, 1H, H-7a), 2.39 – 2.19 (m, 4H, H-
11, H-14), 2.02 (m, 2H, H-17), 1.91 (m, 2H, H-12), 1.80 (m, 2H, H-15), 0.86 (t, J = 7.3 Hz, 
3H, H-18); 13C NMR (101 MHz, CDCl3) δ 207.8 (C-16), 198.2 (C-13), 169.8 (C-5), 155.6 (C-
3), 154.8 (C-2), 136.4 (C-8), 135.1 (C-10), 129.6 (C-Ar), 129.0 (C-Ar), 128.9 (C-Ar), 128.7 
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(C-Ar), 128.5 (C-Ar), 128.3 (C-Ar), 70.0 (C-6), 46.4 (C-7), 44.5 (C-9), 37.8 (C-12), 35.6 (C-
17), 35.6 (C-15), 33.0 (C-14), 31.1 (C-11), 7.6 (C-18); m/z (ES HRMS) C26H29N2O5 requires 
449.2076, found [MH]+ 449.2073; = −3.4 (c 1.2, CHCl3).  
 
Synthesis of (R)-1,4-dibenzyl-6-(3-oxobutyl)-6-(3-oxopentyl)piperazine-2,3,5-trione 317b 
 
To a mixture of triketopiperazine 242 (0.1 mmol, 30.8 mg) and catalyst 201 (4.0 mg, 10 
mol%) dissolved in CH2Cl2 (0.7 mL) at −78 °C, ethyl vinyl ketone (0.1 mmol, 10 µL, 1.05 eq) 
was added neat over 1 minute. The reaction mixture was allowed to warm to –30 °C and left 
to react. After the starting material was completely consumed, methyl vinyl ketone (35 µL, 
0.5 mmol, 5 eq) was added. The temperature was raised to 0 °C and the mixture was left to 
react until complete consumption of the reactive intermediate, 48 hours. Product 317b (36.4 
mg) was obtained as a white solid in 79% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 139 – 140 °C; IR νmax 
/cm-1 2951, 1711, 1676, 1496, 1456, 1420, 1363, 1266, 1169, 1143, 1077, 1030, 734, 702; 1H 
NMR (400 MHz, CDCl3) δ 7.38 (m, 2H, H-Ar), 7.32 (m, 2H, H-Ar), 7.27 – 7.21 (m, 3H, H-
Ar), 7.20 – 7.15 (m, 3H, H-Ar), 5.00 (s, 2H, H-9), 4.63 (d, J = 14.9 Hz, 1H, H-7b), 4.58 (d, J 
= 14.9 Hz, 1H, H-7a), 2.24 – 2.13 (m, 4H, H-11, H-15), 1.89 (m, 2H, H-18), 1.79 – 1.70 (m, 
4H, H-12, H-16), 1.68 (s, 3H, H-14), 0.77 (t, J = 7.3 Hz, 3H, H-19); 13C NMR (101 MHz, 
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CDCl3) δ 207.9 (C-17), 205.1 (C-13), 169.9 (C-5), 155.7 (C-3), 154.9 (C-2), 136.5 (C-8), 
135.2 (C-10), 129.7 (C-Ar), 129.0 (C-Ar), 128.9 (C-Ar), 128.7 (C-Ar), 128.5 (C-Ar), 128.2 
(C-Ar), 70.0 (C-6), 46.4 (C-7), 44.5 (C-9), 37.0 (C-12), 35.7 (C-16), 35.6 (C-18), 32.8 (C-11, 
C-15), 29.5 (C-14), 7.5 (C-19); m/z (ES HRMS) C27H30N2O5Na requires 485.2052, found 
[MNa]+ 485.2055; = 5.0 (c 1.0, CHCl3). 
 
Synthesis of (6S,7R)-1,4-dibenzyl-9-hydroxy-9-methyl-8-nitro-7-phenyl-1,4-diazaspiro 
[5.5]undecane-2,3,5-trione 318 
 
To a mixture of triketopiperazine 242 (0.1 mmol, 30.8 mg) and catalyst 201 (4.0 mg, 10 
mol%) dissolved in CH2Cl2 (0.7 mL) at −78 °C, methyl vinyl ketone (0.1 mmol, 8 µL, 1.05 
eq) was added neat over 1 minute. The reaction mixture was allowed to warm to –30 °C and 
left to react. After the starting material was completely consumed, nitrostyrene (74.5 mg, 0.5 
mmol, 5 eq) was added. The temperature was raised to 0 °C and the mixture was left to react 
until complete consumption of the reactive intermediate, 72 hours. Product 318 (36.3 mg) was 
obtained as a white solid in 69% yield after being purified by flash column chromatography 
(gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 184 – 185 °C; IR νmax /cm-1 3401, 2967, 
2932, 2879, 1740, 1679, 1548, 1498, 1456, 1423, 1368, 1322, 1301, 1209, 1131, 1030, 990, 
752, 701; 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.25 (m, 10H, H-Ar), 7.20 (t, J = 7.3 Hz, 1H, 
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H-19), 7.01 (t, J = 7.3 Hz, 2H, H-18), 6.87 (d, J = 7.3 Hz, 2H, H-17), 5.61 (d, J = 12.1 Hz, 
1H, H-8), 5.55 (d, J = 15.5 Hz, 1H, H-12b), 4.78 (d, J = 13.4 Hz, 1H, H-14b), 4.69 (d, J = 
13.4 Hz, 1H, H-14a), 4.66 (d, J = 15.5 Hz, 1H, H-12a), 4.31 (d, J = 12.1 Hz, 1H, H-7), 2.82 
(d, J = 1.9 Hz, 1H, OH), 2.71 – 2.53 (m, 2H, H-11b, H-10b), 1.94 (m, 1H, H-10a), 1.85 (m, 
1H, H-11a), 1.45 (s, 3H, H-20); 13C NMR (101 MHz, CDCl3) δ 170.1 (C-5), 154.2 (C-3), 
154.1 (C-2), 136.1 (C-13), 134.4 (C-15), 130.5 (C-16), 130.2 (C-Ar), 129.7 (C-Ar), 129.3 (C-
Ar), 128.8 (C-Ar), 128.6 (C-Ar), 128.3 (C-Ar), 127.6 (C-Ar), 126.8 (C-Ar), 91.5 (C-8), 70.1 
(C-9), 69.8 (C-6), 47.3 (C-12), 47.1 (C-7), 44.4 (C-14), 34.3 (C-10), 29.3 (C-11), 26.9 (C-20); 
1 signal in the C-H aromatic region was not observed due to having equivalent resonances; 
m/z (ESI HRMS) C30H29N3O6Na requires 550.1954, found [MNa]+ 550.1947; = −71.7 (c 
0.8, CHCl3). 
 
Synthesis of (6S,7R)-1,4-dibenzyl-9-hydroxy-8-nitro-7,9-diphenyl-1,4-diazaspiro 
[5.5]undecane-2,3,5-trione 319 
 
To a mixture of triketopiperazine 242 (0.1 mmol, 30.8 mg) and catalyst 201 (4.0 mg, 10 
mol%) dissolved in CH2Cl2 (0.7 mL) at −78 °C, phenyl vinyl ketone (0.1 mmol, 13.5 mg, 1.05 
eq) was added neat over 1 minute. The reaction mixture was allowed to warm to –30 °C and 
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left to react. After the starting material was completely consumed, nitrostyrene (74.5 mg, 0.5 
mmol, 5 eq) was added. The temperature was raised to 0 °C and the mixture was left to react 
until complete consumption of the reactive intermediate, 72 hours. Product 319 (45.1 mg) was 
obtained as a white solid in 77% yield after being purified by flash column chromatography 
(gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 129 – 132 °C; IR νmax /cm-1 3031, 1743, 
1677, 1549, 1496, 1448, 1367, 1323, 1203, 1030, 750, 698; 1H NMR (400 MHz, CDCl3) δ 
7.62 (d, J = 7.5 Hz, 2H, H-Ar), 7.53 (m, 1H, H-Ar), 7.49 – 7.43 (m, 4H, H-Ar), 7.42 – 7.24 
(m, 8H, H-Ar), 7.21 (t, J = 7.3 Hz, 1H, H-19), 7.01 (t, J = 7.3 Hz, 2H, H-18), 6.95 (d, J = 7.3 
Hz, 2H, H-17), 6.21 (d, J = 12.0 Hz, 1H, H-8), 5.59 (d, J = 15.5 Hz, 1H, H-12b), 4.88 (d, J = 
13.4 Hz, 1H, H-14b), 4.77 (d, J = 13.8 Hz, 2H, H-12a, H-14a), 4.46 (d, J = 12.0 Hz, 1H, H-7), 
3.99 (d, J = 2.7 Hz, 1H, OH), 3.00 (m, 1H, H-10b), 2.83 (td, J = 13.6, 5.2 Hz, 1H, H-11b), 
2.05 – 1.90 (m, 2H, H-11a, H-10a); 13C NMR (101 MHz, CDCl3) δ 170.3 (C-5), 154.2 (C-3), 
154.0 (C-2), 141.4 (C-20), 136.0 (C-13), 134.4 (C-15), 133.4 (C-16), 130.2 (C-Ar), 129.9 (C-
Ar), 129.3 (C-Ar), 128.9 (C-Ar), 128.7 (C-Ar), 128.5 (C-Ar), 128.4 (C-Ar), 127.7 (C-Ar), 
126.8 (C-Ar), 124.4 (C-Ar), 90.7 (C-8), 75.0 (C-9), 69.8 (C-6), 47.8 (C-7), 47.3 (C-12), 44.4 
(C-14), 35.6 (C-10), 29.8 (C-11); 2 signals in the C-H aromatic region were not observed due 
to having equivalent resonances; m/z (ESI HRMS) C35H31N3O6Na requires 612.2111, found 
[MNa]+ 612.2109; = −33.7 (c 1.0, CHCl3). 
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Synthesis of 1,4-dibenzyl-3-hydroxypiperazine-2,5-dione 322 
 
To a solution of 242 (15.4 mg, 0.05 mmol, 1 eq.) in MeOH
 
(1 mL), NaBH4 (2.4 mg, 0.05 
mmol, 1 eq.) was added in one portion at 0 °C. The mixture was left to react at that 
temperature for 2 h and was then quenched with water (2 mL). The crude was extracted with 
ethyl acetate
 
(3 x 10 mL) and washed with brine (1 x 15 mL). Compound 322 was obtained as 
a white solid in 62% yield (9.7 mg) after being purified by flash column chromatography 
(gradient: hexane/ethyl acetate = (2:1) to (0:1). m.p. 179 – 181 °C; IR νmax /cm-1 3112, 3032, 
2942, 2855, 1639, 1471, 1454, 1310, 1260, 1163, 1104, 1071, 943, 726, 696; 1H NMR (400 
MHz, CDCl3) δ 7.39 – 7.29 (m, 8H, H-Ar), 7.26 (m, 2H, H-Ar), 5.17 (d, J = 14.7 Hz, 1H, H-
7b), 5.09 (s, 1H, H-3), 4.70 (d, J = 14.6 Hz, 1H, H-9b), 4.48 (d, J = 14.6 Hz, 1H, H-9a), 4.27 
(d, J = 14.7 Hz, 1H, H-7a), 4.09 (d, J = 17.6 Hz, 1H, H-6b), 3.86 (d, J = 17.6 Hz, 1H, H-6a); 
13C NMR (101 MHz, CDCl3) δ 165.1 (C-5), 164.8 (C-2), 135.6 (C-8), 134.5 (C-10), 129.0 (C-
Ar), 128.8 (C-Ar), 128.6 (C-Ar), 128.3 (C-Ar), 128.2 (C-Ar), 128.0 (C-Ar), 77.5 (C-3), 49.5 
(C-9), 49.0 (C-6), 46.4 (C-7); m/z (ESI) C18H18N2O3Na requires 333.1215, found [MNa]+ 
333.1231.  
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Synthesis of methyl (2S)-1,4-dibenzyl-5-hydroxy-2-(3-hydroxypropyl)-3,6-dioxopiperazine-
2-carboxylate 323 
 
To a solution of 251 (105.5 mg, 0.25 mmol, 1 eq.) in MeOH
 
(5 mL), NaBH4 (6.6 mg, 0.18 
mmol, 0.70 eq.) was added in one portion at 0 °C. The mixture was left to react at that 
temperature for 1 h and was then quenched with water (3 mL). The crude was extracted with 
ethyl acetate
 
(3 x 15 mL) and washed with brine (1 x 15 mL). Compound 323 was obtained as 
a colourless oil in 71% yield (75.7 mg) as an approximately 1:1 mixture of diastereoisomers 
after being purified by flash column chromatography (gradient: hexane/ethyl acetate = (2:1) to 
(1:2). IR νmax /cm-1 3357, 2953, 1755, 1654, 1496, 1450, 1359, 1233, 1150, 1064, 1030, 986, 
731, 702; 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.20 (m, 20H, H-Ar), 5.50 – 5.24 (m, 3H, H-
7b, H-14b, H-14b), 5.18 (s, 1H, H-5), 5.14 (s, 1H, H-5), 4.71 (d, J = 15.2 Hz, 1H, H-7b), 4.51 
(d, J = 15.2 Hz, 1H, H-7a), 4.31 – 4.17 (m, 3H H-7a, H-14a, H-14a), 3.66 (dt, J = 10.8, 5.4 
Hz, 1H, H-13b), 3.60 – 3.48 (m, 2H, H-13a, H-13b), 3.44 (m, 1H, H-13a), 3.34 (s, 3H, H-10), 
3.30 (s, 3H, H-10), 2.71 (ddd, J = 14.8, 11.0, 6.1 Hz, 1H, H-11b), 2.59 – 2.39 (m, 2H, H-11a, 
H-11b), 2.31 (m, 1H, H-11a), 1.50 (m, 1H, H-12b), 1.44 – 1.28 (m, 3H, H-12a, H-12b, H-
12a); 13C NMR (101 MHz, CDCl3) δ 170.6 (C-9), 167.8 (C-9), 166.8 (C-6), 166.3 (C-6), 
164.0 (C-3), 163.8 (C-3), 135.5 (C-8), 135.0 (C-8, C-15, C-15), 129.4 (C-Ar), 128.9 (C-Ar), 
128.8 (C-Ar), 128.7 (C-Ar), 128.5 (C-Ar), 128.5 (C-Ar), 128.2 (C-Ar), 128.1 (C-Ar), 128.0 
(C-Ar), 128.0 (C-Ar), 77.2 (C-5), 75.6 (C-5), 71.8 (C-2), 70.9 (C-2), 61.8 (C-13), 61.6 (C-13), 
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53.9 (C-10), 52.9 (C-10), 47.0 (C-7), 46.9 (C-7), 46.4 (C-14), 46.1 (C-14), 29.3 (C-11), 28.1 
(C-11), 26.1 (C-12), 25.9 (C-12); 3 signals in the C-H aromatic region were not observed due 
to having equivalent resonances; m/z (ESI) C23H26N2O6Na requires 449.1689, found [MNa]+ 
449.1673.  
 
Synthesis of (3S, 6S)-1,4-dibenzyl-3-hydroxy-6-((S)-3-oxo-1,3-diphenylpropyl)piperazine-
2,5-dione 324 
 
A solution of 295 (99.5 mg, 0.19 mmol, 1.0 eq.) in dry THF
 
(5 mL) was cooled to −78 °C and 
L-selectride (0.20 mL, 1 M, 1.1 eq.) was added dropwise over 2 minutes. The mixture was left 
to react at that temperature for 1 h and quenched with saturated NH4Cl. The crude was 
extracted with ethyl acetate
 
(3 x 15 mL) and washed with brine (1 x 15 mL). Compound 324 
was obtained as a white solid in 87% yield (87.0 mg) after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (4:1) to (2:1). m.p. 62 – 65 °C; IR νmax/cm-1 
3316, 3063, 3031, 2934, 1658, 1598, 1496, 1464, 1451, 1265, 1233, 1163, 1069, 1030, 987, 
729, 694; 1H NMR (400 MHz, CDCl3) δ 7.83 (m, 2H, H-16), 7.47 (m, 1H, H-17), 7.40 – 7.26 
(m, 6H, H-Ar), 7.24 – 7.08 (m, 9H, H-Ar), 6.71 (dt, J = 4.3, 3.0 Hz, 2H, H-Ar), 5.85 (d, J = 
6.6 Hz, 1H, OH), 5.19 (d, J = 6.6 Hz, 1H, H-3), 4.97 (d, J = 15.3 Hz, 1H, H-7b), 4.91 (d, J = 
15.0 Hz, 1H, H-9b), 4.30 – 4.08 (m, 2H, H-11, H-9a), 3.98 – 3.84 (m, 2H, H-13b, H-6), 3.20 
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(dd, J = 18.5, 5.0 Hz, 1H, H-13a), 2.34 (d, J = 15.3 Hz, 1H, H-7a); 13C NMR (101 MHz, 
CDCl3) δ 198.9 (C-14), 167.7 (C-5), 165.8 (C-2), 141.5 (C-12), 136.4 (C-15), 135.8 (C-8), 
135.4 (C-10), 133.5 (C-Ar), 129.4 (C-Ar), 128.8 (C-Ar), 128.8 (C-Ar), 128.7 (C-Ar), 128.5 
(C-Ar), 128.2 (C-Ar), 128.2 (C-Ar), 128.1 (C-Ar), 127.9 (C-Ar), 127.9 (C-Ar), 127.7 (C-Ar), 
79.4 (C-3), 64.6 (C-6), 48.2 (C-7), 47.4 (C-9), 46.0 (C-11), 42.1 (C-13); m/z (ESI) 
C33H30N2O4Na requires 541.2103, found [MNa]+ 541.2099; 
= −85.6 (c 2.3, CHCl3). 
 
Synthesis of methyl (2S)-1,4-dibenzyl-2-(3-hydroxybutyl)-3,5,6-trioxopiperazine-2-
carboxylate 328 
 
To a solution of 250 (43.6 mg, 0.1 mmol, 1 eq.) in MeOH (4 mL), palladium on carbon (5 mg, 
0.1 eq.) was added in one portion. The mixture was flushed with and left under hydrogen 
atmosphere to react at room temperature for 2 h. After the starting material was consumed, the 
crude was filtered through celite and the solvent removed under vacuum. Compound 328 was 
obtained as a colourless oil in 81% yield (35.6 mg) as an approximately 1:1 mixture of 
diastereoisomers after being purified by flash column chromatography (gradient: hexane/ethyl 
acetate = (2:1) to (1:2). IR νmax /cm-1 3482, 2969, 1743, 1686, 1497, 1421, 1369, 1236, 1160, 
1081, 732, 699; 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.29 (m, 4H, H-Ar), 7.28 – 7.16 (m, 
16H, H-Ar), 5.04 (d, J = 13.7 Hz, 1H, H-15b), 5.03 (d, J = 13.6 Hz, 1H, H-15b), 4.96 (d, J = 
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13.6 Hz, 1H, H-15a), 4.95 (d, J = 13.7 Hz, 1H, H-15a), 4.88 (d, J = 15.0 Hz, 1H, H-7b), 4.68 
(d, J = 15.0 Hz, 1H, H-7b), 4.53 (d, J = 15.0 Hz, 1H, H-7a), 4.42 (d, J = 15.0 Hz, 1H, H-7a), 
3.43 (m, 1H, H-13), 3.31 (m, 1H, H-13), 3.23 (s, 3H, H-10), 3.16 (s, 3H, H-10), 2.49 (m, 2H, 
H-11), 2.35 (m, 1H, H-11b), 2.22 (m, 1H, H-11a), 0.93 – 0.86 (m, 2H, H-12b, H-12b), 0.89 
(d, J = 6.2 Hz, 3H, H-14), 0.83 (d, J = 6.2 Hz, 3H, H-14), 0.79 (m, 1H, H-12a), 0.72 (m, 1H, 
H-12a); 13C NMR (101 MHz, CDCl3) δ 166.2 (C-9), 166.1 (C-9, C-3), 166.0 (C-3), 155.4 (C-
5), 155.4 (C-5), 154.2 (C-6), 154.2 (C-6), 135.1 (C-8), 134.9 (C-8), 134.8 (C-16), 134.8 (C-
16), 129.4 (C-Ar), 129.3 (C-Ar), 129.2 (C-Ar), 129.2 (C-Ar), 128.6 (C-Ar), 128.5 (C-Ar), 
128.3 (C-Ar), 73.0 (C-2), 72.7 (C-2), 66.8 (C-13, C-13), 53.5 (C-10), 53.4 (C-10), 47.7 (C-7), 
47.4 (C-7), 44.7 (C-15), 44.7 (C-15), 31.8 (C-12), 31.6 (C-12), 30.0 (C-11), 30.0 (C-11), 23.7 
(C-14), 23.1 (C-14); 5 signals in the C-H aromatic region were not observed due to having 
equivalent resonances; m/z (ESI) C24H26N2O6Na requires 461.1689, found [MNa]+ 461.1692. 
 
SmI2 reactions, General procedure E: 
To a solution of triketopiperazine 250, 276, 303, 304, 305, 308 or 309 (0.05 mmol) in THF (1 
mL) at room temperature, SmI2 solution in THF (2 eq.) was added. The mixture was allowed 
to react for 2-4 minutes before it was quenched by bubbling air through the solution, followed 
by HCl (0.1 M, 10 mL). The crude mixture was extracted with CH2Cl2 (3 x 20 mL), washed 
with brine (1 x 20 mL), dried over MgSO4, filtered and condensed under reduced pressure. 
The crude was purified by flash column chromatography (gradient: hexane/ethyl acetate = 
(2:1) to methanol/ethyl acetate (1:19). 
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SmI2 reactions, General procedure F: 
To a solution of triketopiperazine 303, 304, 305, 308 or 309 (0.05 mmol) in THF/water (2:1; 
1.5 mL) at room temperature, SmI2 solution in THF (2 eq.) was added. The mixture was 
allowed to react for 1-5 minutes before it was quenched by bubbling air through the solution, 
followed by HCl (0.1 M, 10 mL). The crude mixture was extracted with CH2Cl2 (3 x 20 mL), 
washed with brine (1 x 20 mL), dried over MgSO4, filtered and condensed under reduced 
pressure before being purified by flash column chromatography (gradient: hexane/ethyl 
acetate = (2:1) to ethyl acetate (100%). 
 
Synthesis of methyl (4aS,7S,7aR)-1,4-dibenzyl-7,7a-dihydroxy-7-methyl-2,3-dioxooctahydro-
4aH-cyclopenta[b]pyrazine-4a-carboxylate 340 
 
General procedure E using triketopiperazine 250 (22.1 mg) was followed to synthesise 340 
(14.5 mg) in 2 minutes as a white solid in 66% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (2:1) to methanol/ethyl acetate (1:19). m.p. 
195 – 197 °C; IR νmax /cm-1 3304, 2990, 2945, 1731, 1662, 1604, 1497, 1429, 1401, 1362, 
1284, 1140, 1078, 962, 889, 700; 1H NMR (400 MHz, CDCl3) δ 7.35 (m, 2H, H-Ar), 7.29 – 
7.14 (m, 8H, H-Ar), 4.93 (d, J = 14.6 Hz, 1H, H-12b), 4.72 (d, J = 14.9 Hz, 1H, H-10b), 4.51 
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(d, J = 14.9 Hz, 1H, H-10a), 4.26 (d, J = 14.6 Hz, 1H, H-12a), 3.29 (s, 3H, H-15), 2.67 (ddd, J 
= 14.6, 12.8, 8.5 Hz, 1H, H-9b), 2.22 (m, 1H, H-9a), 1.82(m, 1H, H-8b), 1.54 (m, 1H, H-8a), 
1.28 (s, 3H, H-16); 13C NMR (101 MHz, CDCl3) δ 168.4 (C-14), 158.6 (C-2), 155.7 (C-3), 
137.5 (C-13), 135.5 (C-11), 128.8 (C-Ar), 128.5 (C-Ar), 128.3 (C-Ar), 128.0 (C-Ar), 128.0 
(C-Ar), 127.0 (C-Ar), 92.3 (C-6), 81.1 (C-7), 74.3 (C-5), 52.6 (C-15), 47.2 (C-10), 46.2 (C-
12), 36.7 (C-8), 27.7 (C-9), 26.7 (C-16); m/z (ES HRMS) C24H27N2O6 requires 439.1869, 
found [MH]+ 439.1871; = 1.5 (c 0.8, CHCl3). 
 
Synthesis of (4aR,5S,7aS)-1,4-dibenzyl-4a,5-dihydroxy-5-methylhexahydro-1H-
cyclopenta[b]pyrazine-2,3-dione 341 
 
General procedure E using triketopiperazine 276 (18.7 mg) was followed to synthesise 341 
(15.2 mg) in 2 minutes as a white solid in 82% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (2:1) to methanol/ethyl acetate (1:19). m.p. 
148 – 150 °C; IR νmax /cm-1 3419, 3025, 2922, 2851, 1675, 1641, 1603, 1494, 1439, 1361, 
1257, 1159, 1082, 980, 700; 1H NMR (400 MHz, CDCl3) δ 7.42 (m, 2H, H-Ar), 7.36 – 7.28 
(m, 4H, H-Ar), 7.28 – 7.19 (m, 4H, H-Ar), 5.08 (m, 2H, OH, H-12b), 4.89 (d, J = 14.7 Hz, 
1H, H-10b), 4.76 (d, J = 14.7 Hz, 1H, H-10a), 4.32 (d, J = 14.8 Hz, 1H, H-12a), 3.96 (dd, J = 
7.0, 4.2 Hz, 1H, H-5), 2.17 (m, 1H, H-9b), 1.90 – 1.67 (m, 3H, H-8, H-9a), 1.23 (s, 3H, H-14); 
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13C NMR (101 MHz, CDCl3) δ 156.1 (C-2), 155.8 (C-3), 137.7 (C-11), 135.2 (C-13), 128.9 
(C-Ar), 128.6 (C-Ar), 128.5 (C-Ar), 128.3 (C-Ar), 128.0 (C-Ar), 127.4 (C-Ar), 90.7 (C-6), 
82.1 (C-7), 62.6 (C-5), 47.9 (C-12), 46.0 (C-10), 36.2 (C-8), 26.5 (C-9), 24.5 (C-14); m/z (ES 
HRMS) C22H24N2O4Na requires 403.1624, found [MNa]+ 403.1634;  = −3.3 (c 0.7, 
CHCl3). 
 
Synthesis of (4aR,5S,7aR)-7a-allyl-1,4-dibenzyl-4a,5-dihydroxy-5-methylhexahydro-1H-
cyclopenta[b]pyrazine-2,3-dione 342 
 
General procedure E using triketopiperazine 303 (20.9 mg) was followed to synthesise 342 
(18.4 mg) in 3 minutes as a white solid in 88% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (2:1) to methanol/ethyl acetate (1:19). m.p. 
204 – 206 °C; IR νmax /cm-1 3415, 3332, 3034, 2971, 1650, 1603, 1496, 1453, 1410, 1353, 
1260, 1105, 1076, 966, 889, 698; 1H NMR (400 MHz, CDCl3) δ 7.52 (m, 2H, H-Ar), 7.35 (dd, 
J = 7.4, 1.7 Hz, 2H, H-Ar), 7.32 – 7.18 (m, 6H, H-Ar), 5.44 (m, 1H, H-15), 5.16 (d, J = 14.9 
Hz, 1H, H-12b), 4.89 – 4.83 (m, 2H, H-10b, H-16cis), 4.79 (d, J = 17.2 Hz, 1H, H-16trans), 
4.30 (d, J = 13.9 Hz, 1H, H-10a), 4.05 (d, J = 14.9 Hz, 1H, H-12a), 2.65 (dd, J = 14.1, 6.3 Hz, 
1H, H-14b), 2.34 (dd, J = 14.1, 9.1 Hz, 1H, H-14a), 1.96 (m, 2H, H-9), 1.48 (m, 1H, H-8b), 
1.11 (s, 3H, H-17), 1.04 (m, 1H, H-8a); 13C NMR (101 MHz, CDCl3) δ 159.4 (C-3), 156.7 (C-
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2), 137.7 (C-13), 137.4 (C-11), 131.7 (C-15), 129.8 (C-Ar), 128.6 (C-Ar), 128.5 (C-Ar), 128.1 
(C-Ar), 127.7 (C-Ar), 127.4 (C-Ar), 120.3 (C-16), 92.6 (C-6), 81.4 (C-7), 72.8 (C-5), 47.0 (C-
12), 46.2 (C-10), 38.0 (C-14), 36.8 (C-8), 32.4 (C-9), 26.9 (C-17); m/z (ES HRMS) 
C25H28N2O4Na requires 443.1947 found [MNa]+ 443.1938. 
 
Synthesis of (4aR,5S,7aS)-1,4-dibenzyl-4a,5-dihydroxy-5-methyl-7a-propylhexahydro-1H-
cyclopenta[b]pyrazine-2,3-dione 343 
 
General procedure E using triketopiperazine 304 (21.0 mg) was followed to synthesise 343 
(18.8 mg) in 3 minutes as a white solid in 89% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (2:1) to methanol/ethyl acetate (1:19). m.p. 
193 – 195 °C; IR νmax /cm-1 3261, 3066, 2968, 1668, 1643, 1496, 1453, 1409, 1351, 1253, 
1154, 1074, 960, 882, 696; 1H NMR (400 MHz, CDCl3) δ 7.54 (dd, J = 7.5, 1.8 Hz, 2H, H-
Ar), 7.38 (dd, J = 6.1, 3.3 Hz, 2H, H-Ar), 7.32 – 7.23 (m, 6H, H-Ar), 5.79 (s, 1H, OH), 4.99 
(d, J = 14.8 Hz, 1H, H-12b), 4.79 (d, J = 13.8 Hz, 1H, H-10b), 4.70 (d, J = 13.8 Hz, 1H, H-
10a), 4.31 (d, J = 14.8 Hz, 1H, H-12a), 3.41 (s, 1H, OH), 2.05 – 1.87 (m, 3H, H-9, H-14b), 
1.56 (m, 1H, H-8b), 1.47 (m, 1H, H-14a), 1.23 – 1.13 (m, 2H, H-8a, H-15b), 1.10 (s, 3H, H-
17), 0.90 (m, 1H, H-15a) 0.63 (t, J = 7.2 Hz, 3H, H-16); 13C NMR (101 MHz, CDCl3) δ 159.4 
(C-3), 156.7 (C-2), 137.6 (C-13), 137.4 (C-11), 130.0 (C-Ar), 128.6 (C-Ar), 128.5 (C-Ar), 
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128.4 (C-Ar), 127.7 (C-Ar), 92.5 (C-6), 82.3 (C-7), 72.8 (C-5), 46.6 (C-12), 45.5 (C-10), 36.5 
(C-8), 36.1 (C-14), 32.8 (C-9), 27.4 (C-17), 16.8 (C-15), 14.1 (C-16); 1 signal in the C-H 
aromatic region was not observed due to having equivalent resonances; m/z (ES HRMS) 
C25H31N2O4 requires 423.2284, found [MH]+ 423.2273. 
 
Synthesis of (4aR,5S,7aR)-1,4,7a-tribenzyl-4a,5-dihydroxy-5-methylhexahydro-1H-
cyclopenta[b]pyrazine-2,3-dione 344 
 
General procedure E using triketopiperazine 305 (24.1 mg) was followed to synthesise 344 
(20.7 mg) in 2 minutes as a white solid in 86% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (2:1) to methanol/ethyl acetate (1:19). m.p. 
112 – 113 °C; IR νmax /cm-1 3303, 3064, 2937, 1655, 1604, 1495, 1451, 1401, 1354, 1250, 
1133, 1071, 960, 883, 697; 1H NMR (400 MHz, CDCl3) δ 7.38 (dd, J = 7.5, 1.8 Hz, 2H, H-
Ar), 7.32 (dd, J = 6.5, 2.7 Hz, 2H, H-Ar), 7.25 – 7.15 (m, 9H, H-Ar), 7.02 (dd, J = 6.5, 2.9 Hz, 
2H, H-Ar), 5.36 (s, 1H, OH), 5.33 (d, J = 14.8 Hz, 1H, H-12b), 4.73 (d, J = 14.1 Hz, 1H, H-
10b), 4.29 (d, J = 14.1 Hz, 1H, H-10a), 3.65 (d, J = 14.8 Hz, 1H, H-12a), 3.21 (d, J = 14.1 Hz, 
1H, H-14b), 3.04 (d, J = 14.1 Hz, 1H, H-14a), 2.08 (dd, J = 10.7, 6.0 Hz, 2H, H-9), 1.32 (dt, J 
= 10.7, 5.8 Hz, 1H, H-8b), 0.78 (m, 1H, H-8a), 0.69 (s, 3H, H-16); 13C NMR (101 MHz, 
CDCl3) δ 159.2 (C-3), 156.0 (C-2), 137.7 (C-13), 137.2 (C-11), 135.0 (C-15), 130.5 (C-Ar), 
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130.1 (C-Ar), 128.6 (C-Ar), 128.5 (C-Ar), 128.4 (C-Ar), 128.2 (C-Ar), 127.7 (C-Ar), 127.8 
(C-Ar), 127.1 (C-Ar), 93.1 (C-6), 81.3 (C-7), 73.3 (C-5), 48.0 (C-12), 45.8 (C-10), 40.1 (C-
14), 36.3 (C-8), 32.3 (C-9), 26.8 (C-16); m/z (ES HRMS) C29H30N2O4Na requires 493.2103, 
found [MNa]+ 493.2108. 
 
Synthesis of (4aR,5S,7aR)-1,4,7a-tribenzyl-4a,5-dihydroxyhexahydro-1H-cyclopenta[b] 
pyrazine-2,3-dione 345 
 
General procedure E using triketopiperazine 305 (22.2 mg) was followed to synthesise 345 
(21.9 mg) in 2 minutes as a white solid in 98% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (2:1) to methanol/ethyl acetate (1:19). m.p. 
118 – 119 °C; IR νmax /cm-1 3329, 3031, 2922, 1664, 1604, 1495, 1451, 1421, 1354, 1254, 
1145, 1072, 984, 906, 696; 1H NMR (300 MHz, CDCl3) δ 7.41 – 7.20 (m, 13H, H-Ar), 7.13 
(dd, J = 7.6, 1.7 Hz, 2H, H-Ar), 5.45 (d, J = 15.1 Hz, 1H, H-12b), 5.03 (d, J = 14.7 Hz, 1H, H-
10b), 4.60 (s, 1H, OH), 4.27 (d, J = 14.7 Hz, 1H, H-10a), 4.03 (m, 1H, H-7), 3.74 (d, J = 15.1 
Hz, 1H, H-12a), 3.24 (d, J = 14.1 Hz, 1H, H-14b), 3.11 (d, J = 14.1 Hz, 1H, H-14a), 2.17 (m, 
2H, H-9), 1.32 (m, 1H, H-8b), 1.13 (m, 1H, H-8a); 13C NMR (101 MHz, CDCl3) δ 158.6 (C-
3), 154.9 (C-2), 138.3 (C-13), 137.8 (C-11), 134.9 (C-15), 130.3 (C-Ar), 129.3 (C-Ar), 128.7 
(C-Ar), 128.7 (C-Ar), 128.6 (C-Ar), 128.1 (C-Ar), 127.7 (C-Ar), 127.6 (C-Ar), 127.5 (C-Ar), 
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90.4 (C-6), 79.6 (C-7), 72.6 (C-5), 47.8 (C-12), 43.8 (C-10), 38.8 (C-14), 33.1 (C-8), 26.9 (C-
9); m/z (ES HRMS) C28H28N2O4Na requires 479.1947, found [MNa]+ 479.1942. 
 
Synthesis of (4aR,5S,7aS)-1,4-dibenzyl-5-ethyl-4a,5-dihydroxy-7a-propylhexahydro-1H-
cyclopenta[b]pyrazine-2,3-dione 346 
 
General procedure E using triketopiperazine 309 (21.7 mg) was followed to synthesise 346 
(18.4 mg) in 4 minutes as a white solid in 84% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (2:1) to methanol/ethyl acetate (1:19). m.p. 
201 – 203 °C; IR νmax /cm-1 3242, 3285, 2964, 2874, 1680, 1644, 1605, 1495, 1452, 1403, 
1359, 1262, 1140, 1075, 952, 875, 695; 1H NMR (400 MHz, CDCl3/MeOD) δ 7.47 (d, J = 6.9 
Hz, 2H, H-Ar), 7.29 (m, 2H, H-Ar), 7.27 – 7.14 (m, 6H, H-Ar), 5.01 (d, J = 14.9 Hz, 1H, H-
12b), 4.81 (d, J = 13.9 Hz, 1H, H-10b), 4.19 (d, J = 13.9 Hz, 1H, H-10a), 4.15 (d, J = 14.9 Hz, 
1H, H-12a), 1.97 – 1.81 (m, 3H, H-9, H-14b), 1.46 (td, J = 14.1, 3.9 Hz, 1H, H-14a), 1.40 – 
1.14 (m, 3H, H-8b, H-17), 1.14 – 1.00 (m, 2H, H-8a, H-15b), 0.84 (ddd, J = 19.8, 9.7, 6.1 Hz, 
1H, H-15a), 0.74 (t, J = 7.2 Hz, 3H, H-18), 0.55 (t, J = 7.2 Hz, 3H, H-16); 13C NMR (101 
MHz, CDCl3/MeOD) δ 159.3 (C-3), 156.6 (C-2), 137.8 (C.13), 137.3 (C-11), 129.6 (C-Ar), 
128.5 (C-Ar), 128.2 (C-Ar), 127.9 (C-Ar), 127.6 (C-Ar), 127.2 (C-Ar), 92.7 (C-6), 84.5 (C-7), 
72.5 (C-5), 46.5 (C-12), 46.5 (C-10), 36.0 (C-14), 33.2 (C-8), 32.6 (C-9), 32.1 (C-17), 16.8 
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(C-15), 13.9 (C-16), 7.6 (C-18); m/z (ES HRMS) C26H32N2O4Na requires 459.2260, found 
[MNa]+ 459.2258. 
 
Synthesis of (1R,5R)-5-allyl-6,8-dibenzyl-1,2-dihydroxy-2-methyl-6,8-diazabicyclo 
[3.2.2]nonane-7,9-dione 347 
 
General procedure F using triketopiperazine 303 (20.9 mg) was followed to synthesise 347 
(8.9 mg) in 2 minutes as a colourless oil in 42% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (2:1) to ethyl acetate (100%). IR νmax /cm-1 
3393, 2935, 1663, 1496, 1453, 1399, 1353, 1124, 1077, 1028, 704; Major, minor (5:3), 1H 
NMR (400 MHz, CDCl3) δ 7.41 – 7.24 (m, 20H, H-Ar), 5.99 – 5.81 (m, 2H, H-12, H-12), 
5.35 – 5.29 (m, 3H, OH, OH, H-14b), 5.25 – 5.12 (m, 5H, H-13, H-13, H-14b), 5.09 (d, J = 
14.9, 1H, H-16b), 4.95 (d, J = 14.5 Hz, 1H, H-16b), 4.69 – 4.56 (m, 3H, H-14a, H-16a, H-
14a), 4.52 (d, J = 14.5 Hz, 1H, H-16a), 3.04 – 2.89 (m, 3H, H-11, H-11b), 2.81 (dd, J = 16.1, 
7.2 Hz, 1H, H-11a), 2.69 (s, 1H, OH), 2.38 (s, 1H, OH), 1.85 – 1.74 (m, 4H, H-3b, H-4, H-
4b), 1.74 – 1.63 (m, 3H, H-4a, H-3), 1.52 (m, 1H, H-3a), 1.27 (s, 3H, H-10), 1.13 (s, 3H, H-
10); 13C NMR (101 MHz, CDCl3) δ 170.7 (C-7, C-7), 167.8 (C-9, C-9), 138.9 (C-17), 138.4 
(C-17), 137.0 (C-15, C-15), 134.1 (C-12), 133.9 (C-12), 128.9 (C-Ar), 128.7 (C-Ar), 128.5 
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(C-Ar), 128.4 (C-Ar), 128.3 (C-Ar), 128.1 (C-Ar), 128.1 (C-Ar), 127.9 (C-Ar), 127.6 (C-Ar), 
127.6 (C-Ar), 127.2 (C-Ar), 126.9 (C-Ar), 118.8 (C-13), 118.5 (C-13), 85.6 (C-1), 85.5 (C-1), 
73.5 (C-2), 73.2 (C-2), 66.5 (C-5), 66.1 (C-5), 46.3 (C-16), 46.2 (C-14), 46.1 (C-14), 45.3 (C-
16), 38.9 (C-11), 38.7 (C-11), 35.4 (C-4, C-4), 32.8 (C-3), 31.2 (C-3), 24.3 (C-10), 22.8 (C-
10); m/z (ES HRMS) C25H29N2O4 requires 421.2127, found [MH]+ 421.2122. 
 
Synthesis of (1R,5S)-6,8-dibenzyl-1,2-dihydroxy-2-methyl-5-propyl-6,8-diazabicyclo 
[3.2.2]nonane-7,9-dione 348 
 
General procedure F using triketopiperazine 304 (21.1 mg) was followed to synthesise 348 
(14.0 mg) in 2 minutes as a white solid in 66% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (2:1) to ethyl acetate (100%). m.p. 130 – 
131 °C; IR νmax /cm-1 3391, 3345, 2930, 1648, 1495, 1455, 1416, 1340, 1271, 1126, 1080, 
1014, 700; Major, minor (4:1), 1H NMR (400 MHz, CDCl3) δ 7.47 – 7.39 (m, 4H, H-Ar), 7.39 
– 7.21 (m, 16H, H-Ar), 5.35 (d, J = 14.7 Hz, 1H, H-14b), 5.32 (s, 1H, OH), 5.23 (s, 1H, OH), 
5.20 (d, J = 15.1 Hz, 1H, H-14b), 5.09 (d, J = 15.1 Hz, 1H, H-16b), 4.97 (d, J = 14.6 Hz, 1H, 
H-16b), 4.59 (d, J = 15.1 Hz, 1H, H-16a), 4.47 (d, J = 14.6 Hz, 1H, H-16a), 4.33 (d, J = 15.1 
Hz, 1H, H-14a), 4.31 (d, J = 14.7 Hz, 1H, H-14a), 2.64 (s, 1H, OH), 2.43 (s, 1H, OH), 2.29 – 
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2.17 (m, 2H, H-11b, H-11b), 2.04 (m, 1H, H-11a), 1.90 (m, 1H, H-11a), 1.77 – 1.65 (m, 10H, 
H-12, H-12, H-3b, H-3b, H-4, H-4), 1.55 – 1.44 (m, 2H, H-3a, H-3a), 1.25 (s, 3H, H-10), 1.02 
(s, 3H, H-10), 0.99 (t, J = 7.4 Hz, 6H, H-13, H-13); 13C NMR (101 MHz, CDCl3) δ 171.3 (C-
7), 170.7 (C-7), 168.8 (C-9), 167.9 (C-9), 139.0 (C-17), 138.5 (C-17), 136.9 (C-15), 136.8 (C-
15), 129.0 (C-Ar), 128.8 (C-Ar), 128.7 (C-Ar), 128.6 (C-Ar), 128.4 (C-Ar), 128.3 (C-Ar), 
128.2 (C-Ar), 128.0 (C-Ar), 127.4 (C-Ar), 127.3 (C-Ar), 127.0 (C-Ar), 126.8 (C-Ar), 85.2 (C-
1, C-1), 73.7 (C-2), 73.2 (C-2), 67.8 (C-5), 67.3 (C-5), 46.7 (C-14), 46.7 (C-14), 46.1 (C-16), 
45.1 (C-16), 37.3 (C-11), 35.6 (C-4), 35.5 (C-11), 32.9 (C-3), 31.4 (C-4), 31.0 (C-3), 24.0 (C-
10), 22.8 (C-10), 17.9 (C-12, C-12), 14.4 (C-13, C-13); m/z (ES HRMS) C25H30N2O4Na 
requires 445.2103, found [MNa]+ 445.2096. 
 
Synthesis of (1R,5R)-5,6,8-tribenzyl-1,2-dihydroxy-2-methyl-6,8-diazabicyclo[3.2.2]nonane-
7,9-dione 349 
 
General procedure F using triketopiperazine 305 (24.1 mg) was followed to synthesise 349 
(8.5 mg) in 2 minutes as a colourless oil in 35% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (2:1) to ethyl acetate (100%). IR νmax /cm-1 
3379, 2934, 1664, 1606, 1496, 1454, 1401, 1352, 1123, 1077, 1028, 699; Major, minor 
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(2.5:1); 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.24 (m, 20H, H-Ar), 7.23 – 7.09 (m, 6H, H-
Ar), 7.00 (m, 2H, H-Ar), 6.89 (d, J = 6.8 Hz, 2H, H-Ar), 5.53 (s, 1H, OH), 5.42 (s, 1H, OH), 
5.39 (d, J = 15.4 Hz, 1H, H-13b) 5.19 (d, J = 15.1 Hz, 1H, H-13b), 5.14 (d, J = 14.7 Hz, 1H, 
H-15b), 4.96 (d, J = 14.1 Hz, 1H, H-15b), 4.67 (d, J = 14.7 Hz, 1H, H-15a), 4.58 (d, J = 14.1 
Hz, 1H, H-15a), 4.02 (d, J = 17.4 Hz, 1H, H-11b), 3.89 (d, J = 17.5 Hz, 1H, H-11b), 3.87 (d, J 
= 15.1 Hz, 1H, H-13a), 3.82 (d, J = 15.4 Hz, 1H, H-13a), 3.39 (d, J = 17.4 Hz, 1H, H-11a), 
3.27 (d, J = 17.5 Hz, 1H, H-11a), 2.75 (s, 1H, OH), 2.50 (s, 1H, OH), 1.89 – 1.70 (m, 5H, H-
4, H-4, H-3b), 1.64 (m, 2H, H-3), 1.50 (m, 1H, H-3a), 1.33 (s, 3H, H-10), 1.13 (s, 3H, H-10); 
13C NMR (101 MHz, CDCl3) δ 170.7 (C-7), 170.1 (C-7), 168.5 (C-9), 167.7 (C-9), 138.9 (C-
16), 138.2 (C-16), 137.0 (C-14), 137.0 (C-14), 136.5 (C-12), 136.3 (C-12), 129.3 (C-Ar), 
128.8 (C-Ar), 128.7 (C-Ar), 128.7 (C-Ar, C-Ar), 128.6 (C-Ar), 128.4 (C-Ar, C-Ar), 128.3 (C-
Ar), 128.1 (C-Ar), 128.0 (C-Ar), 128.0 (C-Ar), 127.8 (C-Ar), 127.3 (C-Ar), 127.0 (C-Ar), 
126.4 (C-Ar), 126.3 (C-Ar), 85.6 (C-1), 85.4 (C-1), 73.9 (C-2), 73.6 (C-2), 66.7 (C-5), 66.3 
(C-5), 46.8 (C-13, C-13), 46.2 (C-15), 45.2 (C-15), 39.8 (C-11), 39.6 (C-11), 35.4 (C-4), 35.4 
(C-4), 33.5 (C-3), 32.0 (C-3), 24.5 (C-10), 22.9 (C-10); 1 signal in the C-H aromatic region 
was not observed due to having equivalent resonances; m/z (ES HRMS) C29H30N2O4Na 
requires 493.2103, found [MNa]+ 493.2100. 
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Synthesis of (1R,5R)-5,6,8-tribenzyl-1,2-dihydroxy-6,8-diazabicyclo[3.2.2]nonane-7,9-dione 
350 
 
General procedure F using triketopiperazine 305 (22.2 mg) was followed to synthesise 350 
(7.8 mg) in 2 minutes as a colourless oil in 35% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (2:1) to ethyl acetate (100%). IR νmax /cm-1 
3386, 2927, 1665, 1605, 1497, 1455, 1397, 1357, 1135, 1077, 1031, 732, 700; Major, minor 
(3:1),1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 6.5 Hz, 2H, H-Ar), 7.43 – 7.18 (m, 24H, H-
Ar), 7.08 (d, J = 7.1 Hz, 2H, H-Ar), 7.02 (m, 2H, H-Ar), 5.48 – 5.41 (m, 2H, OH, H-12b), 
5.37 – 5.27 (m, 2H, OH, H-12b), 5.16 (d, J = 14.6 Hz, 1H, H-14b), 4.82 (d, J = 14.1 Hz, 1H, 
H-14b), 4.76 (d, J = 14.1 Hz, 1H, H-14a), 4.62 (d, J = 14.6 Hz, 1H, H-14a), 3.98 (d, J = 17.4 
Hz, 1H, H-10b), 3.89 – 3.75 (m, 5H, H-2, H-2, H-12a, H-12a, H-10b), 3.35 – 3.22 (m, 2H, H-
10a, H-10a), 2.98 (d, J = 1.2 Hz, 1H, OH), 2.65 (d, J = 1.3 Hz, 1H, OH), 1.97 (m, 1H, H-4b), 
1.71 – 1.54 (m, 4H, H-4a, H-4, H-3b), 1.50 – 1.27 (m, 3H, H-3a, H-3); 13C NMR (101 MHz, 
CDCl3) δ 170.3 (C-7, C-7), 167.5 (C-9, C-9), 138.6 (C-15), 137.8 (C-15), 137.4 (C-13), 137.0 
(C-13), 136.3 (C-11, C-11), 129.1 (C-Ar), 129.0 (C-Ar), 128.8 (C-Ar, C-Ar), 128.7 (2x C-Ar), 
128.5 (C-Ar, C-Ar), 128.4 (C-Ar), 128.3 (C-Ar), 128.1 (C-Ar, C-Ar), 127.8 (C-Ar), 127.7 (C-
Ar), 127.2 (C-Ar, C-Ar), 126.5 (C-Ar), 126.4 (C-Ar), 84.5 (C-1), 83.4 (C-1), 71.1 (C-2), 70.5 
(C-2), 66.9 (C-5), 66.5 (C-5), 46.8 (C-12), 46.4 (C-12), 46.3 (C-14), 44.5 (C-14), 39.5 (C-10, 
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C-10), 33.3 (C-4), 33.2 (C-4), 28.8 (C-3), 27.8 (C-3); 1 signal in the C-H aromatic region was 
not observed due to having equivalent resonances; m/z (ES HRMS) C28H28N2O4Na requires 
479.1947, found [MNa]+ 479.1951. 
 
Synthesis of (1R,5S)-6,8-dibenzyl-2-ethyl-1,2-dihydroxy-5-propyl-6,8-diazabicyclo 
[3.2.2]nonane-7,9-dione 351 
 
General procedure F using triketopiperazine 309 (42.6 mg) was followed to synthesise 351 
(19.7 mg) in 2 minutes as a colourless oil in 46% yield after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (2:1) to ethyl acetate (100%). IR νmax /cm-1 
3397, 3031, 2965, 1662, 1496, 1427, 1400, 1353, 1077, 1028, 733, 701; Major, minor (4:1); 
1H NMR (400 MHz, CDCl3) δ 7.44 (m, 2H, H-Ar), 7.41 – 7.36 (m, 3H, H-Ar), 7.35 – 7.20 
(m, 15H, H-Ar), 5.32 (d, J = 15.3 Hz, 1H, H-15b), 5.27 (s, 1H, OH), 5.20 (s, 1H, OH), 5.13 
(d, J = 15.0 Hz, 1H, H-15b), 5.10 (d, J = 15.1 Hz, 1H, H-17b), 4.98 (d, J = 14.7 Hz, 1H, H-
17b), 4.60 (d, J = 15.1 Hz, 1H, H-17a), 4.45 (d, J = 14.7 Hz, 1H, H-17a), 4.40 (d, J = 15.0 Hz, 
1H, H-15a), 4.34 (d, J = 15.3 Hz, 1H, H-15a), 2.39 (s, 1H, OH), 2.25 – 2.13 (m, 3H, OH, H-
12b, H-12b), 2.05 (m, 1H, H-12a), 1.91 (m, 1H, H-12a), 1.84 (dt, J = 7.0, 3.9 Hz, 1H, H-3b), 
1.75 – 1.67 (m, 2H, H-3b, H-4b), 1.65 – 1.53 (m, 5H, H-3a, H-4, H-3a, H-13b), 1.51 – 1.38 
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(m, 4H, H-13, H-10b, H-4a), 1.32 – 1.20 (m, 3H, H-10, H-13a), 1.12 (m, 1H, H-10a), 0.98 (t, 
J = 7.4 Hz, 6H, H-14, H-14), 0.92 (t, J = 7.5 Hz, 3H, H-11), 0.79 (t, J = 7.4 Hz, 3H, H-11); 
13C NMR (101 MHz, CDCl3) δ 171.4 (C-7), 170.8 (C-7), 169.0 (C-9), 168.0 (C-9), 139.0 (C-
18), 138.5 (C-18), 136.9 (C-16), 136.8 (C-16), 128.8 (C-Ar), 128.7 (C-Ar, C-Ar), 128.6 (C-
Ar), 128.4 (C-Ar), 128.3 (C-Ar), 128.1 (C-Ar), 128.9 (C-Ar), 127.4 (C-Ar), 127.2 (C-Ar), 
127.0 (C-Ar), 126.8 (C-Ar), 85.8 (C-1), 85.7 (C-1), 75.7 (C-2), 74.7 (C-2), 67.7 (C-5), 67.1 
(C-5), 46.8 (C-15, C-15), 46.1 (C-17), 45.5 (C-17), 37.4 (C-12), 37.2 (C-12), 32.5 (C-4), 31.3 
(C-4), 31.0 (C-3), 30.3 (C-3), 26.4 (C-10), 26.2 (C-10), 17.9 (C-13), 17.9 (C-13), 14.4 (C-14, 
C-14), 7.0 (C-11), 6.8 (C-11); m/z (ES HRMS) C26H32N2O4Na requires 459.2260, found 
[MNa]+ 459.2262. 
 
Synthesis of methyl (1S,6S)-7,9-dibenzyl-8,10-dioxo-2-oxa-7,9-diazabicyclo[4.2.2]decane-6-
carboxylate 367  
 
To a solution of 323 (12.0 mg, 0.025 mmol, 1 eq.) in dry CH2Cl2 (1.5 mL), TMSOTf (5 µL, 
0.028 mmol, 1.1 eq.) was added in one portion at 0 °C. The mixture was left to react at that 
temperature for 30 min and was quenched with saturated NaHCO3. The crude was extracted 
with CH2Cl2 (3 x 5 mL) and washed with brine (1 x 5 mL). Compound 367 was obtained as a 
white solid in 87% yield (8.9 mg) after being purified by flash column chromatography 
(gradient: hexane/ethyl acetate = (3:1) to (2:1) and 96:4 er as determined by HPLC analysis 
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[Phenomenex Lux Cellulose-3, acetonitrile:water, 35:65, 1 mL/min, λ 210 nm, t(minor) = 
28.9 min, t(major) = 35.5 min]. IR νmax /cm-1 2966, 2919, 2872, 2850, 1757, 1668, 1498, 
1422, 1360, 1341, 1256, 1233, 1214, 1161, 1099, 1073, 1065, 1040, 945, 890, 741, 716, 695; 
1H NMR (400 MHz, CDCl3) δ 7.45 – 7.24 (m, 10H, H-Ar), 5.15 (s, 1H, H-1), 5.06 (d, J = 
14.6 Hz, 1H, H-15b), 4.51 (s, 2H, H-13), 4.18 (d, J = 14.6 Hz, 1H, H-15a), 3.81 (dt, J = 17.8, 
8.9 Hz, 1H, H-3b), 3.49 (s, 3H, H-12), 3.33 (m, 1H, H-3a), 2.42 (m, 1H, H-5b), 2.21 (ddd, J = 
11.4, 9.1, 4.5 Hz, 1H, H-5a), 1.75 (m, 1H, H-4b), 1.46 (m, 1H, H-4a); 13C NMR (101 MHz, 
CDCl3) δ 168.6 (C-10), 167.2 (C-11), 165.6 (C-8), 135.6 (C-14), 134.4 (C-16), 128.9 (C-Ar), 
128.8 (C-Ar), 128.7 (C-Ar), 128.4 (C-Ar), 128.3 (C-Ar), 127.9 (C-Ar), 81.5 (C-1), 71.1 (C-6), 
63.8 (C-3), 52.8 (C-12), 47.8 (C-15), 47.5 (C-13), 35.6 (C-5), 25.3 (C-4); m/z (ESI HRMS) 
C23H25N2O5 requires 409.1764, found [MH]+ 409.1763; 
= −10.4 (c 0.8, CHCl3). 
 
Synthesis of methyl (2S)-1,4-dibenzyl-5-(ethylthio)-2-(3-hydroxypropyl)-3,6-
dioxopiperazine-2-carboxylate 368 
 
To a solution of 367 (20.4 mg, 0.05 mmol, 1 eq.) in MeCN/TFA (1:1, 2 mL), ethanethiol (30 
µL, 0.4 mmol, 8 eq) was added in one portion at room temperature. The mixture was left to 
react at that temperature for 3 h and was then quenched with Na2CO3 (3 mL). The crude was 
extracted with CH2Cl2 (3 x 10 mL) and washed with brine (1 x 15 mL). Compound 368 was 
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obtained as a colourless oil in 48% yield (11.3 mg) as an approximately 1:1 mixture of 
diastereoisomers after being purified by flash column chromatography (gradient: hexane/ethyl 
acetate = (4:1) to (2:1). IR νmax /cm-1 3502, 2926, 1755, 1665, 1497, 1434, 1417, 1355, 1261, 
1230, 1168, 1099, 1064, 986, 728, 700; 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.17 (m, 20H, 
H-Ar), 5.49 (d, J = 14.8 Hz, 1H, H-7b), 5.46 (d, J = 14.6 Hz, 1H, H-7b), 4.84 (d, J = 15.4 Hz, 
1H, H-14b), 4.80 (d, J = 15.6 Hz, 1H, H-14b), 4.65 (s, 1H, H-5), 4.61 (s, 1H, H-5), 4.39 (d, J 
= 15.4 Hz, 1H, H-14a), 4.17 (d, J = 14.6 Hz, 1H, H-7a), 4.12 (d, J = 14.8 Hz, 1H, H-7a), 4.09 
(d, J = 15.6 Hz, 1H, H-14a), 3.44 (s, 3H, H-10), 3.42 – 3.33 (m, 2H, H-13b, H-13b), 3.37 (s, 
3H, H-10), 3.34 – 3.23 (m, 2H, H-13a, H-13a), 2.92 (m, 1H, H-16b), 2.84 – 2.69 (m, 3H, H-
16a, H-16), 2.50 (m, 1H, H-11b), 2.39 (m, 1H, H-11b), 2.29 (m, 1H, H-11a), 2.07 (m, 1H, H-
11a), 1.37 (m, 2H, H-12), 1.26 (q, J = 7.4 Hz, 6H, H-17, H-17), 1.19 (m, 1H, H-12b), 1.13 (m, 
1H, H-12a); 13C NMR (101 MHz, CDCl3) δ 168.2 (C-9), 168.0 (C-9), 166.2 (C-3), 165.8 (C-
3), 163.6 (C-6), 163.6 (C-6), 136.5 (C-15), 136.2 (C-15), 134.8 (C-8), 134.7 (C-8), 129.1 (2x 
C-Ar), 129.0 (C-Ar), 128.7 (C-Ar), 128.6 (C-Ar), 128.5 (C-Ar), 128.4 (C-Ar), 128.3 (C-Ar), 
127.7 (C-Ar), 72.5 (C-2), 71.1 (C-2), 62.0 (C-13), 61.7 (C-13), 61.1 (C-5), 59.8 (C-5), 53.1 
(C-10), 53.0 (C-10), 47.2 (C-14), 46.9 (C-7, C-14), 46.5 (C-7), 29.8 (C-11), 29.3 (C-11), 28.3 
(C-16), 27.7 (C-16), 27.0 (C-12), 26.1 (C-12), 14.5 (C-17, C-17); 4 signals in the C-H 
aromatic region were not observed due to having equivalent resonances; m/z (ES HRMS) 
C25H30N2O5SNa requires 493.1773, found [MNa]+ 493.1772. 
 
 
 
Chapter 5   Experimental
  
 
237 
Synthesis of (S)-1,4-dibenzyl-3-((S)-3-oxo-1,3-diphenylpropyl)piperazine-2,5-dione 369 
 
To a solution of 324 (54.9 mg, 0.106 mmol, 1 eq.) in dry CH2Cl2 (3 mL), triethylsilane (168 
µL, 1.06 mmol, 10 eq.) was added in one portion at −78 °C followed by BF3•Et2O (65 µL, 
0.53 mmol, 5 eq.). The mixture was left to stir at that temperature for 10 min and allowed to 
warm up to rt over 3h. The reaction was quenched with saturated NH4Cl and the crude was 
extracted with CH2Cl2 (3 x 5 mL). Compound 369 was obtained as a white solid in 82% yield 
(43.7 mg) after being purified by flash column chromatography (gradient: hexane/ethyl 
acetate = (3:1) to (2:1) and 99:1 er as determined by HPLC analysis [Daicel Chiralpak AD, 
hexanes:IPA, 80:20, 1.0 mL/min, λ 210 nm, t(major) = 21.1 min, t(minor) = 33.9 min]. m.p. 
54 – 56 °C; IR νmax /cm-1 3062, 3031, 2928, 1663, 1598, 1495, 1452, 1356, 1266, 1233, 1208, 
1171, 1073, 1028, 987, 750, 729, 700; 1H NMR (400 MHz, CDCl3) δ 7.81 (m, 2H, H-16), 
7.47 (m, 1H, H-18), 7.35 (dd, J = 10.5, 4.7 Hz, 2H, H-17), 7.32 – 7.14 (m, 11H, H-Ar), 7.09 
(m, 2H, H-Ar), 6.82 (m, 2H, H-Ar), 5.05 (d, J = 15.2 Hz, 1H, H-7b), 4.63 (d, J = 14.7 Hz, 1H, 
H-9b), 4.06 (d, J = 14.7 Hz, 1H, H-9a), 4.00 – 3.86 (m, 3H, H-3b, H-6, H-11), 3.76 (dd, J = 
18.0, 7.5 Hz, 1H, H-13b), 3.69 (d, J = 17.0 Hz, 1H, H-3a), 3.24 (dd, J = 18.0, 5.2 Hz, 1H, H-
13a), 2.64 (d, J = 15.2 Hz, 1H, H-7a); 13C NMR (101 MHz, CDCl3) δ 197.3 (C-14), 166.4 (C-
5), 165.9 (C-2), 140.6 (C-12), 136.7 (C-15), 135.7 (C-8), 135.3 (C-10), 133.3 (C-18), 129.2 
(C-Ar), 128.9 (C-Ar), 128.8 (C-Ar), 128.7 (C-Ar), 128.5 (C-Ar), 128.3 (C-Ar), 128.0 (C-Ar), 
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128.0 (C-Ar), 127.9 (C-Ar), 127.7 (C-Ar), 65.0 (C-6), 49.4 (C-9), 49.1 (C-3), 48.6 (C-7), 43.7 
(C-11), 41.6 (C-13); 1 signal in the C-H aromatic region was not observed due to having 
equivalent resonances; m/z (ESI HRMS) C33H31N2O3 requires 503.2335, found [MH]+ 
503.2334; 
= −43.2 (c 1.6, CHCl3). 
 
Synthesis of 4-acetyl-N,1,2-tribenzyl-5-hydroxy-6-oxo-1,2,3,6-tetrahydropyridine-2-
carboxamide 372 
 
To a solution of 305 (100 mg, 0.31 mmol, 1 eq.) in MeOH
 
(8 mL), potassium hydroxide (30 
mg, 0.60 mmol, 2 eq.) was added in one portion at room temperature. The mixture was left to 
stir at that temperature for 15 min, quenched with saturated NH4Cl and the crude was 
extracted with CH2Cl2 (3 x 15 mL) and washed with brine (1 x 15 mL). Compound 372 was 
obtained as a white solid in 86% yield (86.4 mg). m.p. 138 – 140 °C; IR νmax /cm-1 3385, 
3319, 3028, 2928, 1664, 1634, 1606, 1534, 1496, 1345, 1256, 1216, 1101, 1078, 1030, 780, 
728, 697; 1H NMR (400 MHz, CDCl3) δ 10.44 (s, 1H, OH), 7.36 – 7.17 (m, 11H, H-Ar), 7.03 
(m, 2H, H-Ar), 6.96 (m, 2H, H-Ar), 6.04 (s, 1H, NH), 5.03 (d, J = 15.9 Hz, 1H, H-7b), 4.72 
(d, J = 15.9 Hz, 1H, H-7a), 4.29 (dd, J = 14.5, 6.3 Hz, 1H, H-11b), 3.91 (dd, J = 14.5, 5.0 Hz, 
1H, H-11a), 3.46 (d, J = 13.8 Hz, 1H, H-13b), 3.13 (d, J = 13.8 Hz, 1H, H-13a), 3.00 (d, J = 
16.8 Hz, 1H, H-3b), 2.83 (d, J = 16.8 Hz, 1H, H-3a), 2.24 (s, 3H, H-16); 13C NMR (101 MHz, 
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CDCl3) δ 199.8 (C-15), 170.5 (C-9), 164.0 (C-6), 150.7 (C-5), 137.9 (C-8), 137.1 (C-12), 
135.0 (C-14), 130.3 (C-Ar), 128.9 (C-Ar), 128.6 (C-Ar), 128.6 (C-Ar), 127.9 (C-Ar), 127.6 
(C-Ar), 127.5 (C-Ar), 127.2 (C-Ar), 109.5 (C-4), 68.4 (C-2), 49.2 (C-7), 44.0 (C-11), 41.6 (C-
13), 31.0 (C-3), 29.4 (C-16); 1 signal in the C-H aromatic region was not observed due to 
having equivalent resonances; m/z (ES HRMS) C29H28N2O4Na requires 491.1947, found 
[MNa]+ 491.1949. 
 
Synthesis of N,1,2-tribenzyl-5-hydroxy-5-methylpyrrolidine-2-carboxamide 375 
 
To a solution of 305 (23.4 mg, 0.05 mmol, 1 eq.) in dry THF
 
(3 mL), ethanolamine (36 µL, 
0.6 mmol, 10 eq.) was added in one portion at room temperature. The mixture was left to react 
at that temperature for 2 days until the starting material was consumed. Compound 375 was 
obtained as a yellowish solid in 72% yield (15.0 mg) after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (3:1) to (1:2). m.p. 49 – 51 °C; IR νmax /cm-1 
3385, 3062, 3029, 2924, 1697, 1604, 1495, 1454, 1405, 1290, 1178, 1072, 1029, 732, 697; 1H 
NMR (400 MHz, CDCl3) δ 7.38 – 7.33 (m, 4H, H-Ar), 7.30 (m, 1H, H-Ar), 7.29 – 7.26 (m, 
8H, H-Ar), 7.23 (m, 2H, H-Ar), 4.52 (d, J = 15.2 Hz, 1H, H-10b), 4.28 (d, J = 15.2 Hz, 1H, H-
10a), 3.92 (d, J = 15.5 Hz, 1H, H-6b), 3.54 (d, J = 15.5 Hz, 1H, H-6a), 3.36 (d, J = 15.3 Hz, 
1H, H-12b), 3.13 (d, J = 15.3 Hz, 1H, H-12a), 1.80 (m, 1H, H-4b), 1.61 (m, 1H, H-3b), 1.42 – 
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1.29 (m, 2H, H-3a, H-4a), 1.07 (s, 3H, H-14); 13C NMR (101 MHz, CDCl3) δ 177.1 (C-8), 
140.3 (C-7), 138.4 (C-11), 136.8 (C-13), 130.4 (C-Ar), 128.6 (C-Ar), 128.2 (C-Ar), 128.1 (C-
Ar), 127.9 (2x C-Ar), 127.5 (C-Ar), 126.6 (C-Ar), 126.3 (C-Ar), 84.4 (C-5), 74.0 (C-2), 46.4 
(C-6), 43.7 (C-10), 34.5 (C-4), 32.9 (C-12), 27.9 (C-3), 18.0 (C-14); 1 signal in the C-H 
aromatic region was not observed due to having equivalent resonances; m/z (ES HRMS, 
minus H2O) C27H29N2O requires 397.2280, found [MH]+ 397.2278. 
 
5.4. Experimental for Chapter 4 
Synthesis of (1S,4S,8R)-methyl 2,5-dibenzyl-8-cyano-4-hydroxy-3,6-dioxo-2,5-
diazabicyclo[2.2.2] octane -1-carboxylate 398 
 
General procedure B using triketopiperazine 246 (28.5 mg) was followed to synthesise this 
product (32.7 mg) as a white solid in 99% yield from a reaction catalysed by 201 (10 mol%) 
at 0 °C for 15 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (4:1) to (2:1) gave 398 with 95:5 er as determined by HPLC analysis [Phenomenex 
Lux Cellulose-3, acetonitrile:water, 80:20, 1 mL/min, λ 220 nm, t(minor) = 12.2 min, t(major) 
= 14.5 min]. m.p. 95 – 98 °C; IR νmax /cm-1 3347, 3034, 2955, 1753, 1687, 1496, 1454, 1390, 
1355, 1264, 1180, 1138, 1076, 727, 700; 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.28 (m, 8H, 
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H-Ar), 7.25 (m, 2H, H-Ar), 5.55 (d, J = 14.6 Hz, 1H, H-11b), 5.40 (s, 1H, OH), 4.80 (d, J = 
14.4 Hz, 1H, H-13b), 4.55 (d, J = 14.6 Hz, 1H, H-11a), 4.50 (d, J = 14.4 Hz, 1H, H-13a), 3.82 
(s, 3H, H-10), 2.89 (dd, J = 11.0, 4.3 Hz, 1H, H-8), 2.35 (dd, J = 14.4, 11.0 Hz, 1H, H-7b), 
1.90 (dd, J = 14.4, 4.3 Hz, 1H, H-7a); 13C NMR (101 MHz, CDCl3) δ 166.5 (C-3), 164.2 (C-
6), 163.5 (C-9), 136.4 (C-14), 134.3 (C-12), 129.1 (C-Ar), 129.0 (C-Ar), 129.0 (C-Ar), 128.8 
(C-Ar), 128.7 (C-Ar), 128.2 (C-Ar), 116.6 (C-15), 82.9 (C-4), 67.5 (C-1), 53.5 (C-10), 47.1 
(C-11), 43.6 (C-13), 34.2 (C-8), 32.2 (C-7); m/z (ES HRMS) C23H21N3O5Na requires 
442.1379, found [MNa]+ 442.1377; = −60.4 (c 1.6, CHCl3). 
 
Synthesis of (1S,4S,8R)-methyl 2,5-dibenzyl-4-hydroxy-3,6-dioxo-8-(phenylsulfonyl)-2,5-
diazabicyclo [2.2.2]octane-1-carboxylate 399 
 
General procedure B using triketopiperazine 246 (33.5 mg) was followed to synthesise this 
product (47.3 mg) as a white solid in 97% yield from a reaction catalysed by 201 (10 mol%) 
at 0 °C for 20 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (4:1) to (3:2) gave 399 with 98:2 er as determined by HPLC analysis [Phenomenex 
Lux Cellulose-3, acetonitrile:water, 35:65, 1 mL/min, λ 210 nm, t(major) = 24.5 min, t(minor) 
= 28.7 min]. m.p. 94 – 97 °C; IR νmax /cm-1 3334, 3065, 2954, 1753, 1689, 1496, 1448, 1389, 
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1355, 1260, 1183, 1147, 1075, 1003, 909, 726, 702; 1H NMR (400 MHz, CDCl3) δ 7.79 – 
7.69 (m, 3H, H-16, H-18), 7.60 (t, J = 7.8 Hz, 2H, H-17), 7.45 (d, J = 7.3 Hz, 2H, H-Ar), 7.38 
(t, J = 7.3 Hz, 2H, H-Ar), 7.31 (m, 2H, H-Ar), 7.23 (m, 2H, H-Ar), 7.17 (m, 2H, H-Ar), 5.52 
(d, J = 15.0 Hz, 1H, H-11b), 4.75 (d, J = 14.3 Hz, 1H, H-13b), 4.61 (d, J = 15.0 Hz, 1H, H-
11a), 4.28 (d, J = 14.3 Hz, 1H, H-13a), 3.69 (s, 3H, H-10), 3.42 (dd, J = 11.2, 5.8 Hz, 1H, H-
8), 2.67 (dd, J = 15.1, 5.8 Hz, 1H, H-7b), 2.45 (dd, J = 15.1, 11.2 Hz, 1H, H-7a); 13C NMR 
(101 MHz, CDCl3) δ 166.7 (C-3), 165.0 (C-6), 163.4 (C-9), 139.4 (C-15), 136.4 (C-14), 134.4 
(C-12), 134.0 (C-18), 129.0 (C-Ar), 129.0 (C-Ar), 128.8 (C-Ar), 128.7 (C-Ar), 128.6 (C-Ar), 
128.3 (C-Ar), 128.0 (C-Ar), 82.1 (C-4), 66.9 (C-1), 63.5 (C-8), 53.3 (C-10), 47.8 (C-11), 43.1 
(C-13), 29.3 (C-7); 1 signal in the C-H aromatic region was not observed due to having 
equivalent resonances; m/z (ES HRMS) C28H26N2O7SNa requires 557.1358, found [MNa]+ 
557.1331; = −28.9 (c 1.6, CHCl3). 
 
Synthesis of (1S,4S,8R)-dimethyl 2,5-dibenzyl-4-hydroxy-3,6-dioxo-2,5-diazabicyclo 
[2.2.2]octane-1,8-dicarboxylate 400 
 
General procedure B using triketopiperazine 246 (27.3 mg) was followed to synthesise this 
product (33.1 mg) as a white solid in 98% yield from a reaction catalysed by 201 (10 mol%) 
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at 0 °C for 18 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = 4:1) to (2:1) gave 400 with 87:13 er as determined by HPLC analysis [Daicel 
Chiralpak AD, hexanes:IPA, 80:20, 1 mL/min, λ 210 nm, t(minor) = 23.8 min, t(major) = 36.9 
min]. m.p. 90 – 93 °C; IR νmax /cm-1 3345, 2954, 1744, 1693, 1495, 1436, 1393, 1358, 1266, 
1200, 1078, 703; 1H NMR (300 MHz, CDCl3) δ 7.39 – 7.23 (m, 10H, H-Ar), 5.43 (d, J = 15.0 
Hz, 1H, H-11b), 5.09 (s, 1H, OH), 4.71 (d, J = 14.6 Hz, 1H, H-13b), 4.59 (m, 2H, H-11a, H-
13a), 3.71 (s, 3H, H-16), 3.70 (s, 3H, H-10), 3.01 (dd, J = 10.9, 5.2 Hz, 1H, H-8), 2.38 (dd, J 
= 14.2, 10.9 Hz, 1H, H-7b), 2.12 (dd, J = 14.2, 5.2 Hz, 1H, H-7a); 13C NMR (101 MHz, 
CDCl3) δ 170.7 (C-15), 167.9 (C-3), 165.3 (C-6), 164.2 (C-9), 137.0 (C-14), 135.0 (C-12), 
129.0 (C-Ar), 128.7 (C-Ar), 128.5 (C-Ar), 128.5 (C-Ar), 128.1 (C-Ar), 127.8 (C-Ar), 83.4 (C-
4), 67.5 (C-1), 53.2 (C-10), 52.6 (C-16), 47.8 (C-8), 47.4 (C-11), 43.2 (C-13), 31.9 (C-7); m/z 
(ES HRMS) C24H24N2O7Na requires 475.1481, found [MNa]+ 475.1476; = −28.7 (c 1.5, 
CHCl3). 
 
Synthesis of methyl (1R,4R,8S)-2,5-dibenzyl-4-hydroxy-8-(methylsulfonyl)-3,6-dioxo-2,5-
diazabicyclo [2.2.2]octane-1-carboxylate 401 
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General procedure B using triketopiperazine 246 (32.7 mg) was followed to synthesise this 
product (28.1 mg) as a colourless oil in 67% yield from a reaction catalysed by 210 (10 
mol%) at 0 °C for 30 hours. Purification by flash column chromatography (gradient: 
hexane/ethyl acetate = (4:1) to (3:2) gave 401 with 28:72 er as determined by HPLC analysis 
[Daicel Chiralcel OD, Heptane:EtOH, 70:30, 2 mL/min, λ 210 nm, t(minor) = 4.6 min, 
t(minor) = 6.8 min]. IR νmax /cm-1 3335, 3035, 2954, 1754, 1692, 1497, 1455, 1392, 1355, 
1263, 1185, 1138, 1077, 1005, 733, 702; 1H NMR (400 MHz, CDCl3) δ 7.32 (m, 2H, H-Ar), 
7.30 – 7.16 (m, 7H, H-Ar), 7.08 (m, 1H, H-Ar), 5.58 (s, 1H, OH), 5.42 (d, J = 14.9 Hz, 1H, H-
11b), 4.83 (d, J = 14.4 Hz, 1H, H-13b), 4.48 (d, J = 14.9 Hz, 1H, H-11a), 4.37 (d, J = 14.3 Hz, 
1H, H-13a), 3.60 (s, 3H, H-10), 3.08 (dd, J = 11.3, 6.1 Hz, 1H, H-8), 2.93 (s, 3H, H-15), 2.42 
(dd, J = 15.2, 6.1 Hz, 1H, H-7b), 2.30 (dd, J = 15.2, 11.3 Hz, 1H, H-7a); 13C NMR (101 MHz, 
CDCl3) δ 166.5 (C-3), 165.1 (C-6), 163.3 (C-9), 136.7 (C-14), 134.2 (C-12), 129.1 (C-Ar), 
128.9 (C-Ar), 128.7 (C-Ar), 128.4 (C-Ar), 128.4 (C-Ar), 82.0 (C-4), 66.8 (C-1), 62.7 (C-8), 
53.4 (C-10), 47.6 (C-11), 43.3 (C-13), 42.9 (C-15), 28.3 (C-7); 1 signal in the C-H aromatic 
region was not observed due to having equivalent resonances; m/z (ES HRMS) 
C23H24N2O7SNa requires 495.1202, found [MNa]+ 495.1201. 
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Synthesis of methyl (3aR,4R,7S,7aS)-5,8-dibenzyl-7-hydroxy-2-methyl-1,3,6,9-
tetraoxooctahydro-4H-7,4-(epiminomethano)pyrrolo[3,4-c]pyridine-4-carboxylate 402 
 
General procedure B using triketopiperazine 246 (35.9 mg) was followed to synthesise this 
product (45.0 mg) as a white solid in 96% yield from a reaction catalysed by 210 (10 mol%) 
at 0 °C for 3 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (4:1) to (1:1) gave 402 with 8:92 er as determined by HPLC analysis [Daicel 
Chiralpak IF, Heptane:EtOH-MeOH, 50:50, 2 mL/min, λ 210 nm, t(minor) = 5.3 min, 
t(major) = 9.0 min]. m.p. 169 – 171 °C; IR νmax /cm-1 3298, 2979, 1787, 1754, 1688, 1497, 
1440, 1386, 1355, 1283, 1205, 1137, 1121, 1063, 1008, 931, 725, 694; 1H NMR (400 MHz, 
CDCl3) δ 7.37 – 7.23 (m, 8H, H-Ar), 7.11 (d, J = 3.7 Hz, 2H, H-Ar), 5.11 – 4.95 (m, 2H, H-
15b, OH), 4.73 (m, 3H, H-15a, H-17), 4.03 (d, J = 9.0 Hz, 1H, H-4), 3.98 (s, 3H, H-14), 3.36 
(d, J = 9.0 Hz, 1H, H-11), 2.79 (s, 3H, H-12); 13C NMR (101 MHz, CDCl3) δ 172.0 (C-3), 
170.4 (C-1), 167.4 (C-7), 163.6 (C-10), 163.0 (C-13), 136.5 (C-16), 136.4 (C-18), 128.8 (C-
Ar), 128.6 (C-Ar), 128.4 (C-Ar), 128.0 (C-Ar), 127.5 (C-Ar), 83.0 (C-8), 69.4 (C-5), 53.7 (C-
14), 48.8 (C-11), 48.8 (C-15), 45.9 (C-4), 43.6 (C-17), 25.5 (C-12); 1 signal in the C-H 
aromatic region was not observed due to having equivalent resonances; m/z (ES HRMS) 
C25H24N3O7 requires 478.1614, found [MH]+ 478.1615; = 18.1 (c 1.7, CHCl3). 
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Synthesis of methyl (3aR,4R,7S,7aS)-5,8-dibenzyl-7-hydroxy-1,3,6,9-tetraoxo-2-
phenyloctahydro-4H-7,4-(epiminomethano)pyrrolo[3,4-c]pyridine-4-carboxylate 403 
 
General procedure B using triketopiperazine 246 (36.0 mg) was followed to synthesise this 
product (49.1 mg) as a white solid in 92% yield from a reaction catalysed by 210 (10 mol%) 
at 0 °C for 5 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (4:1) to (1:1) gave 403 with 79:21 er as determined by HPLC analysis [Daicel 
Chiralpak ID2, Heptane:EtOH, 50:50, 2 mL/min, λ 210 nm, t(major) = 4.9 min, t(minor) = 9.4 
min]. m.p. 169 – 172 °C; IR νmax /cm-1 3414, 3047, 2958, 1758, 1695, 1496, 1430, 1383, 
1297, 1245, 1190, 1075, 1003, 909, 727, 692; 1H NMR (400 MHz, CDCl3) δ 7.47 – 7.35 (m, 
3H, H-Ar), 7.33 – 7.19 (m, 5H, H-Ar), 7.19 – 7.11 (m, 3H, H-Ar), 7.06 (m, 2H, H-Ar), 6.98 
(d, J = 3.3 Hz, 2H, H-Ar), 4.90 (d, J = 15.5 Hz, 1H, H-15b), 4.71 (m, 2H, H-17), 4.46 (d, J = 
15.5 Hz, 1H, H-15a), 4.24 (d, J = 9.0 Hz, 1H, H-4), 3.84 (s, 3H, H-14), 3.51 (d, J = 9.0 Hz, 
1H, H-11); 13C NMR (101 MHz, CDCl3) δ 172.0 (C-3), 170.0 (C-1), 167.7 (C-7), 163.7 (C-
10), 163.1 (C-13), 136.5 (C-16), 136.5 (C-18), 130.8 (C-12), 129.3 (C-Ar), 128.7 (C-Ar), 
128.4 (C-Ar), 128.2 (C-Ar), 127.8 (C-Ar), 127.0 (C-Ar), 126.4 (C-Ar), 126.1 (C-Ar), 84.0 (C-
8), 69.9 (C-5), 53.5 (C-14), 49.6 (C-15), 49.2 (C-11), 46.4 (C-4), 43.4 (C-17); 1 signal in the 
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C-H aromatic region was not observed due to having equivalent resonances; m/z (ES HRMS) 
C30H26N3O7 requires 540.1771, found [MH]+ 540.1772; = −21.6 (c 1.5, CHCl3). 
 
Synthesis of (1S,4S,7R)-2,5-dibenzyl-1-hydroxy-3,6-dioxo-2,5-diazabicyclo[2.2.2]octane-7-
carbonitrile 404 
 
General procedure B using triketopiperazine 242 (29.9 mg) was followed to synthesise this 
product (37.1 mg) as a white solid in 98% yield from a reaction catalysed by 201 (10 mol%) 
at −20 °C for 15 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (3:1) to (3:2) gave 404 with 91:9 er as determined by HPLC analysis [Daicel 
Chiralpak AD, heptanes:IPA, 80:20, 1 mL/min, λ 210 nm, t(major) = 19.5 min, t(minor) = 
21.3 min]. m.p. 145 – 147 °C; IR νmax /cm-1 3032, 2943, 1692, 1672, 1496, 1430, 1406, 1352, 
1294, 1226, 1130, 1170, 1067, 902, 754, 705, 698; 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.27 
(m, 3H, H-Ar), 7.25 – 7.17 (m, 7H, H-Ar), 5.29 (s, 1H, OH), 4.91 (d, J = 14.6 Hz, 1H, H-
11b), 4.65 (d, J = 14.6 Hz, 1H, H-9b), 4.43 (d, J = 14.6 Hz, 1H, H-9a), 4.30 (d, J = 14.6 Hz, 
1H, H-11a), 4.01 (dd, J = 3.6, 1.9 Hz, 1H, H-4), 2.86 (dd, J = 10.8, 4.3 Hz, 1H, H-7), 2.04 
(ddd, J = 13.7, 10.8, 1.9 Hz, 1H, H-8b), 1.83 (dt, J = 13.7, 4.3 Hz, 1H, H-8a); 13C NMR (101 
MHz, CDCl3) δ 166.6 (C-3), 166.2 (C-6), 136.9 (C-10), 134.3 (C-12), 129.3 (C-Ar), 128.8 (C-
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Ar), 128.4 (C-Ar), 128.4 (C-Ar), 128.0 (C-Ar), 117.1 (C-13), 83.3 (C-1), 57.8 (C-4), 49.6 (C-
11), 42.8 (C-9), 34.2 (C-7), 29.4 (C-8); 1 signal in the C-H aromatic region was not observed 
due to having equivalent resonances; m/z (ES HRMS) C21H19N3O3Na requires 384.1324, 
found [MNa]+ 384.1318; = −36.1 (c 1.1, CHCl3). 
 
Synthesis of (1S,4S,7R)-2,5-dibenzyl-1-hydroxy-7-(phenylsulfonyl)-2,5-diazabicyclo 
[2.2.2]octane-3,6-dione 405 
 
General procedure B using triketopiperazine 242 (30.1 mg) was followed to synthesise this 
product (38.1 mg) as a white solid in 82% yield from a reaction catalysed by 201 (10 mol%) 
at 0 °C for 18 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (3:1) to (1:2) gave 405 with 93:7 er as determined by HPLC analysis [Daicel 
Chiralpak AD, hexanes:IPA, 80:20, 1 mL/min, λ 210 nm, t(minor) = 26.6 min, t(major) = 31.2 
min]. m.p. 150 – 152 °C; IR νmax /cm-1 3318, 3063, 1687, 1496, 1447, 1402, 1356, 1307, 
1225, 1146, 1084, 931, 754, 727, 700; 1H NMR (400 MHz, CDCl3) δ 7.67 (dt, J = 8.6, 1.6 Hz, 
2H, H-14), 7.62 (m, 1H, H-16), 7.49 (m, 2H, H-15), 7.37 – 7.25 (m, 5H, H-Ar), 7.21 – 7.09 
(m, 3H, H-Ar), 7.04 (m, 2H, H-Ar), 4.89 (d, J = 14.8 Hz, 1H, H-11b), 4.77 (s, 1H, OH), 4.56 
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(d, J = 14.5 Hz, 1H, H-9b), 4.39 (d, J = 14.8 Hz, 1H, H-11a), 4.21 (d, J = 14.5 Hz, 1H, H-9a), 
3.96 (dd, J = 3.6, 2.3 Hz, 1H, H-4), 3.37 (dd, J = 11.0, 5.5 Hz, 1H, H-7), 2.39 (ddd, J = 14.7, 
5.5, 3.6 Hz, 1H, H-8b), 2.03 (ddd, J = 14.7, 11.0, 2.3 Hz, 1H, H-8a); 13C NMR (101 MHz, 
CDCl3) δ 167.3 (C-3), 166.4 (C-6), 139.4 (C-13), 137.0 (C-10), 134.2 (C-12), 133.9 (C-16), 
129.1 (C-Ar), 129.0 (C-Ar), 128.7 (C-Ar), 128.7 (C-Ar), 128.6 (C-Ar), 127.8 (C-Ar), 82.7 (C-
1), 63.8 (C-7), 57.0 (C-4), 49.5 (C-11), 42.3 (C-9), 25.9 (C-8); 2 signal in the C-H aromatic 
region was not observed due to having equivalent resonances; m/z (ES HRMS) 
C26H24N2O5SNa, 499.1304, found [MNa]+ 499.1300; = −13.3 (c 0.45, CHCl3). 
 
Synthesis of (1S,4S,7R)-methyl 2,5-dibenzyl-1-hydroxy-3,6-dioxo-2,5-diazabicyclo 
[2.2.2]octane-7-carboxylate 406 
 
General procedure B using triketopiperazine 242 (31.8 mg) was followed to synthesise this 
product (35.3 mg) as a white solid in 89% yield from a reaction catalysed by 201 (10 mol%) 
at 0 °C for 15 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (3:1) to (3:2) gave 406 with 83:17 er as determined by HPLC analysis [Phenomenex 
Lux Cellulose-3, acetonitrile:water, 20:80, 1 mL/min, λ 220 nm, t(major) = 54.5 min, t(minor) 
= 59.7 min]. m.p. 129 – 131 °C; IR νmax /cm-1 3364, 2953, 1733, 1674, 1655, 1612, 1534, 
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1496, 1431, 1314, 1222, 1168, 1132, 1028, 909, 736, 698; 1H NMR (300 MHz, CDCl3) δ 7.41 
– 7.33 (m, 5H, H-Ar), 7.33 – 7.25 (m, 5H, H-Ar), 4.93 (d, J = 14.7 Hz, 1H, H-11b), 4.92 (s, 
1H. OH), 4.63 (s, 2H, H-9), 4.48 (d, J = 14.7 Hz, 1H, H-11a), 4.03 (dd, J = 3.3, 2.4 Hz, 1H, 
H-4), 3.72 (s, 3H, H-14), 3.06 (dd, J = 10.3, 5.5 Hz, 1H, H-7), 2.04 (m, 2H, H-8); 13C NMR 
(101 MHz, CDCl3) δ 171.1 (C-13), 167.7 (C-3), 167.6 (C-6), 137.5 (C-10), 134.8 (C-12), 
128.9 (C-Ar), 128.6 (C-Ar), 128.6 (C-Ar), 128.4 (C-Ar), 128.1 (C-Ar), 127.5 (C-Ar), 83.9 (C-
1), 57.9 (C-4), 52.5 (C-14), 49.3 (C-11), 48.0 (C-7), 42.4 (C-9), 28.5 (C-8); m/z (ESI) 
C22H22N2O5 requires 394.1529, found [M]+ 394.1537; = 5.1 (c 1.1, CHCl3). 
 
Synthesis of (3aS,4S,7R,7aR)-5,8-dibenzyl-4-hydroxy-2-methyltetrahydro-1H-7,4-
(epiminomethano) pyrrolo[3,4-c]pyridine-1,3,6,9(2H,3aH)-tetraone 407 
 
General procedure B using triketopiperazine 242 (28.8 mg) was followed to synthesise this 
product (33.0 mg) as a white solid in 84% yield from a reaction catalysed by 210 (10 mol%) 
at 0 °C for 5 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (3:1) to (1:1) gave 407 with 60:40 er as determined by HPLC analysis [Daicel 
Chiralpak IF, Heptane:EtOH-MeOH, 50:50, 3 mL/min, λ 210 nm, t(minor) = 1.2 min, 
t(major) = 1.9 min]. m.p. 158 – 159 °C; IR νmax /cm-1 3149, 3029, 2959, 1787, 1696, 1667, 
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1495, 1432, 1382, 1283, 1233, 1131, 1079, 913, 737, 698; 1H NMR (400 MHz, MeOD) δ 7.34 
– 7.20 (m, 8H, H-Ar), 7.13 (m, 2H, H-Ar), 4.82 (d, J = 14.7 Hz, 1H, H-13b), 4.67 (d, J = 14.9 
Hz, 1H, H-15b), 4.58 (d, J = 14.9 Hz, 1H, H-15a), 4.51 (d, J = 2.1 Hz, 1H, H-5), 4.11 (d, J = 
14.7 Hz, 1H, H-13a), 3.44 (dd, J = 8.6, 2.1 Hz, 1H, H-4), 3.39 (d, J = 8.6 Hz, 1H, H-11), 2.83 
(s, 3H, H-12); 13C NMR (101 MHz, MeOD) δ 173.9 (C-3), 172.2 (C-1), 166.7 (C-7, C-10), 
137.3 (C-16), 135.2 (C-14), 128.6 (C-Ar), 128.2 (C-Ar), 128.1 (C-Ar), 128.0 (C-Ar), 127.8 
(C-Ar), 127.2 (C-Ar), 84,6 (C-8), 59.3 (C-5), 49.6 (C-11), 49.4 (C-13), 43.1 (C-4), 42.1 (C-
15), 24.3 (C-12); m/z (ES HRMS) C23H21N3O5Na, 442.1379, found [MNa]+ 442.1381; = 
−6.5 (c 0.8, CHCl3). 
 
Synthesis of (3aS,4S,7R,7aR)-5,8-dibenzyl-4-hydroxy-2-phenyltetrahydro-1H-7,4-
(epiminomethano) pyrrolo[3,4-c]pyridine-1,3,6,9(2H,3aH)-tetraone 408 
 
General procedure B using triketopiperazine 242 (29.0 mg) was followed to synthesise this 
product (20.1 mg) as a white solid in 41% yield from a reaction catalysed by 210 (10 mol%) 
at 0 °C for 5 hours. Purification by flash column chromatography (gradient: hexane/ethyl 
acetate = (3:1) to (1:1) gave 408 with 50:50 er as determined by HPLC analysis [Daicel 
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Chiralcel OD, Heptane:EtOH, 60:40, 2 mL/min, λ 210 nm, t(minor) = 5.4 min, t(major) = 
10.4 min]. m.p. 186 – 188 °C; IR νmax /cm-1 3021, 1713, 1677, 1496, 1377, 1347, 1221, 1180, 
1088, 912, 740, 692; 1H NMR (400 MHz, CDCl3) δ 7.50 – 7.37 (m, 3H, H-Ar), 7.30 – 7.19 
(m, 8H, H-Ar), 7.08 (m, 4H, H-Ar), 4.99 (d, J = 14.6 Hz, 1H, H-13b), 4.69 (d, J = 14.7 Hz, 
1H, H-15b), 4.61 (d, J = 14.7 Hz, 1H, H-15a), 4.55 (d, J = 2.8 Hz, 1H, H-5), 4.01 (d, J = 14.7 
Hz, 1H, H-13a), 3.46 (dd, J = 8.9, 2.8 Hz, 1H, H-4), 3.40 (d, J = 8.9 Hz, 1H, H-11); 13C NMR 
(101 MHz, CDCl3) δ 172.5 (C-3), 170.6 (C-1), 166.5 (C-7), 165.5 (C-10), 137.0 (C-16), 134.0 
(C-14), 130.9 (C-12), 129.3 (C-Ar), 129.2 (C-Ar), 129.1 (C-Ar), 128.7 (C-Ar), 128.6 (C-Ar), 
128.4 (C-Ar), 128.3 (C-Ar), 127.8 (C-Ar), 126.2 (C-Ar), 84.0 (C-8), 59.4 (C-5), 50.1 (C-13), 
49.2 (C-11), 43.0 (C-4), 42.7 (C-15); m/z (ES HRMS) C28H23N3O5Na, 504.1535, found 
[MNa]+ 504.1540; = −188.0 (c 0.1, MeOH). 
 
Synthesis of (1R,4S,7S)-4-allyl-2,5-dibenzyl-1-hydroxy-3,6-dioxo-2,5-diazabicyclo 
[2.2.2]octane-7-carbonitrile 413 
 
General procedure B using triketopiperazine 242 (32.6 mg) was followed to synthesise this 
product (10.1 mg) as a colourless oil in 27% yield from a reaction catalysed by 201 (10 
mol%) at 0 °C for 48 hours. Purification by flash column chromatography (gradient: 
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hexane/ethyl acetate = (3:1) to (3:2) gave 413 with 89:11 er as determined by HPLC analysis 
[Phenomenex Lux Cellulose-3, acetonitrile:water, 35:80, 1 mL/min, λ 220 nm, t(minor) = 
19.1 min, t(major) = 21.3 min]. IR νmax /cm-1 3315, 2947, 1693, 1497, 1454, 1431, 1392, 
1352, 1171, 1077, 1001, 934, 725, 700; 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.26 (m, 8H, H-
Ar), 7.16 (m, 2H, H-Ar), 5.96 (m, 1H, H-12), 5.33 (s, 1H, OH), 5.22 (dd, J = 10.2, 1.4 Hz, 1H, 
H-13cis), 5.16 (dd, J = 17.1, 1.4 Hz, 1H, H-13trans), 4.95 – 4.88 (d, J = 16.0 Hz, 1H, H-14b), 
4.79 (d, J = 14.5 Hz, 1H, H-9b), 4.77 (d, J = 16.0 Hz, 1H, H-14a), 4.59 (d, J = 14.5 Hz, 1H, 
H-9a), 3.06 (dd, J = 10.7, 4.8 Hz, 1H, H-7), 3.00 (dd, J = 14.5, 5.8 Hz, 1H, H-11b), 2.59 (dd, J 
= 14.5, 8.0 Hz, 1H, H-11a), 2.19 (dd, J = 14.3, 10.7 Hz, 1H, H-8b), 2.08 (dd, J = 14.3, 4.8 Hz, 
1H, H-8a); 13C NMR (101 MHz, CDCl3) δ 168.2 (C-6), 167.6 (C-3), 137.0 (C-10), 136.3 (C-
15), 131.6 (C-12), 129.1 (C-Ar), 128.8 (C-Ar), 128.5 (C-Ar), 128.0 (C-Ar), 127.9 (C-Ar), 
126.7 (C-Ar), 120.5 (C-13), 117.3 (C-16), 82.1 (C-1), 63.0 (C-4), 45.7 (C-14), 43.2 (C-9), 
34.5 (C-8), 34.4 (C-11), 33.7 (C-7); m/z (ES HRMS) C24H24N3O3 requires 402.1818, found 
[MH]+ 402.1806; = −3.3 (c 0.5, CHCl3). 
 
Synthesis of methyl 1-benzyl-2-(benzylcarbamoyl)-4-cyano-5-hydroxy-6-oxo-1,2,3,6-
tetrahydro pyridine-2-carboxylate 415 
 
To a solution of 398 (20 mg, 0.05 mmol, 1 eq.) in CH2Cl2 (0.8 mL), triethylamine (10 µL, 
0.07 mmol, 1.4 eq.) was added in one portion at room temperature. The mixture was left to 
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stir at that temperature for 48 h, the solvent was evaporated and compound 415 was obtained 
as a colourless oil in 82% yield (16.4 mg) after being purified by flash column 
chromatography (gradient: hexane/ethyl acetate = (3:1) to (1:1). IR νmax /cm-1 3328, 2924, 
2218, 1741, 1659, 1524, 1497, 1444, 1345, 14a, 1160, 1080, 1028, 727, 696; 1H NMR (400 
MHz, CDCl3) δ 7.64 (s, 1H, OH), 7.39 – 7.27 (m, 6H, H-Ar), 7.24 (m, 2H, H-Ar), 7.16 (m, 
2H, H-Ar), 7.08 (s, 1H, NH), 4.76 (d, J = 15.5 Hz, 1H, H-7b), 4.71 (d, J = 15.5 Hz, 1H, H-7a), 
4.48 (dd, J = 14.6, 6.0 Hz, 1H, H-13b), 4.25 (dd, J = 14.6, 5.1 Hz, 1H, H-13a), 3.64 (s, 3H, H-
10), 3.29 (d, J = 16.5 Hz, 1H, H-3b), 3.16 (d, J = 16.5 Hz, 1H, H-3a); 13C NMR (101 MHz, 
CDCl3) δ 170.1 (C-9), 164.7 (C-11), 162.3 (C-6), 150.7 (C-5), 136.5 (C-14), 135.8 (C-8), 
129.0 (C-Ar), 128.6 (C-Ar), 128.1 (C-Ar), 128.0 (C-Ar), 127.8 (C-Ar), 127.8 (C-Ar), 114.1 
(C-15), 83.1 (C-4), 72.0 (C-2), 54.1 (C-10), 51.0 (C-7), 44.5 (C-13), 32.6 (C-3); m/z (ES 
HRMS) C23H22N3O5 requires 420.1559, found [MH]+ 420.1545. 
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Appendix 1 - NMR Spectra and HPLC Traces 
Appendix 1.1 1H spectrum of 219 (400 MHz, CDCl3) 
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Appendix 1.1 13C spectrum of 219 (101 MHz, CDCl3) 
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Appendix 1.2 1H spectrum of 254 (400 MHz, CDCl3) 
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Appendix 1.2 13C spectrum of 254 (101 MHz, CDCl3) 
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Appendix 1.3 1H spectrum of 263 (400 MHz, CDCl3) 
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Appendix 1.3 13C spectrum of 263 (101 MHz, CDCl3) 
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Appendix 1.4 1H spectrum of 296 (400 MHz, CDCl3) 
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Appendix 1.4 13C spectrum of 296 (101 MHz, CDCl3) 
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Appendix 1.5 1H spectrum of 303 (400 MHz, CDCl3) 
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Appendix 1.5 13C spectrum of 303 (101 MHz, CDCl3) 
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Appendix 1.6 1H spectrum of 318 (400 MHz, CDCl3) 
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Appendix 1.6 13C spectrum of 318 (101 MHz, CDCl3) 
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Appendix 1.7 1H spectrum of 340 (400 MHz, CDCl3) 
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Appendix 1.7 13C spectrum of 340 (101 MHz, CDCl3) 
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Appendix 1.8 1H spectrum of 348 (400 MHz, CDCl3) 
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Appendix 1.8 13C spectrum of 348 (101 MHz, CDCl3) 
 
Appendix 1   Selected NMR spectra and HPLC traces
  
 
271 
Appendix 1.9 1H spectrum of 367 (400 MHz, CDCl3) 
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Appendix 1.9 13C spectrum of 367 (101 MHz, CDCl3) 
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Appendix 1.10 1H spectrum of 369 (400 MHz, CDCl3) 
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Appendix 1.10 13C spectrum of 369 (101 MHz, CDCl3) 
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Appendix 1.11 1H spectrum of 375 (400 MHz, CDCl3) 
 
Appendix 1   Selected NMR spectra and HPLC traces
  
 
276 
Appendix 1.11 13C spectrum of 375 (101 MHz, CDCl3) 
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Appendix 1.12 1H spectrum of 402 (400 MHz, CDCl3) 
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Appendix 1.12 13C spectrum of 402 (101 MHz, CDCl3) 
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Appendix 1.13 1H spectrum of 413 (400 MHz, CDCl3) 
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Appendix 1.13 13C spectrum of 413 (101 MHz, CDCl3) 
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Appendix 1.14 – Example Chiral HPLC chromatograms for 254 
 
Figure 1 Chiral HPLC Chromatogram of a racemic sample of 254 synthesised using Et3N. Peak 1 –  
(–)-254, peak 2 – (+)-254 
 
Figure 2 Chiral HPLC Chromatogram of a sample of (–)-254 with 99:1 er synthesised using catalyst 
201. Peak 1 – (–)-254, peak 2 – (+)-254 
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Appendix 1.15 – Example Chiral HPLC chromatograms for 263 
 
Figure 3 Chiral HPLC Chromatogram of a racemic sample of 263 synthesised using Et3N. Peak 1 – 
(+)-263, peak 2 – (–)-263 
 
Figure 4 Chiral HPLC Chromatogram of a sample of (+)-263 with 92:8 er synthesised using catalyst 
201. Peak 1 – (+)-263, peak 2 – (–)-263 
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Appendix 1.16 – Example Chiral HPLC chromatograms for 296 
 
Figure 5 Chiral HPLC Chromatogram of a racemic sample of 296 synthesised using Et3N. Peak 1 –  
(–)-296, peak 2 – (+)-296 
 
Figure 6 Chiral HPLC Chromatogram of a sample of (–)-296 with 88:12 er synthesised using catalyst 
201. Peak 1 – (–)-296, peak 2 – (+)-296 
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Appendix 1.17 – Example Chiral HPLC chromatograms for 303 
 
Figure 7 Chiral HPLC Chromatogram of a racemic sample of 303 synthesised using Et3N. Peak 1 –  
(–)-303, peak 2 – (+)-303 
 
Figure 8 Chiral HPLC Chromatogram of a sample of (–)-303 with 30:70 er synthesised using catalyst 
201. Peak 1 – (–)-303, peak 2 – (+)-303 
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Appendix 1.18 – Example Chiral HPLC chromatograms for 367 
 
Figure 9 Chiral HPLC Chromatogram of a racemic sample of 367 synthesised using Et3N. Peak 1 – 
(+)-367, peak 2 – (–)-367 
 
Figure 10 Chiral HPLC Chromatogram of a sample of (–)-367 with 4:96 er synthesised using catalyst 
201. Peak 1 – (+)-367, peak 2 – (–)-367 
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Appendix 1.19 – Example Chiral HPLC chromatograms for 369 
 
Figure 11 Chiral HPLC Chromatogram of a racemic sample of 369 synthesised using Et3N. Peak 1 – 
(–)-369, peak 2 – (+)-369 
 
Figure 12 Chiral HPLC Chromatogram of a sample of (–)-369 with 99:1 er synthesised using catalyst 
201. Peak 1 – (–)-369, peak 2 – (+)-369 
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Appendix 1.20 – Example Chiral HPLC chromatograms for 402 
 
Figure 13 Chiral HPLC Chromatogram of a racemic sample of 402 synthesised using Et3N. Peak 1 – 
(–)-402, peak 2 – (+)-402 
 
Figure 14 Chiral HPLC Chromatogram of a sample of (+)-402 with 8:92 er synthesised using catalyst 
210. Peak 1 – (–)-402, peak 2 – (+)-402 
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Appendix 1.21 – Example Chiral HPLC chromatograms for 413 
 
Figure 15 Chiral HPLC Chromatogram of a racemic sample of 413 synthesised using Et3N. Peak 1 – 
(+)-413, peak 2 – (–)-413 
 
Figure 16 Chiral HPLC Chromatogram of a sample of (–)-413 with 11:89 er synthesised using 
catalyst 201. Peak 1 – (+)-413, peak 2 – (–)-413 
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Appendix 2 - X-Ray crystal structure data 
 
The datasets for 263, 264, 267, 295, 296, 348, 340, 372, 406 and 407 were measured on an 
Agilent SuperNova diffractometer u sing an Atlas detector. The data collections were driven 
and processed and absorption corrections were applied using CrysAlisPro.184 The structures 
were solved using ShelXS185 and refined by a full-matrix least-squares procedure on F2 in 
ShelXL.185 All non-hydrogen atoms were refined with anisotropic displacement parameters. 
Figures were produced using OLEX2.186  
All remaining hydrogen atoms in all structures were added at calculated positions and refined 
by use of a riding model with isotropic displacement parameters based on the equivalent 
isotropic displacement parameter (Ueq) of the parent atom. 
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Appendix 2.1 X-Ray Crystal Structure Data for Compound 263 
 
 
 
 
Table 1 Crystal data and structure refinement for 263 
Identification code 263 
Empirical formula C26 H26 N2 O8 
Formula weight 494.49 
Temperature 99.95(17) K 
Crystal system Orthorhombic 
Space group P212121 
Unit cell dimensions a = 7.99873(6) Å 
 b = 15.06796(11) Å 
 c = 20.20372(13) Å 
Volume 2435.04(3) Å3 
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Z 4 
Density (calculated) 1.349 g/cm3 
Absorption coefficient 0.843 mm-1 
Reflections collected 23316 
Independent reflections 4908 [R(int) = 0,0284] 
Final R indices [I > 2σ(I)] R1 = 0.0254, wR2 = 0.0649 
Flack parameter -0.03(5) 
Ellipsoid probability 50% 
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Appendix 2.2 X-Ray Crystal Structure Data for Compound 264 
 
 
 
 
 
 
Table 2 Crystal data and structure refinement for 264 
Identification code 264  
Empirical formula C26 H25 N3 O7  
Formula weight 491.49  
Temperature 99.98(13) K  
Crystal system Monoclinic  
Space group P21/n  
Unit cell dimensions a = 8.38756(14) Å  
 b = 27.5099(4) Å β = 94.2738(13)° 
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 c = 10.06135(13) Å  
Volume 2315.11(6) Å3  
Z 4  
Density (calculated) 1.410 g/cm3  
Absorption coefficient 0.864 mm-1  
Reflections collected 12511  
Independent reflections 4156 [R(int) = 0,0215]  
Final R indices [I > 2σ(I)] R1 = 0.0461, wR2 = 0.1212  
Ellipsoid probability 50%  
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Appendix 2.3 X-Ray Crystal Structure Data for Compound 267 
 
 
 
 
 
 
 
Table 3 Crystal data and structure refinement for 267 
Identification code 267  
Empirical formula C23 H20 Cl N3 O5  
Formula weight 453.87  
Temperature 100.0(2) K  
Crystal system Monoclinic  
Space group I2  
Unit cell dimensions a = 13.6988(3) Å  
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 b = 7.7497(2) Å β = 101.8198(19)° 
 c = 20.8571(4) Å  
Volume 2167.29(8) Å3  
Z 4  
Density (calculated) 1.391 g/cm3  
Absorption coefficient 1.912 mm-1  
Reflections collected 18477  
Independent reflections 3833 [R(int) = 0,0405]  
Final R indices [I > 2σ(I)] R1 = 0.0293, wR2 = 0.0774  
Flack parameter 0.010(8)  
Ellipsoid probability 50%  
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Appendix 2.4 X-Ray Crystal Structure Data for Compound 295 
 
 
 
 
Table 4 Crystal data and structure refinement for 295 
Identification code 295 
Empirical formula C33 H28 N2 O4 
Formula weight 516.57 
Temperature 100.01(10) K 
Crystal system Orthorhombic 
Space group P212121 
Unit cell dimensions a = 12.1648(1) Å 
 b = 12.4912(1) Å 
 c = 17.1070(2) Å 
Volume 2599.46(4) Å3 
Z 4 
Density (calculated) 1.320 g/cm3 
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Absorption coefficient 0.700 mm-1 
Reflections collected 24936 
Independent reflections 5250 [R(int) = 0,0219] 
Final R indices [I > 2σ(I)] R1 = 0.0243, wR2 = 0.0629 
Flack parameter -0.01(4) 
Ellipsoid probability 50% 
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Appendix 2.5 X-Ray Crystal Structure Data for Compound 296 
 
 
 
 
 
Table 5 Crystal data and structure refinement for 296 
Identification code 296  
Empirical formula C33 H27 Br N2 O4  
Formula weight 595.47  
Temperature 100.01(10) K  
Crystal system Monoclinic  
Space group P21  
Unit cell dimensions a = 9.71430(10) Å  
 b = 22.59340(10) Å β = 106.7030(10)° 
 c = 12.66410(10) Å  
Volume 2662.23(4) Å3  
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Z 4  
Density (calculated) 1.486 g/cm3  
Absorption coefficient 2.456 mm-1  
Reflections collected 50958  
Independent reflections 10745 [R(int) = 0,0250]  
Final R indices [I > 2σ(I)] R1 = 0.0185, wR2 = 0.0477  
Flack parameter -0.027(3)  
Ellipsoid probability 50% 
 
Note: 
In 296 there are two crystallographically-independent molecules present. 
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Appendix 2.6 X-Ray Crystal Structure Data for Compound 340 
 
 
 
 
 
Table 6 Crystal data and structure refinement for 340 
Identification code 340  
Empirical formula C24 H26 N2 O6  
Formula weight 438.47  
Temperature 100.01(10) K  
Crystal system Monoclinic  
Space group P21  
Unit cell dimensions a = 8.97919(10) Å  
 b = 13.10046(15) Å β = 107.9910(12)° 
 c = 9.53352(11) Å  
Volume 1066.61(2) Å3  
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Z 2  
Density (calculated) 1.365 g/cm3  
Absorption coefficient 0.815 mm-1  
Reflections collected 20053  
Independent reflections 4119 [R(int) = 0.0175]  
Final R indices [I > 2σ(I)] R1 = 0.0242, wR2 = 0.0619  
Flack parameter -0.01(4)  
Ellipsoid probability 50% 
 
Note: 
In 340 the hydrogen atoms bonded to O(5) and O(24) were located in the electron density and 
refined freely. 
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Appendix 2.7 X-Ray Crystal Structure Data for Compound 348 
 
 
 
 
 
Table 7 Crystal data and structure refinement for 348 
Identification code 348  
Empirical formula C25 H30 N2 O4  
Formula weight 422.51  
Temperature 100.00(10) K  
Crystal system Monoclinic  
Space group P21/c  
Unit cell dimensions a = 12.28524(10) Å  
 b = 16.44821(13) Å β = 98.0951(9)° 
 c = 10.90880(11) Å  
Volume 2182.38(3) Å3  
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Z 4  
Density (calculated) 1.286 g/cm3  
Absorption coefficient 0.702 mm-1  
Reflections collected 40678  
Independent reflections 4438 [R(int) = 0,0274]  
Final R indices [I > 2σ(I)] R1 = 0.0346, wR2 = 0.0915  
Ellipsoid probability 50% 
 
Note: 
In 348 the hydrogen atoms bonded to O(5) and O(24) were located in the electron density and 
refined freely. 
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Appendix 2.8 X-Ray Crystal Structure Data for Compound 372 
 
 
 
 
 
 
Table 8 Crystal data and structure refinement for 372 
Identification code 372  
Empirical formula C29 H28 N2 O4  
Formula weight 468.53  
Temperature 100.00(10) K  
Crystal system Monoclinic  
Space group P21/n  
Unit cell dimensions a = 12.3676(3) Å  
 b = 23.5052(5) Å β = 110.221(3)° 
 c = 17.6271(4) Å  
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Volume 4808.4(2) Å3  
Z 8  
Density (calculated) 1.294 g/cm3  
Absorption coefficient 0.697 mm-1  
Reflections collected 19259  
Independent reflections 8606 [R(int) = 0,0285]  
Final R indices [I > 2σ(I)] R1 = 0.0410, wR2 = 
0.1036 
 
Ellipsoid probability 50% 
 
Note: 
In 372 the hydrogen atoms bonded to O(5), N(4), O(105), N(104) were located in the electron 
density and refined freely. There are two crystallographically-independent molecules present. 
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Appendix 2.9 X-Ray Crystal Structure Data for Compound 406 
 
 
 
 
 
 
Table 9 Crystal data and structure refinement for 406 
Identification code 406  
Empirical formula C22 H22 N2 O5  
Formula weight 394.41  
Temperature 100.01(13) K  
Crystal system Monoclinic  
Space group P21  
Unit cell dimensions a = 12.14306(17) Å  
 b = 6.28576(7) Å β = 108.5659(17)° 
 c = 13.0165(2) Å  
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Volume 941.82(2) Å3  
Z 2  
Density (calculated) 1.391 g/cm3  
Absorption coefficient 0.819 mm-1  
Reflections collected 16277  
Independent reflections 3748 [R(int) = 0,0386]  
Final R indices [I > 2σ(I)] R1 = 0.0281, wR2 = 0.0706  
Flack parameter 0.04(8)  
Ellipsoid probability   50% 
   
 
Note: 
In 406 the hydrogen atom belonging to the hydroxyl group O(2) was located in the electron 
density and freely refined. 
  
Appendix 2   Crystal Structure Data
  
 
308 
Appendix 2.10 X-Ray Crystal Structure Data for Compound 407 
 
 
 
 
 
 
 
 
Table 10 Crystal data and structure refinement for 407 
Identification code 407  
Empirical formula C23 H21 N3 O5  
Formula weight 419.43  
Temperature 100.00(13) K  
Crystal system Monoclinic  
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Space group P21/n  
Unit cell dimensions a = 9.9694(2) Å  
 b = 18.7511(2) Å β = 107.007(2)° 
 c = 10.9554(2) Å  
Volume 1958.41(6) Å3  
Z 4  
Density (calculated) 1.423 g/cm3  
Absorption coefficient 0.842 mm-1  
Reflections collected 12752  
Independent reflections 3677 [R(int) = 0,0300]  
Final R indices [I > 2σ(I)] R1 = 0.0368, wR2 = 0.0936  
Ellipsoid probability 50% 
 
Note: 
In 407 The hydroxyl hydrogen atom belonging to O(3) was located in the electron density and 
the position refined freely while the isotropic displacement parameter was based on the 
equivalent isotropic displacement parameter (Ueq) of the parent atom. 
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